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ABSTRACT 
The PD-1/PD-L1 pathway in T lymphocytes is emerging as one of the most 
promising targets for cancer immunotherapy but few details are yet known about 
how its inhibitory influence is achieved.  
This work set out to investigate the role of plasma membrane dynamics, on both T 
cells and tumour cells, in modulating the pathway. In eukaryotic cells, calcium influx 
leads to rapid changes in the plasma membrane. Exocytosis, phospholipid 
scrambling, membrane shedding and massive endocytosis can all occur.  The calcium 
sensors for these processes, their inter-dependence and their effects on 
transmembrane protein expression remain largely unknown. Here we show that the 
ion channel TMEM16F is the calcium sensor for large exocytosis and that 
phospholipid scrambling and microvesicle shedding are coupled to exocytosis. The 
absence of TMEM16F not only abrogates exocytosis but also results in massive 
endocytosis in response to calcium.  Intracellular polyamines regulate these 
phenotypes, switching cell responses from massive exo- to endocytosis by blocking 
the TMEM16F conductance. This massive endocytosis also occurs during apoptosis 
via a calcium-independent mechanism. In lymphocytes, PD-1 participates 
selectively in both shedding and massive endocytosis, targeting that depends on the 
PD-1 transmembrane region, independent of actin and classical protein adaptors. 
We also found that PD-L1 on tumour cells can be transferred to lymphocytes, and be 
maintained in stable complex with PD-1 on in vitro and in vivo. This may modulate 
the PD-L1/PD-1 pathway in tumours.  
Together, these results provide new insights into the plasma membrane 
reorganization that occurs following calcium transients, establishes a mechanism of 
PD-1 regulation dependent solely on protein-membrane interaction, and also 
introduces a new modality by which PD-L1:PD-1 interactions can be sustained 
beyond cell-cell contact in tumours. 
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1.2 PD-1/PD-L1 Biology 
1.2.1 Cancer Immunotherapy and the PD-1/PD-L1 pathway 
The specific elimination of cancer cells without the parallel destruction of healthy 
tissues is the ultimate objective of cancer therapeutics. Conventional treatments 
have been limited in effectiveness by their lack of such specificity. 
Chemotherapeutic agents eliminate rapidly dividing cells while surgical resection 
and radiotherapy target the abnormal tumour mass, if it can be distinguished from 
normal structures. The need to balance tumour clearance with life threatening side 
effects often prevents successful treatment of cancer by these modalities (Vanneman 
and Dranoff, 2012). A greater understanding of the molecular basis of cancer has 
brought a new generation of targeted therapeutic approaches. Cancer genome 
sequencing has revealed common mutations or chromosomal translocations that 
lead to the activation of specific signalling pathways and promote uncontrolled 
cellular proliferation. Examples include inhibition of the constitutively activated 
BRAF pathway in melanoma and the BCR-Abl kinase in chronic myeloid leukaemia 
(CML) (Holderfield et al., 2014; Weisberg et al., 2007). A greater understanding of 
the relationship between tumours and the immune system has opened a new field of 
therapy, cancer immunotherapy, which is aimed at activating adaptive immune 
towards cancer cells. 
The dysfunctional gene expression that leads to the uncontrolled proliferation of 
cancer cells also causes the expression of tumour antigens that can elicit cytotoxic T 
lymphocyte responses (Burnet, 1970; van der Bruggen et al., 1991). Since this 
discovery, the potential to direct an antigen-specific immune response towards 
cancer has been investigated as a potential therapeutic approach. The first attempts 
conducted in the 1980s employed vaccination protocols, delivering melanoma 
antigens along with immune adjuvants. These studies were almost uniformly 
unsuccessful (Rosenberg et al., 2004). One reason for this dispiriting beginning was a 
failure to address the causes of immune dysfunction in cancer. The tumour 
microenvironment has multiple direct and indirect mechanisms of immune 
suppression, including secreted immunosuppressive cytokines (Dranoff, 2004), 
 20 
inhibitory co-stimulation (Pardoll, 2012), induction of tolerogenic dendritic cells 
(Seliger and Massa, 2013), the recruitment of inhibitory regulatory T cells (T regs) 
(Mougiakakos et al., 2010) and myeloid-derived suppressor cells (MDSCs) (Khaled et 
al., 2013) as well as metabolic interference (Wang et al., 2014). It has been as a result 
of an increasing understanding of these mechanisms that a new generation of 
effective immunotherapies has emerged.  
T lymphocytes receive and integrate many signals through plasma membrane 
receptors that regulate their activity throughout cell activation and effector 
function. Initially, naïve cells recognise their cognate antigen peptide presented by 
MHC on an antigen-presenting cell (APC) (Signal 1) alongside signalling through co-
stimulatory or co-inhibitory receptors (Signal 2) including CD28, CTLA-4 and PD-1. 
These signals together contribute to setting the activity and proliferative capacity of 
the cell. Cytokine signals (Signal 3), IL-12 and IL-10 for example, serve to structure 
the phenotype of the resulting T cell response (Chen and Flies, 2013). Later, when 
activated T cells encounter their antigen expressing target cells in the periphery, co-
receptor signalling again regulates lymphocyte effector function. The diverse 
stimulatory and inhibitory co-receptor signals received by lymphocytes serve as 
immune checkpoints that work to maintain immune tolerance to self-tissues.  
Cancer cells evolve under an immune ‘selection-pressure’, and so are found to 
upregulate immunosuppressive factors that, under physiological conditions, 
maintain tolerance to healthy tissues (Dunn et al., 2004). Immune checkpoint 
therapies attempt to manipulate these auxiliary signals as a way to reverse immune 
dysfunction and break tolerance to cancer. 
The CD28 family of co-stimulatory receptors are critical T lymphocyte regulators. 
They are characterised by a single extracellular immunoglobulin-like domain. 
Stimulatory CD28 signalling is essential for activation of naïve T cells while other 
family members, ICOS (stimulatory), CTLA-4, PD-1 and BTLA (inhibitory), serve to 
tune T cell activity (Riley and June, 2005). These pathways have emerged as crucial 
immune checkpoints and therefore targets for immunotherapeutic interventions. 
The first checkpoint targeted was the inhibitory CTLA-4, a receptor only expressed 
on T lymphocytes, which shares its ligands with the stimulatory CD28 (Krummel and 
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Allison, 1995; Walunas et al., 1994). CTLA-4 signalling is influential at the early 
stage of antigen presentation to a naïve cell as its ligands CD80 and CD86 are only 
expressed on APCs (Walunas et al., 1996). Blocking antibodies that preclude 
ligand/receptor binding prevent inhibition by CTLA-4, and may also serve to 
downregulate regulatory T cell (Treg) function (Peggs et al., 2009). Work in mouse 
models demonstrated that CTLA-4 blockade promoted immune rejection of tumours 
(van Elsas et al., 1999). The humanised blocking antibody impilimumab produced 
clinical responses in patients with diverse tumour types including renal cell 
carcinoma (RCC) (Yang et al., 2007), melanoma (Weber et al., 2008) and ovarian 
cancer  (Hodi et al., 2008) in early phase trials. A subsequent randomised trial 
combining a melanoma-specific vaccine with impilimumab showed a survival 
benefit of over three months in patients with metastatic melanoma (Hodi et al., 
2010). Remarkably, in a subset of patients, treatment with impilimumab has been 
tentatively curative with remission seen for over 10 years (Schadendorf et al., 2015). 
Unfortunately, rates of adverse events were high in all studies with ~30% suffering 
autoimmune complications including severe colitis (Yang et al., 2007) (Weber et al., 
2008) (Hodi et al., 2008). Impilimumab has now been approved by the US Food and 
Drug Administration (FDA) for use in metastatic melanoma.  
In the last five years blockade of the PD-1/PD-L1 pathway has emerged as perhaps 
the most promising strategy for cancer immunotherapy. High PD-1 expression is a 
feature of the ineffective, ‘exhausted’ T cells found in tumours, while PD-L1 (the 
primary PD-1 ligand) is upregulated in multiple cancer types (discussed later). Early 
phase trials demonstrated efficacy of both anti-PD-1 and PD-L1 blocking antibodies 
with clinical responses in melanoma, RCC, bladder and non-small cell lung cancers 
(Brahmer et al., 2012; Powles et al., 2014; Topalian et al., 2012). Several anti-PD-1 
antibodies have recently gained FDA approval for the treatment of metastatic 
melanoma. The antibody pembroluzimab (MK-3475) showed a 37% response rate in 
Phase I trials (Hamid et al., 2013), while Phase III trials testing the antibody 
nivolumab gave a survival rate of 72% vs. 42% in patients treated with the 
chemotherapeutic drug dacrabazine (Robert et al., 2015). A surprising outcome from 
these clinical studies is that PD-1/PD-L1 blockade has effects in classically non-
immunogenic tumour types including NSCLC (Topalian et al., 2012). A recent Phase 
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III trial testing nivolumab for NSCLC was stopped early following a clear survival 
benefit over docetaxel. The rates of drug related adverse events were, however, 
consistently high across trials with ~10% rate of grade 3 or 4 adverse events (life 
threatening or requiring hospitalisation) and some fatalities from drug-induced 
pneumonitis, hepatitis, colitis and thyroiditis (Robert et al., 2015; Topalian et al., 
2012). These side effects may limit these therapies to patient cohorts with severe, 
late stage metastatic disease and render them inappropriate treatments at earlier 
stages where curative and long-lasting interventions are more likely (Pardoll, 2012). 
Immune checkpoint therapy is still at an early stage. Key questions remain, 
including how to predict which patients will respond to specific therapies, whether 
combinations of therapeutic blocking antibodies will have cumulative effects, and 
importantly how to limit the drug related adverse effects (Sharma and Allison, 2015). 
The PD-1/PD-L1 axis is clearly an important pathway in suppressing immune 
responses to cancer as well as a hugely promising target for therapeutics. There are 
many aspects of PD-1/PD-L1 biology that are still poorly understood, as will be 
discussed in this chapter. The molecular basis of PD-1 signalling, how expression at 
the cell surface is regulated, and the nature of the PD-1/PD-L1 interaction are yet to 
be completely understood. As with the field of cancer immunotherapy itself, a 
greater understanding of the underlying mechanisms will hopefully bring 
increasingly effective strategies to modulate this important pathway.  
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1.2.2 PD-1 Expression 
PD-1 is expressed on T cells, B cells, NK cells and DCs (Keir et al., 2008). Expression 
is undetectable on naïve T cells but is induced upon cell activation (Agata et al., 
1996). Expression is rapid, occurring within 6 - 24 hours after T cell receptor (TCR) 
stimulation in vitro and in vivo (Agata et al., 1996; Chikuma et al., 2009), but is 
transient, with levels returning to baseline within a week. During chronic viral 
infection however, T cells revert to a state of ‘anergic’ dysfunction, with low 
cytokine secretion, proliferation and cytotoxic function associated with clonal 
deletion and high expression of PD-1 (Brooks et al., 2005; Moskophidis et al., 1993; 
Wherry et al., 2005; Zajac et al., 1998). In this so-called ‘exhausted’ state, 
administration of PD-1 or PD-L1 blocking antibodies can recover T cell function 
(Barber et al., 2006; Wherry et al., 2007). Exhaustion may constitute a protective 
mechanism of peripheral tolerance, attenuating autoimmune responses to persistent 
‘self’ antigens, but in turn leads to ineffective clearance of viruses and tumour cells 
(Barber et al., 2006; Velu et al., 2009). In the context of cancer, PD-1 expression is 
high on TILs in breast (Sun et al., 2014), melanoma (Ahmadzadeh et al., 2009; 
Chapon et al., 2011), renal cell carcinoma (Thompson et al., 2007), Ovarian 
(Matsuzaki et al., 2010), hepatocellular carcinoma (Shi et al., 2011), non-small cell 
lung (Zhang et al., 2010), prostate (Sfanos et al., 2009), thyroid (French et al., 2012) 
cancers. This expression acts as a biomarker for poor prognosis in many cases (Shi et 
al., 2011; Sun et al., 2014; Thompson et al., 2007). 
Limited work has focused on understanding the transcriptional control of the PDCD1 
gene that transcribes PD-1. The Ca2+ dependent transcription factor NFATc1 induces 
PD-1 expression following TCR-activated Ca2+ influx, via a binding site in the PDCD1 
promoter (Oestreich et al., 2008). This may explain the rapid, transient upregulation 
of PD-1 following activation but not the long-term sustained expression in 
exhaustion. A detailed interrogation of the PDCD1 promoter by serial truncation 
studies found that an Interferon-Stimulated Response Element (ISRE) was present 
(Terawaki et al., 2011). Type I interferon IFN-α treatment led to sustained PD-1 
expression reminiscent of exhaustion via the ISRE. The authors suggested that this 
may explain why IFN-α therapy, which is intended to enhance T cell responses, has 
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had limited success (Amato, 1999). In vivo studies showed that IFN-α therapy given 
alongside PD-1 blockade was synergistic in mouse-tumour models. Other cytokines 
including the γ-chain containing the cytokines IL-2, 7, 15 and 21 can also lead to 
PD-1 expression, but the mechanism for this is unclear. 
Work directed towards understanding PD-1 transcriptional regulation has so far 
provided important insights that may help to guide future therapies. PD-1 
expression constitutes a protective mechanism, preventing inappropriate immunity 
that may threaten important tissues. Adjuvants that promote immunity, such as 
cytokine-based therapies, will therefore likely be balanced by the application of 
immune ‘brakes’ such as PD-1.  Better understanding of PD-1 regulation is therefore 
key to optimal manipulation of immune functions for therapeutic purposes. 
1.2.3 PD-L1 and PD-L2 Expression 
PD-L2 is only expressed on APCs whereas PD-L1 is inducible in the majority of cell 
types. PD-L1 is expressed in ‘immune privileged’ organs such as the eye, testes and 
placenta, where overzealous immune responses could damage important structures. 
IFN-γ and TNF-α rapidly upregulate PD-L1 expression in many cell types (Keir et al., 
2008). 
An immune-inhibitory tumour microenvironment is an important factor in tumour 
persistence and PD-L1 provides cells with protection from immune clearance. PD-L1 
expression is found to be high on tumour cells in breast (Muenst et al., 2014), 
melanoma (Hino et al., 2010; Massi et al., 2014), RCC (Frigola et al., 2011), ovarian 
(Maine et al., 2014), HCC (Gao et al., 2009), NSCLC (Azuma et al., 2014), colon (Shi 
et al., 2013), cervical (Karim et al., 2009), and oesophageal (Ohigashi et al., 2005). In 
all these cases high PD-L1 expression is linked unfavourably to patient prognosis. It 
is unclear how this upregulation occurs in tumours. There is some evidence in 
glioblastoma that PD-L1 is upregulated by signalling downstream of dysfunctional 
PTEN (Parsa et al., 2007) but others have shown this is not the mechanism in 
melanoma (Atefi et al., 2014). Further work is needed to understand how this 
important prognostic factor is regulated in order to develop interventions aimed at 
modulating PD-L1 expression. 
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1.2.4 PD-1 Signalling 
CTLA-4 knockout mice develop a catastrophic lymphoproliferative disorder soon 
after birth and die within 3-4 weeks (Tivol et al., 1995; Waterhouse et al., 1995). The 
phenotype in PD-1 knockout mice is less dramatic, with late development of an 
insidious lupus-like glomerulonephritis and arthritis (Nishimura et al., 1999) or 
inflammatory cardiomyopathy (Nishimura et al., 2001) depending on the mouse 
species. PD-1 is important in setting the threshold for adaptive immune activity, 
with knockout or blockade promoting autoimmune disease (Menke et al., 2007; 
Wang, 2005), while conferring resistance to viral infections (Iwai et al., 2003) and 
tumours (Iwai et al., 2002; Iwai et al., 2005) and promoting graft rejection (Ito et al., 
2005). 
The means by which PD-1 inhibits T cell effector function is complex, with new 
modalities still coming to light. The PD-1 intracellular domain does not possess any 
intrinsic inhibitory properties but instead functions as an adaptor for other 
inhibitory proteins. Two tyrosine-based motifs – an ITIM (V/I/LxYxxL) and ITSM 
(TxYxxL) – are present on its intracellular domain. The ITSM recruits the SHP-1 and 
SHP-2 phosphatases (Chemnitz et al., 2004). Ligation of PD-1 triggers the 
phosphorylation of both ITIM and ITSM, possibly by Lck and/or Src kinases 
(Sheppard et al., 2004). The recruited phosphatase is phosphorylated, changes 
conformation and becomes active. Following PD-1 engagement, de-phosphorylation 
events affect components of T cell signalling including CD3ζ, Zap70, and PKCtheta 
(Okazaki et al., 2001; Sheppard et al., 2004) and downstream PI3K and Akt (Parry et 
al., 2005). This simple picture of PD-1-induced phosphatase activation attenuating 
TCR signalling was added to by Yokosuka et al. who investigated the spatial 
requirements for PD-1 at the immune synapse(Yokosuka et al., 2012). They used 
TIRF Microscopy and planar bilayers to simulate antigen presentation and found 
that PD-1 is rapidly translocated to TCR-containing microclusters in the centre on 
the immune synapse (cSMAC), in a PD-L1 dependent manner. TCR microclusters 
have only been identified since the advent of TIRFM and constitute aggregates of 
TCRs and proximal signalling components. It is in these clusters that PD-1 recruits 
SHP-2. Disruption of clustering prevents PD-1-dependent de-phosphorylation of 
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TCR-associated signalling molecules. PD-1 signalling therefore relies on a dynamic 
spatial co-localisation with TCR for effective inhibition. 
Due to the substantial inhibitory effects of PD-1 on T cell functions, Quigley and 
colleagues asked whether PD-1 stimulation resulted in a change in transcription 
factor expression (Quigley et al., 2010). They first compared the gene expression 
profiles of exhausted CD8+ T cells from HIV patients with PD-1 expressing Jurkat 
cells that had been stimulated with anti CD3CD28 and anti PD-1. They found an 
overlapping gene upregulation of 75 genes that included the inhibitory transcription 
factor BATF. Overexpression of BATF re-capitulated the phenotype of T cell 
exhaustion, with reduced proliferation and IL-2 production. Moreover, knockdown 
of BATF rescued effector functions in ‘exhausted’ HIV specific CD8+ cells. This work 
presents evidence that the inhibitory influence of PD-1 extends beyond TCR signal 
attenuation and involves the upregulation of an inhibitory gene profile. It is 
currently unclear how PD-1 can influence gene transcription in this way. 
In work carried out in the Collins lab, which I contributed to during my BSc project, 
it was found that PD-1 signalling can also modulate the TCR downregulation that 
follows T cell activation (Karwacz et al., 2011). This incidental finding came out of 
work aimed at enhancing anti-tumour immune responses in mice via genetic 
modification of DCs. One of the strategies tested was the shRNA knockdown of PD-
L1. The normal downregulation of the TCR that follows antigen presentation did not 
occur in T cells activated by PD-L1 knockout DCs.  Independent work by Naramura 
et al. and others had demonstrated that the inhibitory E3 Ubiquitin ligase Cbl-b was 
involved in TCR downregulation following antigen presentation (Naramura et al., 
2002; Shamim et al., 2007). This was mediated via ubiquitination of the CD3ζ leading 
to TCR internalisation. Indeed it was found that PD-1 signalling powerfully 
upregulates Cbl-b (Karwacz et al., 2011). This work presented a new mechanism by 
which PD-1 can inhibit effector function - by downregulating TCR expression, and 
thereby limiting ‘Signal 1’.  It is also likely that Cbl-b, known to be inhibitory to T 
cell function, could ubiquitinate other protein targets involved in T cell activation. 
Little is known about the transcriptional regulation of Cbl-b so it would also be 
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interesting to investigate whether the transcription factors identified in Quigley et 
al., shown to be upregulated by PD-1, are involved in Cbl-b regulation. 
Lastly it was recently discovered that PD-1:PD-L1 engagement has profound effects 
on T cell motility. By employing Two Photon Microscopy (TPM), Zinselmeyer et al. 
demonstrated that exhausted T cells exposed to chronic LCMV infection localised to 
the splenic red pulp where they remained relatively immobile (Zinselmeyer et al., 
2013). This paralysis is due to highly stable immune synapse formation mediated via 
PD-L1 that clusters in the cSMAC. Motility could be restored by PD-1 blockade. 
Interestingly, in the model of LCMV (C13) infection, this recovery was associated 
with an excessive immune response, mediated via IFN-γ, which was quickly fatal to 
mice. This demonstrates the important physiological role PD-1 plays in attenuating 
potentially damaging immune responses. 
The PD-1 receptor seemingly has a very simple mechanism of inhibition; 
recruitment and activation of inhibitory phosphatases that limit stimulatory 
signalling. It has however become clear that PD-1 also has other effects on gene 
transcription as well influences on TCR regulation and cell behaviour. As 
interventions that aim to regulate this pathway in the context of cancer enter the 
clinic, evidence is of dramatic tumour rejection but high rates of adverse drug-
related events. More needs to be understood about this promising pathway if we are 
to harness its full therapeutic potential. 
1.2.5 PD-1 Membrane Regulation 
The regulation of other members of the CD28 family has been a focus of 
considerable research but, to our knowledge, only one paper has attempted to 
understand the trafficking of PD-1. CTLA-4 is endocytosed via an AP-2 binding, 
tyrosine-based (YVKM) motif, leading to clathrin and dynamin-dependent 
endocytosis (Bradshaw et al., 1997; Qureshi et al., 2012). It is then either recycled to 
the plasma membrane or degraded in lysosomal compartments. The rate of this 
trafficking is increased during T cell activation (Qureshi et al., 2012) which likely 
enhances the trans-endocytosis of CTLA-4 ligands (discussed later). CD28 
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endocytosis appears to be more complicated, with evidence that a complex of WASp, 
SNX9 and p85 couple CD28 to the clathrin endocytic machinery (Badour et al., 2007). 
Pentcheva-Hoang et al. investigated PD-1 trafficking using confocal microscopy – 
co-staining PD-1 and other organelle markers over a time course of OT-II T cell 
activation (Pentcheva-Hoang et al., 2007). At day three following activation, PD-1 
could be seen on the plasma membrane as well as in Trans Golgi Network (TGN), 
demonstrated by co-localisation with TGN38, suggesting that it is sorted through 
this compartment on the way to the plasma membrane. PD-1 did not co-localise 
with trafficking endosomes (marked with anti-TfR and fluorescent transferrin) or 
lysosomes (marked with anti-LAMP1), which suggested to the authors that ‘PD-1 is 
internalised via a different endocytic pathway’. 
No further work has built on these insights or attempted to understand the 
mechanism of PD-1 endocytosis. PD-1 has no known internalisation motifs and it 
seems not to be trafficked through normal endocytic compartments. Nevertheless, 
despite no obvious leads, further investigation is warranted. 
1.2.6 Intercellular Transmembrane Protein Transfer 
In recent years, new mechanisms of intercellular communication have emerged 
beyond simple membrane-bound or secreted ligand-receptor interactions. It has 
been discovered that membrane proteins can be captured and transferred from one 
cell to another during cell contact. This transfer can take different forms, with 
proteins either being recycled or degraded by the recipient cell. CD28 family 
members have been found to take part in two forms of this protein exchange: Trans-
endocytosis and Trogocytosis. 
CTLA-4 is another inhibitory member of the CD28 family with both intrinsic and 
extrinsic mechanisms of T cell inhibition. A salient feature of CTLA-4 is that it 
shares the ligands CD80 and CD86 with the stimulatory receptor CD28. CTLA-4 has 
been shown to indirectly recruit SHP-2 and PP2A phosphatases that 
dephosphorylate factors downstream of TCR in a similar way to PD-1 though with 
distinct targets. This model does not seem to fully explain the inhibitory effects of 
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CTLA-4 as it can still be inhibitory without phosphatase recruitment, and in other 
cases is not inhibitory when associated with phosphatases (Alegre et al., 2001). 
CTLA-4 can disrupt lipid raft and microcluster formation (Schneider et al., 2007) 
(Chikuma et al., 2003) and therefore normal TCR signalling. Affinity studies have 
demonstrated that CTLA-4 has a much higher binding affinity for its ligands 
(especially CD80) than CD28 (Collins et al., 2002). This suggests that CTLA-4 can 
compete favourably with CD28 for ligands and therefore reduce stimulatory 
signalling through CD28. CTLA-4 can also inhibit by cell extrinsic mechanisms 
including secretion of soluble CTLA-4 and induction of the enzyme indoleamine 2,3-
dioxy-genase (IDO) in APCs (Rudd, 2008). 
In 2011, Qureshi and colleagues discovered an exciting new modality for cell 
extrinsic CTLA-4 inhibition (Qureshi et al., 2011). In experiments using 
fluorescently tagged CD80 and CD86 expressed on DCs, they discovered that these 
ligands were transferred onto CTLA-4 expressing T regulatory cells (Tregs) in co-
culture. This transfer was enhanced when TCR stimulation was applied in parallel. 
Using a membrane dye the authors showed that small amounts of membrane were 
also transferred with the ligands. Crucially, ligands were swiftly degraded in the T 
cell, a process that could be blocked using the lysosome inhibitor bafilomycin A. 
These experiments suggested that complete ligands, still associated with membrane 
fragments, were depleted from DC surface and degraded by CTLA-4 expressing T 
cells. This process of ligand removal and degradation is named Trans-endocytosis 
and was first observed in the context of early development, occurring during Notch 
receptor signalling (Klueg and Muskavitch, 1999) and EPH-Ephrin interactions 
(Marston et al., 2003). In the case of CTLA-4, it constitutes a novel means of immune 
inhibition, by depleting the pool of CD28 ligands available. This may have effects on 
the cell undergoing trans-endocytosis, as well as on other cells that subsequently 
come into contact with that DC. The strong affinity CTLA-4 possesses for its ligands 
is thought to be crucial in allowing Trans-endocytosis to occur, although the 
mechanism behind trans-endocytosis is still unclear. 
Following this discovery, it was important to ask whether PD-1 could also engage in 
ligand capture. Using surface plasmon resonance and isothermal titration calimetry, 
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Cheng et al. conducted a comprehensive interrogation of PD-1-ligand binding 
properties (Cheng et al., 2013). They found that PD-1 has a surprisingly weak 
interaction with its ligands. The half lives of human PD-1:PDL1 (Kd=8µM) and PD-
1:PD-L2 (Kd=2µM) were between 1000-5000 shorter than for CTLA-4:CD80 and even 
more short-lived for mouse PD-1:PD-L (Kd = 30-35µM). PD-1 takes part in 
monovalent interactions with its ligands, unlike CTLA-4 which can form very stable 
bivalent interactions (Zhang et al., 2004). PD-1:PD-L1 interactions were shown to be 
entropically driven and three-fold weaker than PD-1:PD-L2 interactions, which are 
enthapically driven. Due to this very weak affinity, the authors concluded that PD-1 
would be incapable of trans-endocytosis. They also raised the important question as 
to what the functional role of trans-endocytosis would be in the case of PD-1 that 
does not compete for ligands with other receptors. Despite this, in 2012 Gary et al. 
found that it was possible for PD-L1 to be transferred to PD-1 expressing T cells via 
trogocytosis (Gary et al., 2012). 
In trogocytosis, the transfer of membrane protein with membrane patch results in 
the expression of that protein on the plasma membrane of the recipient cell rather 
than intracellular retention and degradation as in the case of trans-endocytosis. 
Trogocytosis has been shown to occur in mouse and human T lymphocytes where 
peptide -MHC and co-stimulatory receptors, ligands and receptors are transferred 
from DC to T cell (Game et al., 2005; Huang et al., 1999) or visa versa (Busch et al., 
2008) in vitro and in vivo (Riond et al., 2007). There is also evidence of transfer of 
proteins from endothelial cells to T cells during migration (Brezinschek et al., 1999). 
Gary et al. found that in co-culture experiments, PD-L1 could be transferred from 
DCs and tumour cells onto CD8+ T cells in a cell-cell contact dependent and 
antigen-specific manner (Gary et al., 2012). They also showed that functional actin 
cytoskeletion was necessary as well as vATPases. They also presented some evidence 
that once the PD-L1 had been transferred onto the T cell, those cells were able to 
induce apoptosis in other T cells. This effect was abolished by PD-L1 blocking 
antibodies, implying that the transferred PD-L1 was functionally active. The authors 
concluded that this process might serve to spread the inhibitory influence beyond 
the original PD-L1 expressing DC/tumour cell. No further studies have investigated 
the role that this protein transfer may play on immune responses in vivo. 
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An apparent conflict appears here, in that affinity studies demonstrate that the PD-
1:PD-L1 interaction is very weak and transient, whilst in vitro cellular studies show 
that it is capable of transferring ligands, which presumably requires a more stable 
interaction.  
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1.3 Ca2+-activated plasma membrane responses 
Signal transduction across cell membranes is essential for life. The ability of cells to 
receive extracellular signals and convert them to an intracellular response allows 
multicellular organisms to coordinate the actions of billions of cells under ever-
changing environmental pressures. These signals can take many forms – 
crosslinking of transmembrane proteins can lead to phosphorylation events, while 
activation of pumps and channels can change the intracellular makeup of ions and 
molecules. These changes may later lead to the upregulation of new proteins with 
functions able to subtly or dramatically change cell behaviour. Calcium ions (Ca2+) 
and phosphate are perhaps the most ubiquitous messengers in cell biology and the 
majority of cell signalling constitutes changes in concentration of these messengers 
over time.  
Cells use ion gradients as a stored signal that can rapidly be triggered by plasma 
membrane channel opening; for example the gradients of sodium and potassium in 
the neuron are used to transmit depolarisation signals across large distances in 
milliseconds. The normal ion gradients between cellular cytoplasm and the 
extracellular space for human cells are shown in Figure 1.X. 
The size of the Ca2+ gradient is striking, with ~20,000 calcium ions outside the cell 
for every one ion in the cytosol. The Ca2+ ATPase pump maintains this steep gradient 
by pumping Ca2+ out of the cell (PMCA ATPase) or into the endoplasmic or 
sarcoplasmic reticulum (SERCA ATPase). The reason for such a significant exclusion 
of Ca2+ from the cell arises from its chemical properties, which can be both beneficial 
and highly toxic to the cell. The major hazard of Ca2+ is its ability to precipitate 
phosphate, unlike other bivalent cations such as magnesium. Despite this danger, 
Ca2+ is also essential to many cell processes including cell activation, exocytosis, and 
apoptosis, and is further essential in its capacity as an indicator of plasma 
membrane integrity. 
 
 
 
 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Ion gradients across the eukaryotic plasma membrane. Approximate 
intracellular and extracellular concentrations (mM) and ratios of key ions across the 
plasma membrane as well as a pictorial representation of the ion ratios with one 
square equivalent to one ion.  
 
The properties of proteins depend on their structure and charge. Whilst 
phosphorylation links anionic phosphate to certain amino acid hydroxyl groups, Ca2+ 
acts like a portable cation, able to rapidly provide proteins new functions. Ca2+ 
sensing domains such as EF hands and C2 domains possess structures of anionic 
amino acids that accommodate Ca2+ binding. In the case of C2 domains, once in 
complex with Ca2+, these newly cationic structures are able to bind anionic 
phospholipids on the inner leaflet of the plasma membranes like PS and PIP2. Ca2+ 
binding domains have varying affinities to Ca2+ that provide distinct thresholds for 
different Ca2+ dependent cellular responses.  
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Cell activation often involves the influx of Ca2+ ions through the Ca2+ -release 
activated current (CRAC) channel. Activation of PLCs leads to the release of IP3, 
which triggers rapid release of Ca2+ from the endoplasmic reticulum via IP3 receptors. 
ER Ca2+ depletion causes the aggregation of ER STIM proteins that activate the PM 
Orai 1 CRAC channel. This is the basis for T cell Ca2+ influx following TCR 
stimulation and is essential for T cell activation (Clapham, 2007). 
This section will provide an overview of some of the changes that occur to the 
cellular plasma membranes following Ca2+ influx, and highlight the important 
questions that remain unanswered. 
1.3.1 Regulated Exocytosis 
Exocytosis is the process by which intracellular membranes fuse with the plasma 
membrane. It is a ubiquitous activity across eukaryotic cells and can serve many 
diverse purposes. Secretory cells eject the contents of cytoplasmic vesicles into the 
extracellular environment via exocytosis whilst other cells use them to bring 
internal membrane and associated proteins to the cell surface to participate in 
signalling or to patch damaged plasma membrane. Both secretory and non-secretory 
exocytosis are highly regulated events and intense research has focused on 
understanding the protein machinery that orchestrates this important cellular 
function (Chieregatti and Meldolesi, 2005). The uniting feature of many types of 
regulated exocytosis, across cell types and species, is the trigger – calcium ions.   
1.3.1.1 Secretory Exocytosis 
Regulated secretion is a pathway for intercellular communication. The majority of 
exocytosis research has focused on its role in the brain. The basic functional unit of 
the brain is the neuronal synapse where communication between nerve cells occurs. 
There are over 1000 trillion of these synapses in a human brain. Depolarisation of 
the presynaptic neuron leads to the opening of voltage-gated Ca2+ channels on the 
presynaptic membrane. Ca2+ influx triggers the secretion of neurotransmitter into 
the synapse by exocytosis, leading to the opening of ligand-gated ion channels on 
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the postsynaptic plasma membrane, transferring the depolarising signal from one 
nerve cell to the other. Neurotransmitter release occurs on a millisecond time scale 
in a discrete area of the synapse, known as the active zone. Bernard Katz at UCL was 
the first to show that neurotransmitters were released in ‘quanta’ (Del Castillo and 
Katz, 1954; Fatt and Katz, 1952) and that these corresponded to the fusion of 
individual vesicles. He was awarded the Nobel Prize in 1970 for this discovery. One 
of Katz’s post-doctoral fellows John Heuser went on to pioneer the technique of 
quick-freeze deep-etch electron microscopy which later allowed vesicular fusion to 
be visualised (Heuser et al., 1979).  
Exocytosis in neurons is the key step in communicating signals between adjacent 
cells. More long-range communication in the brain is achieved by neurosecretory 
cells that exocytose dense-core vesicles (containing neuropeptides, hormones and 
neurotransmitters) uniformly into the pericellular space, which can have effects 
both on the brain and peripherally if they enter the blood stream (Chieregatti and 
Meldolesi, 2005). Non-excitatory cells of exocrine and endocrine glands undergo 
regulated secretory exocytosis, an example being the pancreatic acinar cells that 
secrete the hormone insulin. 
Exocytosis by cells of the immune system is important to their ability to 
communicate and orchestrate an effective immune response. The release of 
cytokines, chemokines and effector molecules by different cell types, at specific 
times, following specific stimuli, is key in regulating an appropriate response to 
diverse pathogens. This can occur at short range in the immune synapse by T 
lymphocytes (discussed later), or in bulk for example by mast cells. 
1.3.1.2 Non-secretory exocytosis 
Non-secretory exocytosis can be separated into two main types – protein exposing 
and membrane expanding. Channels, transporters, pumps and receptors can all be 
brought to the plasma membrane following cell activation. For example, regulated 
expression of aquaporins on the surface of kidney duct cells occurs by exocytosis 
triggered by cAMP (Brown, 2003; Lorenz et al., 2003) a failure of which results in 
diabetes insipidus. In response to insulin, adipocytes and muscle cells translocate 
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GLUT4 transporter to their surface by exocytosis for glucose uptake, a failure of 
which leads to diabetes mellitus (Stöckli et al., 2011). 
Non-secretory exocytosis can also be employed to expand the plasma membrane. 
This is important during phagocytosis when large amounts of plasma membrane are 
donated to the phagosome. This loss is compensated for by membrane exocytosis (Di 
et al., 2003; Holevinsky and Nelson, 1998). During the final stages of cell division 
there is exocytosis adjacent to the cleavage furrow that provides sufficient 
membrane for cytokinesis (Danilchik et al., 2003). Large exocytosis is also an 
important mechanism of cell membrane repair and is discussed in detail later. 
1.3.1.3 Exocytosis machinery 
The role of exocytosis machinery is to bring two membranes into close proximity, 
overcome the energy barrier to fusion posed by the electrostatic and elastic 
properties of the membranes, induce merger of the membrane bilayers and thus 
open a ‘fusion pore’ connecting the lumen of the vesicle with the extracellular space. 
All this must occur while maintaining the continuity of the plasma membrane. 
The 2013 Nobel Prize in Physiology or Medicine was awarded to Randy Schekman, 
James Rothman and Thomas Südhof for their work on vesicle traffic and the 
machinery of exocytosis. Schekman screened for mutants in yeast (sec mutants) that 
displayed defective vesicular transport and consequently accumulated vesicles in 
different cellular compartments (Novick et al., 1980). Rothman meanwhile found 
and purified N-ethylmaleimide-sensitive factor (NSF) and soluble NSF-attachment 
protein (SNAP) through studies using a cell-free system that was able to mimic the 
movement of vesicles through the Golgi stack (Block et al., 1988; Malhotra et al., 
1988). These proteins were necessary for vesicular fusion and later a collaboration 
showed that Schekman’s sec18 mutant corresponded to NSF (Wilson et al., 1989) and 
sec17 to SNAP (Griff et al., 1992) demonstrating that the machinery for exocytosis is 
ancient and highly conserved. Rothman went on to discover more proteins, which he 
named soluble NSF-attachment protein receptors (SNAREs), that formed a complex 
necessary for fusion (Söllner et al., 1993).  
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Südhof was interested in how Ca2+ controlled vesicular exocytosis in the synapse and 
he demonstrated the role of synaptotagmin I as the Ca2+ sensor (Geppert et al., 1994; 
Perin et al., 1990). He also showed that the protein Munc 18-1 is necessary for 
vesicular fusion in neurons and that it corresponds to Schekman’s sec1 (Rizo and 
Südhof, 2012).  Together the work of these three and many others has provided a 
model for vesicular fusion, although much is yet unknown. The model of SNARE 
machinery in neurons is detailed below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 SNARE machinery of exocytosis.  
 
The SNARE machinery (Figure 1.2) is made up of proteins with attachments to either 
the vesicular or plasma membrane. Synaptobrevin (or VAMP) is inserted on the 
vesicle membrane whilst SNAP25 and syntaxin are attached to the plasma 
membrane. These proteins have similar coiled-coil stretches known as SNARE 
motifs. SNAP25 contributes two of these SNARE motifs to the complex and is 
Synaptotagmin  
Synaptobrevin  
SNAP25  
Syntaxin  
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attached to the plasma membrane by a palmitoylated linker rather than a 
transmembrane region. During the complex association, the four alpha helices form 
a tight bundle, known as zippering, that brings the membranes into close proximity.  
The Ca2+ sensor for fusion, synaptotagmin, is present on the vesicle membrane and 
possesses two C2 domains. C2 domains are formed of B sandwiches that contain Ca2+ 
binding loops. These C2 domains are able to bind to phospholipids on the inner 
leaflet of the plasma membrane only once they are in complex with Ca2+. It has also 
been found that the synaptotagmin C2 domains can also bind syntaxin (Jahn and 
Fasshauer, 2012).  
The mechanism by which Ca2+ binding to synaptotagmins initiates the final steps of 
fusion is unclear. The accepted models either have synaptotagmins interacting with 
SNARE proteins or with the plasma membrane. In the former case, Ca2+ binding 
either releases a synaptotagmin clamp on fusion (Chicka et al., 2008), or does the 
opposite and displaces a clamp to SNARE-zippering and fusion (Yang et al., 2010). 
Alternatively, it might bind the membrane through the C2 domains, overcoming the 
energy barrier to fusion either by disrupting the phospholipids close to the fusion 
site (Stein et al., 2007), or by increasing the membrane curvature stress (Hui et al., 
2009; Martens et al., 2007). 
Botulinum toxin and tetanus toxin both act by cleaving components of the SNARE 
machinery. BotNT cleaves SNAP-25 whilst TeNT cleaves synaptobrevin (VAMP2). In 
both cases the inhibition of exocytosis in the brain is typically fatal. These toxins 
have provided valuable research tools for uncovering the roles of SNARE proteins in 
different exocytic events. 
Though the SNARE-synaptotagmin model goes a long way to explaining exocytosis 
in neurons, this model does not account for a large range of Ca2+ activated fusion 
events occurring in cells.  After deletion of multiple synaptotagmin isoforms, 
extensive Ca2+ activated exocytic processes still occur in classical secretory cells over 
seconds (Schonn et al., 2008), and Ca2+ activated exocytosis that doubles the surface 
membrane area in non-secretory cells is entirely unaffected by the deletion of 
synaptotagmins(Wang and Hilgemann, 2008). No other mechanisms for exocytosis 
have so far been proposed. 
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1.3.1.4 Exocytosis in T lymphocytes 
Regulated exocytosis triggered by Ca2+ influx in T lymphocytes is crucial for their 
effector function. A key focal point for these events is the immune synapse. In this 
space the membranes of the lymphocyte and APC/target cell come into close contact 
and signals are sent and received both by transmembrane and secreted proteins. 
Polarised secretion of lytic granules by CD8+ CTLs is the primary mechanism of 
target-cell killing. These granules contain two major effector proteins – the pore-
forming protein perforin that facilitates the entry of the other, granzyme, which in 
turn initiates apoptosis of the target cell (Stinchcombe and Griffiths, 2007).  
Several SNARE proteins have been associated with lytic granule exocytosis although 
there is uncertainty about the exact machinery involved. Syntaxin 11 is strongly 
implicated as its congenital deficiency gives rise to familial hemophagocytic 
lymphohitiocytosis type 4 (FHL4) in which CTLs lose their cytotoxic function (zur 
Stadt et al., 2005). This may be due to defects in vesicular traffic upstream of lytic 
granule exocytosis (Valdez et al., 1999). However there is evidence of Syn11 
accumulation at the immune synapse, co-localised with lytic granules, implying a 
direct role (Halimani et al., 2014). Knockdown of VAMP 7 and 8 does inhibit but does 
not block granule exocytosis (Loo et al., 2009; Marcet-Palacios et al., 2008). There is 
recent evidence that synaptobrevin 2 (VAMP2) may be the v-SNARE for lytic granule 
exocytosis in cytotoxic T cells, with both expression of tetanus toxin and knockdown 
of VAMP2 preventing lytic granule fusion (Matti et al., 2013). 
Lytic granules are also known as secretory lysosomes; this is because their 
exocytosis is also associated with the expression of Lysosomal Associated Membrane 
Proteins 1 and 2 (LAMP 1/2)(Betts and Koup, 2004). These are not the only proteins 
to be trafficked to the synapse by non-secretory exocytosis. In Soares et. al. it was 
demonstrated that Lck, TCR-ζ chain and LAT are all trafficked to the immune 
synapse in vesicles and exocytosed in distinct nano-territories (Soares et al., 2013). 
This was shown to be important for TCR signalling and downstream Erk activation, 
CD69 expression and IL-2 and IFN-g production. The Ca2+ sensor for LAT and TCR-ζ 
chain vesicular fusion is Syn7 with knockdown leading to deficient T cell activation. 
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1.3.1.5 Cell Membrane Repair by Exocytosis 
So far much of the regulated exocytosis discussed has involved small cargos 
exocytosed in a targeted manner into defined areas such as the immune or neuronal 
synapse in response to localised increases in Ca2+ through gated-channels. Another 
form of large, bulk exocytosis occurs following cell membrane injury when the cell is 
flooded with Ca2+.  
Plasma membrane injury can have rapid and catastrophic implications for the cell, 
so mechanisms are therefore in place for rapid resealing. Physiologically, certain cell 
types are constantly subject to mechanical disruptions of the plasma membrane, 
including skeletal muscle and fibroblasts. Other cell types are subject to the effects 
of pore forming toxins (McNeil and Kirchhausen, 2005). Ca2+ influx through the 
disrupted plasma membrane is the trigger for membrane resealing. Though 
necessary for repair, Ca2+ can also be highly toxic to cells, so speed of responses is 
crucial to cell survival. Membrane fusion events have been shown to be essential for 
the timely repair of plasma membranes. The Ca2+ threshold for this type of 
exocytosis is significantly higher than that needed for other forms of regulated 
exocytosis, in the range of 10-30µM or higher (Coorssen et al., 1996; Yaradanakul et 
al., 2008). This raises several important questions: how does exocytosis promote 
repair? What is the membrane lipid exocytosed? How is Ca2+ influx sensed? What is 
the machinery for cell repair by exocytosis?  
It is widely accepted that the exocytosis of membranes serves to form a membrane 
patch that restores the continuity of the plasma membrane. It is also known that a 
decrease in membrane tension promotes membrane repair and that exocytosis of 
new membrane can facilitate this loss in tension (Togo et al., 2000). The patch 
hypothesis has been confirmed by multiple studies that have shown the 
accumulation of internal membranes at the site of disruption. The identity of these 
membranes is, however, a matter of controversy. 
In 1995 it was discovered that lysosomal membranes localise and fuse to the site of 
Trypanosoma cruzi invasion (Andrews, 1995) and later the same group discovered 
that lysosomal fusion occurs at the site of plasma membrane injury in a Ca2+ 
dependent manner (Reddy et al., 2001). Cell injury was rapidly followed by the 
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appearance of lysosomal associated proteins on the plasma membrane, reinforcing 
this hypothesis. However subsequent work has found that normal membrane repair 
can occur in cells with defective lysosomal exocytosis, and in the presence of the 
small molecule vacuolin that blocks lysosomal exocytosis (Cerny et al., 2004). There 
is no current evidence that other organelles such as the endoplasmic reticulum or 
the Golgi donate membranes for repair. There has, however, emerged a new 
organelle named the “enlargesome” which may provide the source membrane. This 
poorly characterised pool of membranes is ubiquitous and can patch damaged 
plasma membrane in a Ca2+ dependent manner (Cerny et al., 2004; Cocucci et al., 
2004). The requirement for lysosomes and enlargesomes for membrane repair in 
different cell types remains unclear. 
A key question that arose following the discovery that lysosomes could fuse and 
repair damaged membranes was as to the identity of the Ca2+ sensor. Work from the 
original lysosomal repair group implicated synaptotagmin VII. Using blocking 
antibodies against SynVII, that were micro-injected into cells, lysosomal fusion and 
membrane repair could be inhibited (Andrews, 2002; Chakrabarti et al., 2003; 
Martinez et al., 2000). Subsequent SynVII knockout studies showed no inhibition of 
lysosomal fusion or membrane repair (Jaiswal et al., 2004; Wang and Hilgemann, 
2008). SynIII blocking peptide has been shown to inhibit membrane repair in giant 
squid axons (Detrait et al., 2000), but no further follow-up studies have confirmed 
this in other cell types.  
Following membrane damage, intracellular Ca2+ levels may reach levels sufficient for 
direct binding of Ca2+ to anionic phospholipids on the inner leaflet of the membrane. 
High Ca2+ has been found to induce fusion of artificial membrane vesicles (Wilschut 
et al., 1981). However, magnesium is not able to induce membrane repair responses 
despite binding to anionic lipids with equal affinity (Steinhardt et al., 1994).  
As discussed above, the protein complex necessary for regulated exocytosis in many 
cell types is the SNARE machinery. Tetanus toxin blocks cell repair in 3T3 cell (Togo 
et al., 1999) and sea urchin eggs (Bi et al., 1995) indicating that at least 
synaptobrevin is important in exocytosis based repair, but no further work has 
identified which SNARE proteins are involved (for example by knockout studies) or 
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shown consistency across cell types. A new class of proteins that may be important 
in the fusion machinery is the dysferlins. Dysferlin localises to sites of membrane 
injury and dysferlin-null mice show defects in membrane repair (Bansal et al., 2003). 
Moreover, lack of dysferlin in humans leads to a profound muscular dystrophy that is 
thought to be due to defective muscular repair (Liu et al., 1998).  However no role for 
dysferlins in regulated exocytosis has yet been demonstrated. Other proteins 
implicated in repair are the Ca2+ dependent membrane binding proteins annexins, 
but despite observed binding of annexins to sites of membrane damage, no 
functional role or link to exocytosis has been shown (McNeil and Kirchhausen, 
2005). 
Despite considerable work directed towards understanding the mechanisms and 
protein players involved in membrane repair by exocytosis, few answers have 
emerged. Research so far has failed to demonstrate consistently that either 
lysosomal membranes or SynVII are necessary for plasma membrane repair or to 
uncover alternative mechanisms for Ca2+ sensing. Contradictory studies demonstrate 
that this process may be more complex than initially thought and that answers may 
lie outside the existing paradigms of the proteins and membranes thought to be 
involved. 
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1.3.2 Endocytosis 
Endocytosis is the process by which areas of surface plasma membrane, with 
associated transmembrane proteins or extracellular cargos, are taken inside the cell. 
This can rapidly change the way in which cells interact with their environment by 
remodelling the array of functional proteins able to signal across the membrane. 
This is especially important in lymphocytes whose function is to detect and respond 
appropriately to extracellular signals transmitted by other cells. Endocytosis can be 
highly selective, with mechanisms initiated by single transmembrane proteins, or 
non-selective, with large areas of membrane internalised, as in the case of 
phagocytosis and macropinocytosis. 
For endocytosis to occur the plasma membrane must curve inwards to the point at 
which it can be split and resealed, a process known as fission, thereby detaching the 
newly formed endocytic vesicle from the plasma membrane. There are multiple 
forms of endocytosis employed by different cells with many mechanisms that carry 
out curvature and fission. 
A classical and extensively researched form is clathrin-mediated endocytosis in 
which protein adapters coordinate the polymerisation of clathrin into a curved 
basket structure. Once the membrane has been curved sufficiently to produce a 
constricted neck, the protein GTPase dynamin completes membrane fission. The 
primary adapter for clathrin-mediated endocytosis is adapter protein-2 (AP2) that 
binds to specific di-leucine or tyrosine-based motifs on the intracellular domains of 
transmembrane receptors. 
1.3.2.1 Ca2+ and endocytosis 
Many studies have shown that raised intracellular Ca2+ is linked to the rapid 
internalisation of membrane. This endocytosis results in the generation of large 
non-acidified intracellular vesicles, and has been described as ‘massive’, ‘excessive’ 
and ‘bulk’. Though these studies agree on the extent and speed of membrane intake, 
they differ on the machinery involved. Some have found dynamins are necessary 
(Clayton and Cousin, 2009), others found it to act independently of clarthrin 
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(Thomas et al., 1994), and Larricia et al. found it to be independent of all classical 
endocytic machinery (Lariccia et al., 2011). What is clear is that this Ca2+ induced 
endocytosis is very different to other forms of endocytosis and warrants further 
investigation.  
The Ca2+ threshold and mechanism of Ca2+ entry is likely to be key to understanding 
the role of this endocytosis. In Oocytes endocytosis can be triggered following influx 
through Ca2+ channels (Vogel et al., 1999), but in most cell types the Ca2+ threshold 
for endocytosis is high, suggesting a role in cell membrane repair. Indeed Idone et al. 
observe that a rapid Ca2+ activated endocytosis is necessary for membrane repair of 
SLO toxin pores in NRK cells (Idone et al., 2008). 
As described earlier, exocytosis has been shown to be a general mechanism for 
membrane repair where internal membranes are used to patch wounds. Lariccia et 
al. found exocytosis to precede large Ca2+ induced endocytosis in BHK and HEK293 
cells. This was an observation also made by Tam et al. who then proposed that 
exocytosis was necessary for subsequent endocytosis (Tam et al., 2010). They 
presented evidence that lysosomal exocytosis secreted acid sphingomyelinases onto 
the outer leaftlet of the plasma membrane. These enzymes break down 
sphingomyelin to ceramide and phosphitidylcholine. Production of ceramide 
domains on one leaflet of the membrane causes inward membrane curvature, 
budding and fission of artificial membrane liposomes (Bollinger et al., 2005; Goñi 
and Alonso, 2009; Holopainen et al., 2000).  
This was an attractive model, uniting exocytosis and endocytosis and providing a 
mechanism that is independent of internal protein machinery. However subsequent 
work by the Hilgemann lab has cast this model into question. Lariccia et al. found 
that endocytosis could indeed be induced by the extracellular application of SMases, 
but that this was not linked to Ca2+ activated endocytosis. Firstly, endocytosis was 
unaffected by application of high concentrations of the SMase inhibitor desipramine 
(reported to be effective in Tam et al.). Secondly, exocytosis and endocytosis could 
be uncoupled completely by addition of intracellular polyamines. Both these 
findings are incompatible with the idea that endocytosis is triggered by secreted acid 
sphingomyelinases. No further lines of evidence have emerged to support the 
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hypothesis proposed by Tam et al. but no alternative models have been proposed 
either. 
Larricia et al. describe a form of Ca2+ activated endocytosis they call ‘Massive 
endocytosis’ (MEND) which was demonstrated in BHK and HEK293 as well as in 
mouse myocytes. The Hilgemann lab are able to track membrane movements in real-
time using measurements of cell capacitance via whole cell patch clamp. As well as 
being a very accurate method for measuring exocytosis and endocytosis, this 
technique also provides access to the cytoplasm of the cell, allowing for the use of 
cell-impermeable proteins and inhibitors that facilitate the manipulation of multiple 
signalling pathways. MEND comes in both immediate (fast) and delayed forms. The 
mechanism for the ‘delayed’ form of MEND involves the palmitoylation of surface 
proteins by DHHC5, following release of CoA from mitochondria (Hilgemann et al., 
2013).  
In fast MEND, up to 50% of the plasma membrane can be taken up in a matter of 
seconds. Lariccia et al. directed a lot of effort towards understanding which proteins 
were involved in both Ca2+ sensing and endocytosis, and what was remarkable is that 
they found no answers. Fast MEND is independent of ATP, GTP, actin, microtubules, 
dynamin, clathrin, calmodulin, Ca2+ activated phosphatases and proteases. Having 
been unable to implicate any classical structural or adapter proteins in the 
mechanism, they next looked to constituents of the plasma membrane. PIP2 was an 
attractive candidate as it is a substrate for adapters and G proteins that possess PH 
domains but also there was evidence that reagents affecting membrane composition 
such as cholesterol loading or depletion had an effect on endocytosis. Unfortunately 
PIP2 depletion was unable to block fast endocytosis. Parallel work in Fine et al. 
found that the application, or application and then washing, of amphipaths on the 
outer leaflet of the plasma membrane led to rapid MEND (Fine et al., 2011). This 
presented the possibility that Ca2+ activated MEND was triggered by rapid changes in 
plasma membrane composition with generation of new lipids causing membrane 
curvature. The only positive result in this direction was the potent inhibition of 
MEND by the phospholipase (PLA2) inhibitor BEL.  Perhaps Ca2+ activation of PLA2 
induces endocytosis in a similar way to internally applied lysolipids. As BEL is a 
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reasonably non-specific reagent, further work will be necessary, involving 
knockdown studies of phospholipases, in order to further investigate this 
hypothesis. 
1.3.3 Microvesicles 
It was previously thought that cells communicated only by secreted factors or 
through the interactions of plasma membrane-bound proteins. However, a new form 
of intercellular communication has become the focus of much research in recent 
years. It is now known that cells can release portions of their plasma and internal 
membranes as vesicles, bearing protein messengers. These vesicles come in a variety 
of sizes and are formed by different mechanisms. Microvesicles are sized up to 1µm 
and are shed directly from the plasma membrane, whilst exosomes are less than 
200nm in size and are released via the exocytosis of multi-vesicular bodies (MVB) in 
which they are produced. Exosomes will not be discussed in detail here but instead 
the focus will be on the lesser-characterised plasma membrane-derived 
microvesicles. 
As the study of these novel signalling effectors is still at an early stage, with many 
labs characterising them in different cell types, microvesicles have been christened 
with many names: ectosomes (Lee et al., 1993), microparticles (Cauwenberghs et al., 
2006) and shedding bodies (Cocucci et al., 2007) to name a few. They play a diverse 
role in many biological processes from blood coagulation to signalling in the brain. 
The specific study of microvesicles has proved challenging, as discriminating 
between microvesicles and exosomes in cellular supernatants is problematic. 
Nevertheless insights are emerging as to how they are produced and which proteins 
are sorted with them. 
1.3.3.1 Biogenesis 
Microvesicles derive from plasma membrane protrusions that have detached by 
fission. This process is poorly understood but has been linked to cell activation, and 
more specifically to increases in intracellular Ca2+. In multiple cell types, activation 
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of purinergic receptors or treatment with Ca2+ ionophores is quickly followed by 
extensive release of microvesicles (Heijnen et al., 1999; MacKenzie et al., 2001). 
Others have implicated protein kinase C activation (Pilzer et al., 2005) and recently 
the ESCRT machinery in microvesicle production (discussed later). 
 
Inherent in the process of microvesicle release is the loss of plasma membrane from 
the cell. This might be compensated for by compensatory exocytosis of internal 
membranes (Cocucci et al., 2007). The relationship between exocytosis and vesicle 
release is unclear. Whether one is necessary for the other or whether one precedes 
the other is unknown. One consistent observation, with special relevance to this 
study, is a delay of seconds to minutes between the onset of Ca2+ influx and 
microvesicle release (Cocucci et al., 2007; Lee et al., 1993; MacKenzie et al., 2001; 
Moskovich and Fishelson, 2007; Stein and Luzio, 1991). It has been hypothesised 
that this delay may be due to the need for preceding exocytosis (Cocucci et al., 
2009). 
1.3.3.2 Protein sorting 
As microvesicles play an important role in cellular communication it is important to 
understand which proteins are sorted onto their membranes. It has been 
demonstrated that specific molecules are both included and excluded in released 
microvesicle membranes with a variety of microscopic techniques (Cocucci et al., 
2007; Moskovich and Fishelson, 2007). Some studies have implicated membrane-
intrinsic factors in this sorting of proteins as the disruption of cholesterol 
metabolism has been found to have an impact on protein inclusion, suggesting the 
role of lipid domains (Del Conde et al., 2005; Stein and Luzio, 1991). The role of 
exocytosis is also an important factor in this sorting as microvesicles have also been 
found to be enriched in exocytic proteins such as annexins and desmoyokin whilst 
plasma membrane proteins such as Ka/K/ ATPase are excluded (Cocucci et al., 2007).  
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1.3.3.3 Physiological roles 
Microvesicles are shed from the surface of activated platelets following contact with 
collagen. These vesicles are thought to provide a surface upon which different stages 
of the clotting cascade can initiate (Sims et al., 1988). 
Microvesicles have been implicated in both pro-inflammatory and anti-
inflammatory responses and have been linked to inflammatory diseases including 
arthritis (Distler et al., 2005; Köppler et al., 2006). Inflammatory mediators can be 
located both in vesicle membranes and contained within shed in vesicles. 
Microvesicles have been found to constitute a novel secretory pathway, for example 
in the case of interleukin-1β, which cannot be secreted as it lacks the relevant 
secretory leader sequences. MacKenzie and colleagues found that IL-1β was 
contained within the lumen of shed microvesicles that were released following Ca2+ 
influx through purinergic receptors, stimulated by ATP. This secretory pathway 
operates by release of protein containing vesicles rather than direct secretion. 
Microvesicles are highly enriched in the tumour microenvironment and have been 
found to play a number of roles. These vesicles can be coated in matrix proteases 
that can digest the extracellular matrix, aiding metastasis and angiogeneisis 
(Ginestra et al., 1998; Giusti et al., 2008; Mochizuki and Okada, 2007). Vesicles can 
also absorb chemotherapeutic drugs, diluting the drugs’ ability to directly target 
cancer cells (Shedden et al., 2003). Lastly there is evidence that FasL bearing 
tumour-derived microvesicles can inhibit TILs, suppressing anti-tumour immune 
responses (Albanese et al., 1998; Kim et al., 2005). 
1.3.3.4 Microvesicles at antigen presentation 
As discussed previously, the immune synapse is the site at which T cells and APCs 
exchange and integrate signals that dictate the magnitude and characteristics of the 
following adaptive immune response. Recent work by Choudhuri and colleagues has 
changed the way in which we view the immune synapse (Choudhuri et al., 2014). It 
had previously been observed that a diffusion barrier exists at the centre of the 
immune synapse where TCRs and cytoplasm seem confined (Varma et al., 2006). 
 49 
This is in contrast to the borders of the synapse where protein movement is highly 
dynamic. In elegant work using planar bilayers that reconstitute APC membranes 
the authors imaged the immune synapse using a combination of transmission 
electron microscopy and TIRF microscopy. In this way they constructed a three-
dimensional model of the synapse and found a centrally located cavity in which 
TCR-enriched microvesicles were formed in an antigen-dependent manner. These 
microvesicles were fully detached from the plasma membrane and served to explain 
the diffusion barrier that existed at the IS centre. Interestingly the majority of these 
vesicles remained on the planar bilayer after the termination of antigen 
presentation. These remaining vesicles were able to induce Ca2+ signalling via TCR-
pMHC in primary B-cells. The authors next sought to understand the mechanism 
underlying microvesicle release in the synapse. They looked to the endosomal 
ESCRT protein complex known to cause budding and scission of vesicles into MVBs 
and viral particles from the cell membrane. They found that the ESCRT-I protein 
TSG101 is necessary for TCR enrichment into microvesicles and that the ESCRT-III 
protein VSP4 was necessary for vesicle scission. Questions remain as to how these 
proteins are recruited to the immune synapse and what factors drive membrane 
protrusion. 
In this way, vesicles may serve to regulate the two-way nature of antigen 
presentation in the IS. TCR downregulation, through sequestering receptors into 
microvesicles rather than by internalisation, might serve to terminate TCR 
signalling, whilst vesicle TCR-pMHC signalling persists. This could provide a form of 
T cell help – reinforcing B cell activity directed at a common target whilst limiting 
TCR signalling. The insights gained into the mechanism underlying vesicle 
formation provide clear avenues for future work directed towards understanding 
how vesicle release is important in regulating outcomes after antigen presentation. 
1.3.3.5 Cell membrane repair 
Patching of damaged membrane by exocytosis was discussed earlier, but another 
form of protective pathway exists. It has been demonstrated that pore-forming 
toxins induce budding and release of membrane microvesicles; presumably in order 
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to quickly remove small patches of damaged membrane(Atanassoff et al., 2014; 
Babiychuk et al., 2009; Keyel et al., 2011). Given this, Jimenez et al investigated the 
role of the ESCRT machinery in this process(Jimenez et al., 2014). They found a co-
localisation of the ESCRT protein CHMP proteins and ALIX at the sites of cell injury 
just preceding cell repair, and that this occurred in a Ca2+ dependent manner. 
Knockdown studies confirmed the role of these proteins in the rapid repair of small 
membrane holes. They also found that ESCRT recruitment to sites of damage was 
ATP independent, but microvesicle shedding was not.  
A key question that arises is as to the mechanism of Ca2+ dependent ESCRT 
recruitment to the plasma membrane. This has generally only been seen when 
ESCRT-III is overexpressed, lacks inhibitory domains or in the case of viral 
budding(Bodon et al., 2011; Hanson et al., 2008). It remains possible that exocytosis 
of endosomal membranes bearing ESCRT machinery could be involved in 
recruitment. The ESCRT component ALIX is localised to endosomes owing to a 
LBPA-binding domain. This phospholipid is found on endosomes but not on the 
plasma membrane. Their data ALIX can bind the plasma membrane suggests that 
either ALIX is able to bind other plasma membrane phospholipids, or that LBPA 
appears at sites of plasma membrane damage. Could this then be due to membrane 
exocytosis? The authors think not for two reasons. Firstly, because co-staining of 
endosomal and lysosomal markers LBPA, Lamp1 and EEA1 with ESCRT protein 
CHMP4 showed no co-localisation at sites of membrane injury, and secondly 
because the recruitment was energy independent. Recent work also implicates the 
EF-hand containing ALG-2 in the Ca2+ dependent accumulation of the ESCRT 
complex at sites of injury (Scheffer et al., 2014). Recruitment of soluble ESCRT-III 
proteins may therefore be a plausible alternative to vesicular transport. It should 
however be noted that in the absence of clarity surrounding the internal membranes 
or protein machinery (whether ATP dependent or independent) involved in exocytic 
membrane repair, vesicular transport may not be rejected as a possible mechanism 
for ESCRT-III recruitment to the plasma membrane. 
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1.3.4 Phospholipid Scrambling 
1.3.4.1 Plasma Membrane Phospholipid Structure and Distribution 
Segregation, concentration and compartmentalisation are necessities of living cells. 
Life cannot occur without a barrier to enclose, protect and define biochemical 
reactions. The 30Å thick membranes that provide these boundaries are complex 
structures composed mainly of lipids on which proteins can be organised. 
The plasma membrane is composed of amphipathic phospholipids that form a 
continuous bilayer, defining the cell boundaries and providing a diffusion barrier. 
Proteins are able to move, cluster and be organised in membrane territories. 
Membrane lipids can themselves act as signalling messengers, with changes in 
plasma membrane phospholipid distribution providing apoptotic ‘eat me’ signals 
(Miyanishi et al., 2007; Park et al., 2007) and surface to initiate coagulation.  
The plasma membrane is composed mainly of the glycerophospholipids: 
Phophatidylcholine (PC), Phosphatidylethanolamine (PE), and Phosphatidylserine 
(PS), which have diacylglycerol (DAG) backbones, and Sphingomyelin (SM) which 
has a ceramide backbone. Phosphatidylinositides are also present at low 
concentrations that serve as important signalling molecules in different 
phosphorylation states. Cholesterol provides important stability and flexibility to 
the membrane and forms high-density domains in complex with sphingolipids (van 
Meer et al., 2008).  
A striking feature of the plasma membrane phospholipids is their asymmetric 
distribution across outer and inner monolayer. PC and SM are found mostly on the 
outer monolayer and PS and PE on the inner. This is maintained by ATP dependent 
flippases and floppases that pump phospholipids to their respective leaflet. The 
‘flippase’ protein responsible for translocating PS and PE to the inner monolayer is 
ATP11C and is well characterised whereas the identity of the ‘floppase’ is unknown 
(Paulusma and Elferink, 2010). 
From studies on model membranes, it is believed that spontaneous movement of 
phospholipids from one leaflet to the other is very slow – taking from hours to days 
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(Pomorski and Menon, 2006). Under certain physiological conditions, very rapid 
‘scrambling’ of membrane phospholipids occurs.  
1.3.4.2 Functions of Phospholipid Scrambling 
It was discovered in 1992 that PS appearance on the outer leaflet of the plasma 
membrane is a hallmark of apoptotic cells. The PS binding protein Annexin V is 
therefore widely used as a maker of cell death. It has also been found that PS 
exposure can be non-apoptotic in B cells, platelets, macrophages, skeletal muscle 
cells, red blood cells, sperm cell capacitation mast cells, and T lymphocytes, a 
process linked to Ca2+ influx and cell activation (Bevers and Williamson, 2010; 
Fischer et al., 2006). 
Functionally, membrane scrambling during apoptosis is thought to tag dead cells 
with an ‘eat-me’ signal, helping phagocytes to recognise and clear dead cells 
(Miyanishi et al., 2007; Park et al., 2007). Non-apoptotic functions of PS exposure 
are best characterised in the platelet, where membrane PS serves as binding sites for 
clotting factors. In erythrocytes it is thought to promote adhesion to endothelial 
cells (Manodori et al., 2000) and in muscle development aid myotube formation(van 
den Eijnde et al., 2001). In immune cells it has been linked to mast cell 
degranulation (Demo et al., 1999), and microvesicle shedding in both T lymphocytes 
and macrophages (Elliott et al., 2005; MacKenzie et al., 2001). It is unclear whether 
scrambling is a cause or consequence of these processes. 
Elliot et al. were the first to notice non-apoptotic PS exposure in T lymphocytes, on 
a subset of activated memory CD4+ mouse T cells (Elliot Nat cell biology 2005). They 
found an inverse correlation between PS exposure and CD45 expression as well as 
purinergic P2X7 receptor activity. There was an association also with CD62L 
shedding in microvesicles. Furthermore PS exposure caused both a reversal in 
multidrug transporter P-glycoprotein and supported cell migration. The authors 
concluded that these wide-ranging effects of PS distribution constituted a novel 
signalling modality in T lymphocytes. 
Independent work by Fischer et al demonstrated that PS exposure occurred in 
Melan-A-specific human T cells when activated with antigen or antiCD3CD28 
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antibodies. This exposure was rapid, not associated with apoptosis and reversible 
over three days following activation. Interestingly, following imaging studies on the 
activated primary T cells, the authors found the distribution of PS was non-
homogenous and appeared in patches. These patches were colocalised to lipid rafts 
when cells were stimulated with anti-CD3CD28. When imaging CTLs in association 
with antigen-loaded T2 cells, they found PS exposure was restricted to the immune 
synapse. Further work is needed to confirm and clarify the roles of membrane 
scrambling in T lymphocyte biology. It will be important to establish whether 
membrane scrambling is itself functional or whether it is a consequence of other 
processes occurring at the plasma membrane.  
Without an understanding of the identity of the protein responsible for scrambling, 
further insights into the physiological significance of PS exposure in other tissues 
were not forthcoming.  
1.3.4.3 The Search for a Scramblase 
With the discovery that normal asymmetric phospholipid redistribution on the 
plasma membrane can be rapidly scrambled in the response to certain stimuli, the 
search began for a protein responsible. Work in this area had a confused beginning 
as initially it was unclear whether there was one or several scramblases. The first 
protein to be isolated and cloned from a fraction of platelet and red blood cell lysate 
that scrambled membranes in reconstitution experiments was named Phospholipid 
Scramblase 1 (PLSCR1). Cell scrambling seemed to correlate well with mRNA and 
protein levels in different cell types (Zhao et al., 1998; Zhou et al., 1997) and 
expression of PLSCR1 in low-scrambling cells seemed to activate scrambling(Zhao et 
al., 1998). However later knockout and knockdown studies showed no impact on 
scrambling, indicating that the wrongly named PLSCR1 is not the membrane 
scramblase (Fadeel et al., 1999; Zhou et al., 2000). Other proteins - ABC1 (Hamon et 
al., 2000) and Tat-1 (Züllig et al., 2007) have been implicated but that implication 
later disputed. The Ca2+ threshold for scrambling is reasonably high at around Ca2+ 
25-100µM (Williamson et al., 2001; Woon et al., 1999). 
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Work on cells from patients with Scott Syndrome (discussed below), which do not 
scramble their membranes in response to Ca2+, showed that apoptotic scrambling 
was maintained whilst Ca2+-induced was abolished (Williamson et al., 2001). This 
suggested that there are two scramblases, one Ca2+ and one apoptosis induced. Work 
in the last five years has confirmed this assertion by identifying the ‘scramblases’ 
involved. 
1.3.4.4 TMEM16F 
In 1979 a case report was published describing a severe bleeding disorder in a 34-
year-old woman named Mrs MA Scott. The authors speculated that this was due to a 
deficiency in factor Xa binding sites on platelets (Weiss et al., 1979). In 1985 it was 
found that these binding sites were phosphatidylserine molecules on the outer 
leaflet of activated platelet cell membranes (Rosing et al., 1985). Ca2+ activated 
translocation of phosphatidylserine from the inner to the outer leaflet of the plasma 
membrane is seen in the majority of cell types and is known as membrane 
scrambling. The search for the protein responsible has been a focus of much 
research since. 
In 2010 Suzuki and colleagues adopted a methodical approach to identifying the Ca2+ 
activated scramblase (Suzuki et al., 2010). Using multiple rounds of cell sorting they 
were able to isolate a clone of Ba/F3 cells that had constitutively scrambled 
membranes with low Ca2+ activation. They then constructed a cDNA library from that 
clone and transformed the cDNA back into the parental Ba/F3 cell line. They then 
sorted transformed cells that now constitutively scrambled their membranes and by 
sequencing the introduced cDNA identified TMEM16F as the gene responsible. An 
A-G nucleotide mutation caused a mutation (D409G) in TMEM16F which confers 
constitutive scrambling capacity. The authors went on to sequence the TMEM16F 
gene in immortalised B-cell from a patient with Scott syndrome as well as the 
patient’s parents. They found a homozygous G-to-T mutation at the splice-accepter 
site in intron 12 in the patient and the heterozygous mutation in both parents’ 
genes. Analysis of the patient TMEM16F mRNA demonstrated that Exon 13 was 
skipped in the transcripts, causing a frame shift that resulted in premature 
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termination at exon 14. Subsequent studies by other groups have since confirmed 
that mutations in TMEM16F are the cause of Scott syndrome (Castoldi et al., 2011). 
Attention then turned to the phenotype of the knockout mouse. These mice indeed 
have a clotting disorder very similar to that of Scott syndrome, with increased 
bleeding time and impaired thrombus formation (Yang et al., 2012). In addition 
these mice have impaired bone mineralisation, a phenotype not present in patients 
with Scott syndrome, and potentially more subtle phenotypes yet to be identified. 
Remarkably researchers had correctly predicted that the location of the ‘scramblase’ 
gene would be on chromosome 12 earlier in 2010. An inbred strain of German 
shepherd dogs possess a clotting and scrambling defect identical to Scott Syndrome 
and genome-wide studies had revealed causative defect of the canine Ch27, 
equivalent to human chromosome 12 (Brooks et al., 2010; Brooks et al., 2002). 
TMEM16F is a member of the anoctamin family of Ca2+ activated ion channels. Every 
member possesses eight transmembrane domains. TMEM16A and B are Ca2+ 
activated chloride channels. It was thought that the whole family were anion 
channels hence the name Ano- (anion) –octamin (eight transmembrane domains) 
but this has slowly come into question, hence the reversion to the TMEM16 name. A 
striking feature of the family is the wide variation in Ca2+ sensitivity and the 
unconventional site of Ca2+ sensing. None of the family possesses classical Ca2+ 
binding domains but the family thought to bind Ca2+ with motifs in one of their 
membrane spanning domains. 
There are conflicting reports concerning the function of TMEM16F as an ion 
channel. Different groups have reported it as a Ca2+ activated chloride channel (Tian 
et al., 2012), a volume activated chloride channel (Almaça et al., 2009), and others as 
a hyperpolarisation activated chloride channel (Martins et al., 2011). TMEM16F has 
been demonstrated to be a delayed activation channel in multiple studies (Grubb et 
al., 2013; Kim et al., 2015). This means that the channel can delay activation even 
having reached its Ca2+ threshold for firing – a delay that decreases with increasing 
intracellular Ca2+.  
Yang et al carried out considerable work directed towards resolving the issue of ion 
conduction by TMEM16F. Surprisingly they found TMEM16F to be a non-selective 
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cation channel capable of conducting large ions including Ca2+. The authors 
concluded that the channel resembled a large 6Å pore able to non-selectively 
conduct cations when activated by Ca2+. They found that in multiple cell lines, 
including HEK293 cells, heterologous expression of TMEM16F was not able to induce 
Ca2+ activated phospholipid scrambling – a result also found by Suzuki et al. The 
authors concluded that the channel is necessary but not sufficient for membrane 
scrambling and that it is the cation current induced by TMEM16F that operates 
alongside an unknown scramblase. The findings that supported this hypothesis were 
that megakaryocytes (precursors to platelets) possessed a Ca2+ activated cation 
current similar to that of TMEM16F and that the D409G mutation had a significant 
impact on the thresholds of the ion current. 
Other groups however have drawn different conclusions. Some have shown that 
heterologous expression of TMEM16F is capable of enhancing phospholipid 
scrambling, arguing for direct scrambling by TMEM16F (Yu et al., 2015), and others 
have found that TMEM16F induced ion currents and phospholipid scrambling could 
be separated (Kmit et al., 2013) using channel inhibitors, whereas another study 
showed that channel blockers could inhibit phospholipid scrambling (Taylor et al., 
2008b). 
With many conflicting and incompatible findings and conclusions being made by 
multiple groups adopting different approaches, the need for some structural insights 
was clear. This came at the end of 2014 when Brunner and colleagues published the 
crystal structure of an ancestral TMEM16F from Nectria haematococca (Brunner et 
al., 2014). Firstly, having purified large amounts of protein, the authors used a 
liposome-based assay to assess the ability of the protein to translocate 
phospholipids. They demonstrated that there was phospholipid translocation in 
liposome that bore nhTMEM16 and that this was non-selective to phospholipids and 
enhanced by the addition of Ca2+. This was backed up by work carried out by 
Malvezzi and colleagues who had reconstituted TMEM protein from Aspergillus 
fumigatus and reported similar results in liposome-based assays (Malvezzi et al., 
2013). They also were able to detect non-selective anion and cation currents in 
afTMEM containing vesicles. 
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Brunner et al next solved the crystal structure and found there to be a hydrophilic 
cleft that the authors concluded might be capable of translocating phospholipids as 
well as conducting ions. Yu et al. were also able to afford TMEM16A with scrambling 
capacity by transferring this domain from TMEM16F. These lines of evidence point 
towards the fact that TMEM16 is indeed a protein with the dual ability to conduct 
ions and phospholipids mediated through a protein intrinsic domain.  
There are however a number of factors to consider that add uncertainty to these 
conclusions. Firstly, it was found that considerable scrambling could occur even in 
the absence of Ca2+ in liposomes containing the ancestral TMEM proteins. Other 
proteins have previously been implicated as phospholipid scramblases using similar 
cell-free reconstitution assays (Acharya et al., 2006; Bevers and Williamson, 2010; 
Fadeel and Xue, 2009; Ory et al., 2013). This calls into question the validity of a 
liposome based assay as a surrogate for the plasma membrane. Also experiments 
directed towards characterising the ion conduction through afTMEM16 may be 
unreliable as the channel activity was shown to be very low. Although the hypothesis 
that a hydrophilic cleft is able to translocate phospholipid is compelling no direct 
evidence of this exists beyond reconstitution assays. Finally conclusions drawn from 
fungal homologues may not be transferable to mammalian or indeed human 
TMEM16F. 
1.3.4.5 An Alternative Model to a ‘Scramblase’ 
Though the popular model for membrane scrambling is the activation of a protein 
‘scramblase’, work by a number of labs has suggested an alternative hypothesis. 
It has long been observed that mast cells expose PS following exocytosis of their 
granules. This degranulation is triggered by Ca2+ influx so may just be concurrent 
activation of a protein scramblase. However, studies have shown that PS exposure 
(measured by AnxV binding) appears in distinct punctae on the plasma membrane, 
which coincide with sites of vesicle fusion (Demo et al., 1999). The link is so strong 
that AnXV binding is even used as a read out for mast cell degranulation by many 
labs (Martin et al., 2000).  
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Given that Ca2+ influx is known to cause both membrane scrambling and trigger cell 
repair by the exocytosis of lysosomes (or other internal membranes), Mirnikjoo and 
colleagues investigated the possibility that the two events were linked. The authors 
loaded cells with Rhodamine conjugated PE at 37oC until it was internalised into 
endosomal membranes, then the PM was washed of Rhod-PE and cells treated with 
Ca2+ ionophore. What they found was a rapid redistribution of the fluorescent lipid 
back to the plasma membrane and concurrent membrane scrambling. They observed 
the same phenomenon when triggering apoptosis in the cells using STS. 
Furthermore they could block both membrane scrambling and Rho-PE redistribution 
using the lysosomotropic chloroquine. This suggested that fusion of internal 
membranes with the plasma membrane was the origin of scrambled membrane. The 
authors concluded that membrane scrambling constituted a suicidal ‘pseudo-
membrane repair’ mechanism. 
Follow-up work to this study was carried out by Lee et al., prompted by the 
observation that some cells scramble their membranes more than others (Lee et al., 
2013). Having gathered cell lines with both high and low membrane scrambling in 
response to Ca2+ ionophore and apoptosis the authors asked some simple questions. 
Do cells that scramble their membrane contain more phosphatidylserine? They 
carried out total cell AnxV staining and found no difference. Do some cells contain 
intrinsic scramblase inhibitors? Fusing T98G cells that do not scramble with Jurkat 
cells that do did not inhibit membrane scrambling. Can overexpression of TMEM16F 
convert the phenotype? Overexpression of TMEM16F did nothing. Further work 
carried out in the paper implicated the fusion of internal membrane vesicles with the 
PM as the trigger for PS exposure.  This study will be reviewed in further detail and 
has relevance to Chapter 5 as the internal membranes implicated were a pool that 
only appear during apoptosis. These two studies are however not entirely in 
agreement. Lee et al found no decrease in lysosomal bulk or inhibition of PS 
exposure by chloroquine.  
Taken together, though the model of a protein ‘scramblase’ is generally accepted 
and recent work has even suggested there to be a ‘scrambling domain’ in the 
structure of TMEM16F that may be the active site for phospholipid translocation, 
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certain factors in the model do not make sense. An alternative hypothesis that the 
fusion of internal membranes is the trigger linked to PM scrambling has recently 
been proposed. This also raises many questions such as: what is the machinery for 
this exocytosis? How is it linked to TMEM16F? How does membrane fusion cause 
membrane scrambling? How do red blood cells, that have no internal membranes, 
still scramble membranes? Further work is needed to reconcile these opposing 
models. 
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2.1 Materials 
2.1.1 Buffers and Reagents 
 
 
Table 2.1 Buffers and Gels 
 Buffers Recipe 
Phosphate Buffered Saline (PBS) 137 mM NaCl 
 
2 mM KCl 
 
10 mM Sodium Hydrogen Phosphate 
 2 mM Potassium Hydrogen Phosphate  
Blocking Buffer PBS 
  10% Goat Serum 
LB Broth 10% NaCl 
 
1% bacto-trptone 
 0.5% bacto-yeast extract 
LB Agar LB Broth w/bacto-agar 15g/L 
Agarose Gel 1% Agrose 
 
1X TAE Buffer 
 5ug/ml Ethidium Bromide 
Tris -acetate EDTA (TAE Buffer) 40 mM Tris HCl 
 
1 mM EDTA 
 20 mM Sodium Acetate 
Transformation Buffer (TBF)-I 100 mM rubidium chloride 
 
50 mM magnesium chloride 
 
30 mM potassium acetate 
 
10 mM calcium chloride 
 
15% glycerol 
 to pH 5.5 with acetic acid 
TBF-II 75 mM calcium chloride 
 
10 mM MOPS 
 
10 mM rubidium chloride 
 
15% glycerol 
 to pH 6.5 with KOH 
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Table 2.2 Solutions for Electrophysiology  
 Buffers pH Recipe 
Standard Ringer Solution 7 145 mM NaCl 
  
10 mM HEPES 
  
2 mM CaCl2 
  
2 mM MgCl2 
Standard Cytoplasmic Solution (KCl) 7.4 145 mM KCl 
  
10 mM HEPES 
  
0.5 mM EGTA 
  
0.25 mM CaCl2 
  
8 mM MgATP 
  
2 mM Tris ATP 
    0.2 mM GTP 
NMDG Aspartate 7 145 mM N-Methyl-D-glucamin 
  
145 mM Aspartic Acid 
  
10 mM HEPES 
when intracellular 
 
 + 8 mM MgATP + 2 mM Tris ATP + 0.2 mM GTP 
when extracellular  
 
 + 2 mM CaCl2 + MgCl2 
Sucrose Solution 7 240 mM sucrose 
  
5 mM KCl 
when intracellular 
 
 + 8 mM MgATP + 2 mM Tris ATP + 0.2 mM GTP 
when extracellular  
 
 + 2 mM CaCl2 +2 mM MgCl2 
NCX1 Cytoplasmic 7 80 mM LiOH 
  
20 mM TEA-OH 
  
15 mM HEPES 
  
40 mM NaOH 
  
 0.5 mM MgCl2 
  
 0.5 mM EGTA 
  
0.25 mM CaCl2 
  to pH with aspartate 
NCX1 Extracellular  7 120 mM LiOH 
  
4 mM MgCl2 or 4 mM CaCl2 
  
20 mM TEA-OH 
  
10 mM HEPES 
  
0.5 mM EGTA 
  to pH with aspartate 
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Table 2.3 Reagents, Dyes and Proteins 
  Reagent Conc. Manufacturer 
Ionomycin Free Acid 2-20 µM Carbiochem 
Tetanus Toxin L-chain 400 nM Alpha Universe LLC 
Latrunculin A 3 µM Sigma-Aldrich 
Philloidin 10 µM Tocris 
Myristoylated Dynamin inhibitory peptide 3 µM Tocris 
Spermine 50 - 500 µM Sigma-Aldrich 
FM 4-64 5 µM Life Technologies 
Fluo 4 AM 1 µM  Life Technologies 
K7 - Rhodamine 3 µM NeoMPS, Inc. 
PD-L1-Fc Chimera 1-2 µg/ml R&D Systems 
Etoposide 2 µM Sigma-Aldrich 
 
 
 
 
 
 
 
 
Table 2.4 FACS Antibodies and Reagents 
  Target Species Clone Fluorophore Manufacturer Dilution 
PD-1 Human MIH4 APC / PE BD Biosciences 1:100 
PDL1 Human MIH5 APC BD Biosciences 1:100 
CD28 Human CD28.2 PE Biolegend 1:100 
ICAM-1 Human HA58 PE BD Biosciences 1:100 
LFA-1 Human HI111 PE Biolegend 1:100 
CD4 Human OKT4 PE Biolegend 1:100 
CD3 Human UCHT1 PECy7 Biolegend 1:200 
TfR Human M-A712 PE BD Biosciences 1:100 
HLA ABC Human W6/32 PE Biolegend 1:200 
PD-1 Mouse 29F.1A12 PerCP-Cy5.5 Biolegend 1:100 
CD4 Mouse RM4-5  v500 BD Biosciences 1:100 
CD8 Mouse 53-6.7  v450 eBioscience  1:100 
Viability Dye     eFluor® 780 eBioscience  1:1000 
Annexin V     PE Biolegend 9ng/ml 
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2.1.2 Plasmids 
Table 2.5 Plasmids produced for this study 
Plasmid pSFFV Species pUbiquitin 
pDUAL PD1WT Human GFP 
pDUAL PD1WT Human Cherry 
pDUAL PD1Δ∆223 Human GFP 
pDUAL PD1Δ∆217 Human GFP 
pDUAL PD1Δ∆211 Human GFP 
pDUAL PD1Δ∆205 Human GFP 
pDUAL PD1Δ∆199 Human GFP 
pDUAL PD1Δ∆193 Human GFP 
pDUAL PD1Δ∆187 Human GFP 
pDUAL PD1Tm Human GFP 
pDUAL HLATm Human GFP 
pDUAL HLA-A2 Human GFP 
pDUAL PD-L1 Human GFP 
pSIN PD1-GFP Human   
pSIN PD1-Cherry Human 
 pSIN PDL1-Cherry Mouse 
 
2.1.3 Primers 
Table 2.6 Cloning Primers 
 Amplicon Dir. Enzyme Primer sequence (5'--3') 
PD1WT FW BamHI GGGGGGATCCGCCACCATGCAGATCCCACAGGCGCC 
 
RS NotI CCCCGCGGCCGCTCAGATCAGACCCAGACTAGCAGCACCAG 
PD1Δ∆223 RS NotI CCCCGCGGCCGCTCAGATCAATAGTCCACAGAGAACACAGGC 
PD1Δ∆217 RS NotI CCCCGCGGCCGCTCAGATCAAGGCACGGCTGAGGGGTCCTCCT 
PD1Δ∆211 RS NotI CCCCGCGGCCGCTCAGATCACTCCTTCAGGGGCTGGCCGGTG 
PD1Δ∆205 RS NotI CCCCGCGGCCGCTCAGATCAGGTGCGCCTGGCTCCTATTGTC 
PD1Δ∆199 RS NotI CCCCGCGGCCGCTCAGATCATGTCCCTCGTGCGGCCCGGGAG 
PD1Δ∆193 RS NotI CCCCGCGGCCGCTCAGATCAGGAGCAGATGACGGCCAGG 
PD1Δ∆187 RS NotI CCCCGCGGCCGCTCAGATCAGACCCAGACTAGCAGCACCAG 
HLA-A2 FW BamHI GGGGGGATCCGCCACCATGACAAGAGTTACTAACAGCCCCTCT 
 
RS NotI CCCCGCGGCCGCTCACACTTTACAAGCTGTGAGAGACACATCAG 
hPD-L1 FW BglII GGGGAGATCTGCCACCATGAGGATATTTGCTGTCTTTATATTCATGA 
  RS NotI CCCCGCGGCCGCTTACGTCTCCTCCAAATGTGTATCA 
mPD-L1 FW BglII GGGGAGATCTGCCACCATGAGGATATTTGCTGGCATTATATTCA 
  RS NotI CCCCGCGGCCGCTTACGTCTCCTCGAATTGTGTATCA 
GFP RS NotI CCCCGCGGCCGCTTTACTTGTACAGCTCGTCCATGCCGAGAGTGATCCC 
Cherry RS NotI CCCCGCGGCCGCTTACTTGTACAGCTCGTCCATGCCGCC 
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Table 2.7 Chimeric Protein Primers 
Amplicon Direction Primer sequence (5'--3') 
PD1-GFP Sense GGCTCCGGCTCCGGCTCCGTGAGCAAGGGCGAGGAGCT 
  Antisense GGAGCCGGAGCCGGAGCCGAGGGGCCAAGAGCAGTGTC 
PD1-Cherry Sense GGCTCCGGCTCCGGCTCCGTGAGCAAGGGCGAGGAGGA 
  Antisense GACACTGCTCTTGGCCCCTCGGCTCCGGCTCCGGCTCC 
mPDL1-Cherry Sense GGCTCCGGCTCCGGCTCCGTGAGCAAGGGCGAGGAGGATA 
  Antisense GGAGCCGGAGCCGGAGCCCGTCTCCTCGAATTGTGTATCA 
PD1Tm Sense TCTGGGTCCTGGCCGTCATCAGGAGGAAGAGCTCAGATAG 
  Antisense CTATCTGAGCTCTTCCTCCTGATGACGGCCAGGACCCAGA 
HLATm Sense CAGCCGGCCAGTTCCAAACCATCGTGGGCATCATTGCTGG 
  Antisense CCAGCAATGATGCCCACGATGGTTTGGAACTGGCCGGCTG 
 
 
 
 
 
Table 2.8 Sequencing Primers 
Gene Direction Primer sequence (5'--3') 
pDUAL /pSIN FW CGAGCTCTATAAAAGAGCTCA 
  RS TAAAGCAGCGTATCCACATAGCGTAAAAGGA 
PJET FW CGACTCACTATAGGGAGAGCGGC  
  RS AAGAACATCGATTTTCCATGGCAG 
TMEM16F Set 1 FW GTGCAGGTTCATGCTTCATTT 
  RS GCACAGTCCCTGCAATAAGA 
TMEM16F Set 2 FW CCCGGTGCTGCTGATTTA 
  RS GGATCTACAGCCATTGAAGGAA 
TMEM16F Set 3 FW AGTGGTGGTCTCTGTATTGTTT 
  RS AAACAGCAGGTTCCAAATTACC 
CRISPR gRNA FW GAGGGCCTATTTCCCATGATT 
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2.2 Molecular Biology 
2.2.1 Polymerase Chain Reaction (PCR) 
PCR reactions were performed using a Hybriad thermal cycler. The proof-reading 
Phusion® Polymerase (NEB) was used to generate DNA amplicons for cloning into 
lentiviral transfer vectors (pSIN or pDUAL). The Phusion® PCR reaction mixture is 
shown in Table 2.9 and the cycling parameters are described in Table 2.12. GoTaq® 
polymerase (Promega) was used for bacterial colony screening. The GoTaq® PCR 
reaction mixture is shown in Table 2.10 and cycling parameters in Table 2.13. 
HotStar Taq Plus® was used for amplification of genomic DNA for verification of 
CRISPR gene editing. HotStar Taq Plus ® PCR reaction mixture is shown in Table 
2.11 and cycling parameters in Table 2.14. Genomic DNA PCRs were performed in 
collaboration with Julia Sung at the National Institute for Biological Standards and 
Control. 
 
 
 
Table 2.9 Phusion Reaction Mix 
  Reagent Stock Conc. Volume  
HF or GC Buffer* 5X 1X 
dNTP 10 mM 1 µl 
FW Primer 10 µM 1 µl 
RS Primer 10 µM 1 µl 
DNA Template 100 ng 1 µl 
Phusion Polymerase 2 units/µl 0.5 µl 
Nuclease-free H2O 
 
to 50 µl 
Total Volume   50 µl 
*High Fidelity (HF) Buffer used unless amplicon was GC rich 
or PCR failed, in which case GC Buffer was used 
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Table 2.10 GoTaq Reaction Mix 
 Reagent Stock Conc. Volume  
GoTaq Green Mastermix 2X 1X 
FW Primer 10 µM 1 µl 
RS Primer 10 µM 1 µl 
DNA Template E. coli scraping from colony 
Nuclease-free H2O 
 
to 50 µl 
Total Volume   50 µl 
 
 
 
Table 2.11 HotStar Taq Plus Reaction Mix 
 Reagent Stock Conc. Volume  
Qiagen's HotStar Taq Plus MM  2X 20 µl 
Forward primer 10 µM 1 µl 
Reverse primer  10 µM 1 µl 
Coral Load concentrate 10X 4 µl 
DNA Template 
 
1 µl 
Nuclease-free H2O 
 
13 µl 
Total Volume   40 µl 
 
 
 
Table 2.12 Phusion PCR Cycling Parameters 
 Phase Cycles Temperature. Time (s) 
Activation 1 98oC 30 
Denaturation   98oC 10 
Primer annealing 25-30 5oC below primer Tm 20 
Extension   72oC 30/kb 
Final Extension 1 72oC 10 min 
Hold 1 4oC ∞ 
 
 
 
Table 2.13 GoTaq PCR Cycling Parameters 
 
Phase Cycles Temperature. 
Time 
(s) 
Activation 1 95oC 2 min 
Denaturation   95oC 30 
Primer annealing 25-30 5oC below primer Tm 30 
Extension   72oC 1min/kb 
Final Extension 1 72oC 10 min 
Hold 1 4oC ∞ 
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Table 2.14 HotStar Taq Plus PCR Cycling Parameters 
Phase Cycles Temperature. Time (s) 
Activation 1 95oC 15 min 
Denaturation   94oC 30 
Primer annealing 36 57oC 30 
Extension   72oC 1 min 
Final Extension 1 72oC 10 min 
Hold 1 8oC ∞ 
	  
 
2.2.2 Overlap Extension (OE) PCR 
Chimeric proteins were produced by OE PCR using the Phusion® proof-reading 
polymerase (Figure 2.1). Three PCRs were carried out in two stages as described in 
Figure 2.1. Both genes were amplified with a complimentary primer pair (Sense and 
Antisense). This produces two amplicons which overlap at the 3’ end of Gene A and 
the 5’ end of Gene B. These two PCR products were then combined in a third PCR 
with the Gene A FW and Gene B RS primers. The PCR product of this reaction is a 
fusion of the two genes (Heckman and Pease, 2007). 
Sequencing of the DNA fragment was performed before cloning into an expression 
vector. 
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Figure 2.1 Overlap extension PCR. Three PCRs are needed to create a chimeric 
protein composed of Gene A fused to Gene B. A set of complimentary primers (Sense 
and Antisense) are synthesised consisting of the last 20 base pairs at the 3’end of 
Gene A and the first 20 base pairs at the 5’ end of Gene B. Gene A is then amplified 
with the FW primer of Gene A and the Antisense primer. Gene B is amplified with 
the RS primer of Gene B and the Sense primer. These two PCR products are then 
combined in a third PCR with the Gene A FW primer and the Gene B reverse primer. 
The product of this PCR will transcribe the GeneA-GeneB fusion protein.  
 
 
 
Gene A FW
Gene A Gene B
Gene B  RS
Sense
Antisense
STEP 1
STEP 2
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2.2.3 Restriction digestion and ligation 
Double restriction digestions to isolate the plasmid backbone and an insert were 
carried out with appropriate buffers as directed by NEB. Digestions were performed 
at 37oC in a final volume of 30ul consisting of 3ul DNA, 3ul 10X Buffer, 1ul of each 
enzyme and 23ul of water for 1 hour. For diagnostic digestions a final volume of 10ul 
was used. 
Plasmid- insert ligations were performed with the Rapid DNA Ligation Kit (Thermo 
Scientific). Reactions were performed at room temperature for 5 minutes with a total 
volume of 20ul consisting of 4ul 5X Ligation Buffer and 1ul T4 Ligase (5U/ul). 
2.2.4 Agrose gel electrophoresis 
To isolate DNA fragments, DNA samples were mixed with 6X TriTrack Loading 
Buffer (Thermo Scientific) and loaded into 1% Agarose gel containing 5ug/ml 
ethidium bromide (Sigma Aldrich). The sample was run alongside a 1kb  Plus DNA 
Ladder (Invitrogen) to allow DNA band identification by size. A UV light box was 
used to visualise and excise the DNA bands. DNA was purified from the agarose 
using the QIAquick Gel Extraction Kit (Qiagen). 
2.2.5 Preparation and transformation of competent bacteria 
XL10 Gold (Agilent) bacteria were expanded using the following method: cells were 
plated onto a Tetracycline (10ug/ml) LB Agar plate and incubated overnight. The 
next day a colony was picked and grown overnight in 10ml LB buffer containing 
10ug/ml Tetracycline. The following day 1ml of this solution was added to 100ml of 
antibiotic-free LB Buffer for 1 – 2 hours until an OD600 of 0.5-0.6 was reached.  The 
solution was then cooled on ice for 10 min and spun at 3000 rpm at 4oC for 10 min. 
The bacteria were resuspended and incubated in TFB-I buffer for 5 mins on ice and 
then spun again. The pellet was resuspended in TBF-II buffer and incubated for a 
further 15 mins on ice. Competent cells were then aliquoted and stored at -80oC. 
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Transformation of competent bacteria was performed after bacteria were thawed 
slowly on ice. Plasmid (~500ng) was added to the bacterial suspension and heat 
shocked at 37oC for 2 minutes before being returned to ice for a further 2 mins. 
Bacteria were then plated on an antibiotic impregnated LB agar plate (Ampicillin 
used at 50ug/ml, Kanamycin at 30ug/ml) and placed at 37oC overnight.  
2.2.6 DNA purification and quantification 
For the purification of plasmid DNA, bacterial colonies were picked and grown 
overnight in LB Broth (5ml for miniprep and 100ml for midiprep) containing 
antibiotic (Ampicillin 50ug/ml, Kanamycin 30ug/ml). Bacteria were isolated by 
centrifugation at 3000rpm for 30mins at 4oC before DNA purification was performed 
with either a Miniprep or Midiprep kit (Qiagen), following the manufacturer’s 
protocol. DNA was eluted in either EB Buffer (Qiagen) or nuclease free water. DNA 
concentration and purity were assessed using a NanoDrop 3300 spectrophotometer 
(Thermo Scientific).  
2.2.7 DNA sequencing 
Sequencing primers are shown in Table 2.8. DNA was sequenced either by the UCL 
Cancer Institute Sequencing Service or Beckman Coulter.  
2.3 Tissue Culture 
Jurkat T cells (E6.1) were acquired from ECACC. THP-1 cells were a gift from Dr 
Mahdad Noursadeghi, UCL. These suspension cells were grown in Roswell Park 
Memorial Institute (RPMI) medium (Sigma) supplemented with 10% Foetal Calf 
Serum (FCS)(Gibco), 2mM L-glutamine, 100U/ml Penicillin and 100ug/ml 
Streptomycin (Gibco) in a 5% CO2 incubator. Cells were maintained in upright T25 
flasks (Nunc) and passaged 1:10 every other day.  
HEK 293T (Collins lab), HEK 293 TRex cells (Life Technologies), B16.F10 and GM-
CSF expressing B16.F10 cells (GVAX) (Quezada lab) were grown in Dulbecco’s 
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Modified Eagle’s Medium (DMEM) (Sigma) supplemented with 10% Foetal Calf 
Serum (FCS), 2mM L-glutamine, 100U/ml Penicillin and 100ug/ml Streptomycin in a 
10% CO2 incubator. Cells were maintained in T75 flasks (Nunc) and passaged 1:10 
every other day. 
Cell counting was performed with Neubauer chamber slide. Cells were frozen in FCS 
with 10% dimethyl sulfoxide (DMSO). 
 
2.4 Lentiviral vectors 
2.4.1 Packaging cells 
HEK 293T cells were used for lentiviral vector packaging and viral titrations. These 
are derived from human embryonic kidney cells and express the simian virus 40 large 
T antigen. This antigen promotes episomal maintenance and increases the 
replication of vectors that contain the SV40 promoter (Pear PNAS 1993). 
2.4.2 Plasmids 
The single promoter (pSIN) and dual promoter (pDUAL) lentiviral transfer vectors 
used in this study are shown in Figure 2.2. The use of these plasmids has been 
described by this lab and others (Rowe et al., 2009). pSIN has an SFFV promoter 
whilst pDUAL has both an SFFV and Ubiquitin promoter. With pDUAL, the SFFV 
promoter drives target gene expression whilst the ubiquitin promoter drives 
expression of either GFP or mCherry. 
Cloning of target genes into these vectors is a four step process. Firstly the chosen 
sequence is amplified by Phusion® polymerase PCR with a forward primer that 
introduces a 5’ BamHI site (GGATCC) with a Kozak sequence (GCCACC) and a 
reverse primer that introduces a 3’ NotI site. In cases where the target gene has an 
internal BamHI site, a Bglll site was instead introduced (AGATCT) as the cut site is 
compatible with BamHI. This PCR product was then blunt ligated into the PJET 
cloning vector (Thermo Scientific) with 2ul PCR product, 10ul 2X ligation buffer, 1ul 
 73 
T4 ligase and 1ul PJET vector 6ul water incubated for 10 minutes at room 
temperature. Bacteria were then transformed with the ligation mixture. Colony PCR 
was conducted to confirm the presence of the insert and positive colonies were 
grown. DNA was purified and digested with the relevant enzymes. Cut vector and 
insert were then ligated as described above.  
For lentiviral production the 2nd generation packaging plasmid p8.91 expressing HIV 
proteins gag, pol, tat and rev was used along with the pMD.G plasmid expressing the 
envelope of vesicular stomatitis virus (VSV-G). These plasmids originate from the 
Naldini lab (Zufferey et al., 1998) and were synthesised by Plasmid Factory.  
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Figure 2.2 Lentiviral vector Plasmids. A pDUAL B pSIN C CRISPRlenti v2 D p8.91 E 
pMD.G . RRE: Rev response element. cPPT: central poly purine tract. SFFV: spleen 
focus-forming virus promoter. Ubiq: Ubiquitin promoter. WPRE: woodchuck 
hepatitis virus post-transcriptional regulatory element. U6: human RNA polymerase 
III U6 promoter. EFS: elongation factor 1α promoter. P2A: self-cleaving 2A peptide. 
VSV-G: vesicular stomatitis virus glycoprotein. 
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2.4.3 Lentiviral vector Production 
1x107 HEK 293 T cells were seeded in a 15cm plate and by the end of the following 
day the plate was ~80% confluent. Cells were transfected with the transfer vector 
(pSIN or pDUAL), packaging plasmid (p8.91) and envelope plasmid (pMD.G) using 
Fugene 6 transfection reagent in the proportions given in Table 2.15. The 
transfection mixture was combined 20 minutes prior to transfection and then added 
dropwise over the cells. The following day the cell media was collected, discarded 
and replaced. Cell media was then collected on days 2 and 3 after transfection and 
kept at 4oC. 
To concentrate the lentiviral vectors, collected cell media was first filtered through a 
0.45µm filter to remove cells and debris and then loaded into sterile ultracentrifuge 
tubes (Beckman Coulter). A 2ml 20% sucrose cushion was loaded at the base of the 
tube before the tubes were spun at 20,000 rpm for 2 hours at 4oC in a Sorvall ultra-
centrifuge (Beckman Coulter). Following centrifugation supernatant was discarded, 
viral pellets were resuspended in normal media, kept on ice for 30 minutes, and then 
resuspended again before being aliquoted and stored at -80oC. 
 
Table 2.15 Lentivector Transfection Mix  
Reagent Amount 
p8.91  2.5 µg 
pMD.G 2.5 µg 
Transfer Plasmid 3.75 µg 
Fugene 6 45 µl 
Opti-MEM 500 µl 
 
	  
2.4.4 Lentiviral vector Titration 
Concentrated lentiviral vectors were titrated to establish the infectious units per ml 
(IU/ml). 0.5ml of complete DMEM containing 2x105 HEK 293T cells were seeded per 
well in a 24 well plate. Once cells had adhered (~4 hours later), serial dilutions of 1 in 
5, 25, 125, 625, 3125 of virus were added to the cells. The following day a further 1 
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ml of DMEM was added to each well. Three days after transduction, cells were 
collected and the percentage of cells expressing fluorescent protein measured by 
FACS (described later). These values were plotted and dilutions that that fell within 
the linear phase (10-30% transduced) were applied to the following formula: 
 
 
	  
 
2.5 CRISPR-Cas9 Genome Editing 
CRISPR is a new and revolutionary method of genome editing. The process employs 
the machinery of a prokaryotic adaptive immune pathway. CRISPR loci in bacterial 
genomes contain Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR) along with short DNA sequences derived from pathogenic bacteriophages 
that have previously infected the prokaryotic cell line. These short non-coding 
sequences guide nuclease enzymes to pathogenic DNA sequences if the 
bacteriophage reinfects the cell (Marraffini and Sontheimer, 2010). 
Heterologous expression of the Cas9 nuclease from Streptococcus pyogenes with a 
guide RNA (gRNA) specific for the target gene of interest in eukaryotic cells leads to 
gene disruption and knockout. Cas9 introduces a double stranded break that is 
repaired by ‘non-homologous end joining’. Small insertions or deletions introduced 
by this form of DNA repair lead to frame shift mutations and therefore block protein 
expression (Sander and Joung, 2014). 
The lentiCRISPR v2 plasmid was used as described previously (Sanjana et al., 2014) 
and is shown in Figure 2.2. The gRNA sequence targeting TMEM16F Exon 2 was 5’-
TCAGCATGATTTTCGAACCC-3’ and TMEM16F Exon 5 was 5’-
TGTAAAAGTACACGCACCAT-3’. The primers that contain these sequences, shown 
in Table 2.16, were annealed in a PCR thermocycler with a 30 minute hold at 37oC, 
then a 5 min step at 95oC followed by a ramp down to 25oC over 14 minutes. The 
annealed primers were then ligated into the lentiCRISPR plasmid that had been cut 
No. of Cells x % Transduced x Dilution Factor 
Volume of Virus 
 
x 1000 = Infectious units / ml 
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with BsmBI (Fermentas) according to the Zhang Lab protocol. The plasmid was then 
sequenced to confirm the presence of the gRNA using the primers shown in Table 
2.8. 
Transient transfection of the lentiCRISPR plasmid is preferred as this reduces the 
risk of accrued off-target genome editing. TREx-293 cells were transiently 
transfected with the plasmid using Lipofectamine (Life Technologies). Jurkat T cells 
cannot be transfected so virus was produced as described in 2.4.3 and cells were 
transduced. 48 hours after transfection/transduction cells were selected in 0.5ug/ml 
Puromycin for Jurkat and 5ug/ml Puromycin for TREx-293 for 24 hours before 
single-cell clones were isolated. Jurkat T cells stably expressing Cas9 and gRNA after 
transduction were frozen following initial expansion and aliquots thawed as needed 
to avoid off-target effects resulting from long-term culture. Gene editing was 
confirmed by sequencing (Beckman Coulter) (Figure 3.5). Genomic DNA for 
sequencing of the edited region of interest was extracted from 1x106 cells using the 
DNeasy Blood and Tissue kit (Qiagen). Two different primer sets were used to 
amplify Exon 2 (Set 1 and 2) and one for Exon 5 (Set 3). Amplicons were sequenced 
using the same primers (Table 2.8).  
 
Table 2.16 CRISPR gRNA sequences 
Gene Exon Side Primer sequence (5'--3') 
TMEM16F 2 Top CACCGTCAGCATGATTTTCGAACCC 
 
  Bottom AAACGGGTTCGAAAATCATGCTGAC 
 
5 Top CACCGTGTAAAAGTACACGCACCAT 
   Bottom AAACATGGTGCGTGTACTTTTACAC 
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2.6 Flow cytometry (FACS) 
Cells were collected, transferred into a 96-well plate (Helena Biosciences) and 
washed twice with ice cold PBS. Cells were centrifuged at 1500rpm for 5 minutes in 
all steps unless otherwise stated. All steps subsequent to initial washed were carried 
out in blocking buffer (Table 2.1). Cells were incubated in blocking buffer for 30 mins 
prior to antibody staining. Changes in intracellular Ca2+ concentration were 
measured with 1µM Fluo 4 AM (Life Technologies) loaded into cells for 30 mins at 
37oC prior to the experiment. Surface phosphatidylserine was detected with 9ng/ml 
Annexin V applied in Annexin binding buffer (BioLegend). Microvesicles were 
distinguished from apoptotic bodies using the DNA (Viability) eFluor® 780 dye 
(eBioscience). This dye was also used to gate for viable cells in all experiments. 
Surface staining for receptors was carried out for 30 mins on ice using the antibodies 
detailed in Table 2.4. Flow cytometry was performed using a BD Fortessa (BD 
Bioscience) with FACS Diva software (BD Biosciences) and data was analysed with 
FlowJo (Treestar). 
 
2.7 Electrophysiology 
Whole cell patch clamp recording of cells was performed to simultaneously measure 
membrane capacitance, conductance and current in real-time.  
Glass electrode tips were pulled with a Narishige PP-830 microelectrode puller, 
dipped in molten wax (Kerr Corp.) before being cut and polished on a forge. These 
were made with an opening of appropriate size to minimize access resistance and 
allow for stable patch formation. Tips were filled with intracellular solution before 
being mounted on a micromanipulator. Cells were kept in a microscope-mounted 
bath containing extracellular solution. All experiments were conducted within a 
faraday cage to remove electromagnetic interference. One silver chloride electrode 
was present in the tip and one in the cell bath paired to a Nation Instruments digital 
acquisition board and an Axopatch 200b patch clamp amplifier connected to 
Capmeter 6v3 software running in MATLAB (Wang and Hilgemann, 2008). Suction 
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was used to bring the cell onto the electrode tip and the cell was opened with further 
suction or a high voltage pulse.  
Parameters were measured using the Lindau-Neher method (Lindau and Neher, 
1988) in Capmeter (Figure 2.3). Square-wave voltage perturbation (20 mV; 0.5 kHz) 
was controlled using the Capmeter software. Like an electrical capacitor, the 
capacitance of a cellular membrane is directly proportional to its surface area 
(membrane area), with 1mF equal to 1cm2 of cell membrane. Initial input resistances 
were generally between 2-10 MΩΩ and apparent cell resistance was 0.1-2 GΩΩ. 
External solutions were water-bath heated to 35-37°C in a multi-chamber gravity fed 
solution switcher set to a flow rate of approximately 200 µl/min. To switch solutions, 
the microscope platform and solution switcher were moved to position the cell in 
the middle of the appropriate solution stream. 
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Figure 2.3 Whole cell patch clamp recording. 
A The minimum equivalent circuit of the whole cell patch clamp configuration. A 
square wave voltage pulse is applied across the membrane with one terminal in the 
patch pipette and the other in the cell bath. When a cell is in this configuration, the 
current trace in response to the voltage pulse is shown in B. Capacitance is 
proportional to the rate of current relaxation in response to a voltage step (area 
under the curve). The conductance is proportional to the difference between the 
asymptote of the curve and the origin. C The view from above a Jurkat T cell in 
whole cell patch clamp configuration as seen through a Nikon Eclipse Ti-U light 
microscope with a 40X lens. 
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2.8 Confocal Microscopy 
Confocal imaging was performed by a Nikon TE2000-U microscope; 60× oil 
immersion, 1.45-NA objective paired with the EZ-C1 confocal system (Nikon) 
containing a 40-mW 163-Argon laser  (Spectra Physics; Newport Corporation) 
operating at 488 nm at 7.5% maximum capacity for FM4-64 recordings and a 1.5 mW 
Melles Griot cylindrical HeNe laser at 543 nm at 55% of maximum capacity for K7-
Rhodamine. Emission filters were set to either 500-540 nm or 580LP respectively. 
Typically resolution was 512 x 512, set with a pixel dwell time yielding <1-s exposure 
times per frame and a pinhole of 150µm. Image analysis was performed using either 
the EZ-C1 v3.9 (Nikon Instruments) or ImageJ (NIH). Photobleaching was negligible 
for these experiments. For experiments where confocal imaging and 
electrophysiology were combined, a RC-26 recording chamber (Warner Instruments) 
was used. For independent confocal imaging of intact cells, 800µl of media 
containing Jurkat cells was placed in a glass bottom 4-chamber dish (Nunc).  200µl of 
warmed ionomycin solution was rapidly added manually and cells imaged using the 
same conditions as above. 
 
2.9 Super-resolution Structured Illumination Microscopy 
The resolution of conventional light microscopy is limited by the diffraction limit of 
visible light, to approximately 300nm. Super-resolution (SR) microscopy techniques 
allow for image resolution above the diffraction limit. Many SR techniques such as 
PALM and STORM rely on stochastically activated fluorophores which facilitate the 
detection of single emitting molecules. Structured illumination microscopy is a SR 
approach that permits the use of conventional fluorophores (e.g. GFP and mCherry). 
Images are taken through a series of rotating optical gratings. By analysing the 
fringes of light that appear through the Moire pattern produced through the grating, 
and combining this information over the different rotations, spatial resolution can 
be increased by a factor of two (Kner et al., 2009). 
SR-SIM was used in this case to resolve the membranes of individual microvesicles 
and endocytic vesicles bearing fluorescently conjugated PD-1. 
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SR-SIM imaging was performed using Plan-Apochromat 63x/1.4 oil DIC M27 
objective in an Elyra PS.1 microscope (Zeiss). Images were acquired using 5 phase 
shifts and 3 grid rotations, with 34µm grating period for the 561nm laser and filter 
set 4 (1851-248, Zeiss). SR-SIM Images were acquired using an sCMOS camera and 
processed using ZEN software (2012, version 8.1.6.484, Zeiss). 
 
2.10 In vivo Tumour Experiment 
At Day 0, Female C57BL/6 mice (three per group) were injected subcutaneously on 
the flank with 2x105 WT or PDL1-Cherry expressing B16.F10 mouse melanoma cells. 
At day 6 and day 8 1x106 irradiated (150 Gy) GM-CSF-expressing B16 cells (GVAX) 
were injected on the contralateral flank. At Day 13 mice were sacrificed and the 
blood, lymph nodes and spleen were collected. Cells from lymph nodes, spleen and 
tumours were mashed through a 70µm nylon mesh filter (BD Falcon). Cells from 
spleen and blood were treated for 5 mins in red blood cell lysis buffer (Sigma 
Aldrich) for 5 minutes at room temperature. TILs were isolated from tumours by 
Ficoll (GE) gradient.  Cells were then stained for FACS as described above. Mice were 
kept and bred by UCL Biological Services and used at 6 - 8 weeks of age. This 
experiement was performed under supervision from Dr Dana Briesmeister from the 
Quezada lab. 
 
2.11 Statistical Analysis 
Data analysis was performed in Prism 6 (GraphPad). Unless stated otherwise, error 
bars represent standard error with significance assessed by Student’s t-tests. 
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CHAPTER 3 
 
 
 
Ca2+ ACTIVATED PLASMA 
MEMBRANE CHANGES 
REGULATED BY TMEM16F  
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3.1 Introduction 
It has long been recognised that increases in intracellular Ca2+ have profound and 
wide-ranging effects on the plasma membrane of cells.  Ca2+ activated fusion of 
intracellular vesicles allows secretion of effector molecules, the rapid expression of 
transmembrane proteins and the addition of new membranes to the plasma 
membrane. This exocytosis is fundamental to cellular functions ranging from 
endocrine signalling to membrane repair. Ca2+ activated microvesicle shedding 
constitutes a pathway for intercellular signalling while Ca2+ activated changes in 
plasma membrane phospholipid distribution can catalyse the coagulation cascade 
and facilitate the phagocytosis of dead cells. Endocytosis of large volumes of 
membrane can also follow large Ca2+ influx. Though many of these events have been 
extensively studied and well characterised, the mechanisms that underlie them 
remain unclear. 
As well as sharing the common trigger of Ca2+ influx, these events can often 
coincide. This has led researchers to question whether these events are 
mechanistically linked. Does phospholipid scrambling cause microvesicle release 
(Elliott, 2006; MacKenzie et al., 2001)? Does exocytosis cause phospholipid 
scrambling (Lee et al., 2013; Mirnikjoo et al., 2009)? Does exocytosis have to precede 
endocytosis, through secretion of membrane-altering enzymes (Tam et al., 2010)? 
Though evidence has emerged to support many of these hypotheses, few firm 
conclusions can be drawn from the fragmented and often contradictory literature. 
Key to solving these mysteries is identifying the protein machinery involved and the 
mechanisms by which they operate. The synaptotagmins have emerged as the Ca2+ 
sensors for exocytosis in many cell types (Südhof, 2013), though exocytosis still 
occurs in the absence of multiple synaptotagmins in secretory (Schonn et al., 2008) 
and non-secretory (Wang and Hilgemann, 2008) cells. No Ca2+ sensor has yet been 
identified for the large exocytosis necessary for membrane repair (McNeil and 
Kirchhausen, 2005).  
There may be multiple mechanisms for microvesicle release, some of which are Ca2+ 
dependent and some of which are Ca2+ independent. The endosomal ESCRT 
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machinery has recently been implicated in microvesicle release in a number of 
contexts including Ca2+ activated membrane repair, but the mechanism of ESCRT 
Ca2+ dependence and recruitment to the plasma membrane is uncertain (Jimenez et 
al., 2014; Scheffer et al., 2014).  
The Ca2+ activated phospholipid scramblase has recently been identified as 
TMEM16F and its deletion has been shown to cause of the rare bleeding disorder 
Scott Syndrome. Controversy surrounds how a Ca2+ activated ion channel can 
translocate phospholipids, with some reports concluding that TMEM16F is not 
sufficient for membrane scrambling (Yang et al., 2012) while other contradictory 
reports showing that TMEM16F alone can scramble artificial membrane liposomes 
(Brunner et al., 2014; Malvezzi et al., 2013). 
These events have wide-ranging effects in multiple cell types, though they have all 
been investigated in T lymphocytes. Exocytosis, phospholipid scrambling and 
microvesicle release are seen during T cell activation (Choudhuri et al., 2014; Fischer 
et al., 2006; Soares et al., 2013).  
We began to be interested in the response of cells to large Ca2+  influx following the 
discovery that the important T cell regulator PD-1 is specifically downregulated 
following Ca2+ influx in lymphocytes (Chapter 4). We found there to be much 
confusion and contradiction in the literature. Several events were seen to coincide 
with Ca2+ influx: exocytosis, MEND, microvesicle shedding and phospholipid 
scrambling. How these are linked and whether they accounted for the 
downregulation of PD-1 was unclear. Prof. Hilgemann has worked extensively on 
these problems and first demonstrated and characterised Ca2+-activated MEND.  
We set out to methodically investigate Ca2+ triggered membrane changes in T 
lymphocytes. In order to best achieve this we had to employ a diverse array of 
techniques, from lentiviral vector-based genome manipulation to flow cytometry to 
whole cell patch clamp electrophysiology. This work was performed between Prof. 
Collins’ lab in London, UK and Prof. Hilgemann’s lab in Dallas, US where I spent five 
months on a Bogue research fellowship.  
The model upon which we based much of this research is the human Jurkat 
leukaemic T cell line. These cells are of great historic importance in T cell biology, 
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with many of the key discoveries in T cell signalling having been first demonstrated 
in Jurkats. The discoveries that TCR ligation leads to an increase in cytoplasmic Ca2+ 
(Imboden et al., 1985) and protein tyrosine phosphorylation activation (Veillette et 
al., 1988), the discovery and characterisation of ZAP70 (Chan et al., 1992), the 
identification of PLCγ1 as a TCR signalling molecule (Weiss et al., 1991), and the 
identities and significance of many ion channels (Lewis and Cahalan, 1995), were all 
discoveries first made in Jurkat T cells (Abraham and Weiss, 2004). Importantly in 
our case, Jurkat T cells are a suitable size for patchclamp experiments, are amenable 
to genetic manipulation using lentiviral vectors, while behaving similarly to primary 
human T cells in plasma membrane protein expression. 
This chapter presents our findings, which draw connections between many of these 
Ca2+-activated plasma membrane changes, and implicate one protein as their master 
regulator. 
3.1.1 Research questions 
- What is the response of T lymphocytes to large Ca2+ influx? 
- What is the mechanism underlying: 
- Ca2+ activated large exocytosis? 
- Ca2+ activated microvesicle shedding? 
- Ca2+ induced phospholipid scrambling? 
- Ca2+ activated massive endocytosis (MEND)? 
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3.2 Results 
3.2.1 Ca2+ activated exocytosis in Jurkat T cells is associated with ion 
conduction through a Ca2+ activated ion channel  
In order to study Ca2+ activated membrane responses we employed real-time 
capacitance recording via whole-cell patch clamp. As detailed in chapter 2, this 
assay allows very accurate measurement of plasma membrane area as well as of 
movement of ions across the plasma membrane over time. Capacitance data alone, 
however, only provides information on net membrane area changes, not 
directionality, so if exocytosis and endocytosis occur at the same time, this will not 
be obvious.  In order to gain information about the directionality of membrane 
movements, we employed concurrent confocal imaging with the membrane tracer 
dye FM4-64. This dye is highly suited for these experiments as it is cell-
impermeable, it rapidly binds and can be completely and rapidly washed from the 
membrane. Endocytosis in the presence of FM dye leads to the irreversible retention 
of dye in endocytic vesicles whilst exocytosis leads to an increase in bound dye 
which can be completely washed.  
Figure 3.1 shows the response of WT Jurkat T cells to Ca2+ influx facilitated by the 
ionophore ionomycin. Following Ca2+ influx cell plasma membrane area doubles in 
~30 seconds. FM dye binding to the plasma membrane increases with identical 
kinetics to capacitance increase and this binding is entirely reversible by washing 
(Images 1-4), demonstrating that there is no contemporaneous endocytosis. 
Exocytosis is accompanied by a large membrane conductance of ~60nS that activates 
within five seconds and inactivates over approximately one minute. 
Next we analysed the relationship between exocytosis and conductance. As Figure 
3.2A shows, the rate of change of capacitance (dCm/dt) closely matches the rate of 
change in ion movement i.e. the conductance. Crucially when a +20mV membrane 
potential is applied to the cell (Figure 3.2B), the conductance is associated with a 
persistent transmembrane current. This indicates that ions are flowing between the 
cytoplasm and the extracellular space. 
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As this large membrane exocytosis is always associated with a flow of ions across the 
plasma membrane through a Ca2+ activated ion channel, we next investigated 
whether this ion movement was necessary for exocytosis. When normal intracellular 
and extracellular ions were replaced with NMDG aspartate, the level of Ca2+ activated 
exocytosis was reduced, as was the case when cytoplasmic ions were replaced with 
sucrose solution.  Interestingly, replacing all ions with symmetrical sucrose solution 
facilitated a complete block in exocytosis. These data suggest that ion conduction 
through the channel is necessary in the mechanism of exocytosis. 
Next we asked whether the same SNARE machinery necessary for regulated 
exocytosis in many cell types, including neurons and lytic granule exocytosis in 
cytotoxic T cells (Matti et al., 2013; Südhof, 2013), was involved in this large Ca2+ 
activated exocytosis. These types of membrane fusion employ synaptobrevin 
(VAMP2) that is rapidly degraded by tetanus toxin. Inclusion of 400nM tetanus toxin 
in the cytoplasmic solution did not block exocytosis. We also confirmed that neither 
cellular ATP nor GTP were necessary as exocytosis was unaffected in their absence. 
Together these data demonstrate a form of Ca2+ activated exocytosis that relies on 
ion flux through a Ca2+ activated ion channel by a mechanism independent of ATP 
and classical SNARE machinery. 
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Figure 3.1 Ca2+-activated exocytosis and channel opening. Real-time membrane 
area (capacitance) and transmembrane ion movement (conductance) of WT Jurkat T 
cells were measured by whole-cell patch-clamp with concurrent confocal imaging 
using standard Ringer and cytoplasmic solutions. FM4-64 and ionomycin were 
applied and washed as shown. Membrane area and FM4-64 fluorescence are shown 
as percentage of baseline values. Images are of FM4-64 binding to the cell at 
indicated time points with a scale bar of 5µm. 
  
1
2
3
4
WT
1 2 3 4
100
150
200
%
  M
em
.  A
re
a
 
0 80 160 240 320
0
30
60
Time (s)
C
on
du
ct
an
ce
 (n
S)
0
200
400
600
800
 
%
  F
M
 4
-6
4
4-
64
 
 
Ionomycin
FM
 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Kinetics of Ca2+-activated exocytosis, conductance and current. A 
Membrane capacitance and conductance following treatment with 5µM ionomycin 
with standard extracellular and cytoplasmic solutions. The rate of change of 
membrane area (dCm/dt), was calculated from capacitance records (Cm) and filtered 
at 1 Hz.   In 8 experiments analyzed, the peak of conductance occurred within 3 s of 
the maximal rate of exocytosis. B, Membrane capacitance, current and conductance 
changes following treatment with 5µM ionomycin in standard Ringer solution. A 
membrane potential of +20mV was applied across the membrane.    
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Figure 3.3 Exocytosis is dependent on ion movement but is not tetanus toxin 
sensitive nor ATP dependent. Percentage of initial membrane area at 30s after 
ionomycin treatment of WT Jurkat cells. Cells were perfused with given cytoplasmic 
solutions for more than 200s before ionomycin treatment. Conditions were 
extracellular Ringer and standard cytoplasmic solution (KCl), symmetrical NMDG 
Aspartate, extracellular Ringer with cytoplasmic sucrose, symmetrical sucrose, 
extracellular Ringer with 400nM Tetanus Toxin L chain in standard cytoplasmic 
solution and extracellular Ringer with standard cytoplasmic solution containing no 
ATP or GTP. 
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3.2.2 Ca2+ activated exocytosis is followed by the shedding of plasma 
membrane microvesicles 
We were next interested in the fate of the plasma membrane following this large 
exocytosis. Figure 3.4A shows long-term capacitance recording of WT Jurkat cells 
stimulated with ionomycin. Following exocytosis there is a gradual loss in plasma 
membrane area over approximately 10 minutes plateauing at approximately 80% of 
baseline.  
In Figure 3.4B and Supplementary Video 3.1, confocal imaging of whole cells 
incubated in FM4-64 membrane dye, revealed a dramatic shedding of plasma 
membrane microvesicles following exocytosis.  From these images there appears to 
be no concurrent endocytosis. 
These data confirm findings made by others that Ca2+ influx leads to plasma 
membrane microvesicle shedding. However, it demonstrates for the first time that 
large exocytosis precedes microvesicle shedding. 
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Figure 3.4 Slow loss of plasma membrane area following exocytosis is due to 
microvesicle shedding. A Capacitance recording of WT Jurkat T cell treated with 
5µM ionomycin with standard Ringer extracellular and cytoplasmic solutions. B 
Confocal imaging of whole cells in a bath containing FM4-64 dye. 5µM ionomycin 
was added to the dish at 60 seconds. The scale bar equates to 10µm. 
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3.2.3 Loss of TMEM16F converts Ca2+ activated exocytosis to massive 
endocytosis (MEND) 
Data presented so far implicates a Ca2+ activated ion channel as the trigger for large 
exocytosis. We next aimed to establish the identity of this channel. The phenotype 
of the channel we observed had many of the features of TMEM16F. The channel was 
Ca2+ activated (Picollo et al., 2015), had a high Ca2+ threshold for activation (Grubb et 
al., 2013; Yang et al., 2012), was often delayed in activation by seconds to minutes at 
low ionomycin concentrations (data not shown) (Grubb et al., 2013; Kim et al., 
2015), and was still able to conduct large ions such as NMDG (Yang et al., 2012). 
The recent emergence of CRISPR-Cas9 gene editing has provided researchers with 
the ability for total gene knockout rather than knockdown by techniques such as 
RNA interference. In this case we suspected that the channel might still function at 
low expression levels so a gene knockout strategy was preferable.  
Figure 3.5 shows the strategy for CRISPR-Cas9 targeting of the TMEM16F gene. As 
transfection of Jurkat T cells is not possible, we used the lentiviral vector-based 
approach pioneered by the Zhang lab at MIT (Sanjana et al., 2014). We separately 
targeted both Exon 2 and 5 of the gene (Figure 3.5A and 3.5E) to ensure the 
knockout phenotypes were consistent and not due to off-target deletion of other 
genes. Single cell clones were isolated and genomic DNA was sequenced to confirm 
gene editing. PCRs were performed with two different primer sets and both 
amplicons were sequenced. The sequence of control cell TMEM16F Exon 2 is shown 
in Figure 3.5B. In the Exon 2-targeted clone, a single base insertion across alleles has 
led to a frame shift mutation and early termination of the gene (Figure 3.5C).   
CRISPR vector transduced cells targeting Exon 5 of TMEM16F as well as control cells 
were sequenced (Figure 3.5F and 3.5G). In this case, gene editing was not consistent 
across alleles and so it is hard to establish the exact mutations in each allele by 
sanger sequencing, however it is clear from Figure 3.5G that profound gene 
disruption had occurred at the targeted site. At several sites there is no WT 
nucleotide present indicating that no WT transcripts are present. It was not possible 
to carry out western blots to confirm knockdown due to a lack of commercially 
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available antibodies to TMEM16F. Experiments were performed on both Exon 2 and 
5 targeted clones to confirm that responses corresponded. Unless otherwise stated, 
all electrophysiology data appearing in this thesis was performed on the Exon 2 
targeted clone. 
Figure 3.6 shows whole cell patch clamp experiments with concurrent confocal 
imaging performed on TMEM16F-null cells following the same protocol described 
for Figure 3.1. In striking contrast to WT cell responses, Ca2+ influx triggers massive 
endocytosis, with ~50% of the plasma membrane taken in over ~20 seconds. 
Endocytosis is confirmed by retention of FM4-64 tracer dye which can no longer be 
washed. As expected, no Ca2+ activated membrane conductance is seen in the 
absence of TMEM16F.  
These data confirm the identity of the channel necessary for exocytosis as 
TMEM16F. They also reveal a pathway of massive endocytosis that operates, in the 
absence of TMEM16F-induced exocytosis, in response to large Ca2+ influx. 
This Ca2+ activated endocytosis appeared similar to that described previously in BHK, 
HEK 293 and mouse cardiomyocytes (Lariccia et al., 2011), and which was found to 
be independent of all endocytic and cytoskeletal protein machinery. To confirm this 
phenotype, we carried out patch-clamp experiments on the TMEM16F-null Jurkat T 
cells using targeted inhibitors (Figure 3.7). Endocytosis was not blocked by 
cytoskeletal disruption by Latrunculin A or Phalloidin. Latrunculin A inhibits actin 
polymerisation while Phalloidin crosslinks actin filaments. Clathrin-dependent 
endocytosis does not occur in the absence of intracellular potassium (K+) (Ivanov, 
2008) and K+ free cytoplasmic solutions had no effect on this endocytosis. Neither 
did the dynamin inhibitory peptide, which prevents amphiphysin-dynamin binding 
and therefore CCP formation (Grabs et al., 1997). Lastly absence of ATP and GTP had 
no effect on endocytosis. This marked independence from conventional endocytic 
proteins strongly suggests the endocytosis seen in TMEM16F-null cells is that 
described previously as MEND. 
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Figure 3.5 CRISPR-Cas9 mediated TMEM16F deletion in Jurkat T cells. 
TMEM16F was edited using the lentiviral vector-based CRISPR-Cas9 system as 
described (PubMed 25075903). A TMEM16F Exon 2 and target sequence is shown. B 
Two sets of primers were used to amplify TMEM16F Exon 2 from vector-only 
transduced Jurkat T cell genomic DNA. The two amplicons were then sequenced. C 
The same amplicons were sequenced from a clone transduced with TMEM16F Exon 
2-targeted CRISPR-Cas9 lentiviral vector. D the result of the single nucleotide 
insertion in Exon 2 on the amino acid sequence. A stop codon results 10 nucleotides 
downstream of the insertion that truncates TMEM16F from 910 to 50 amino acids. E  
TMEM16F Exon 5 and target sequence. F One primer set were used to amplify 
TMEM16F Exon 5 from vector-only transduced Jurkat T cell genomic DNA and 
sequenced G The same amplicon was sequenced from a clone transduced with 
TMEM16F Exon 5-targeted CRISPR-Cas9 lentiviral vector. 
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Figure 3.6 Ca2+ triggers massive endocytosis in the absence of TMEM16F. Real-
time membrane area (capacitance) and transmembrane ion movement 
(conductance) of TMEM16F-null Jurkat T cells were measured by whole-cell patch-
clamp with concurrent confocal imaging using standard Ringer and cytoplasmic 
solutions. FM4-64 and ionomycin were applied and washed as shown. Membrane 
area and FM4-64 fluorescence are shown as percentage of baseline values. Images 
are of FM4-64 binding to the cell at indicated time points with a scale bar of 5µm. 
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Figure 3.7 Massive endocytosis is independent of classical endocytic 
machinery. Percentage of initial membrane area at 30s after ionomycin treatment 
of TMEM16F-null Jurkat cells is shown as compared to initial value. Conditions were 
standard extracellular Ringer and cytoplasmic solution (Control); standard solutions 
with added 3µM cytoplasmic dynamin inhibitory peptide, symmetrical 3µM 
Latrunculin A or cytoplasmic 10µM Phalloidin, K+-free symmetrical NMDG Aspartate 
solutions and standard extracellular Ringer with cytoplasmic solution lacking ATP 
and GTP. 
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3.2.4 Intracellular Spermine blocks TMEM16F function in a dose-dependent 
manner 
Introduction of intracellular polyamines such as spermidine, spermine and 
ethalenediamine (EDA) is able to convert cellular responses from exocytosis to 
endocytosis (Lariccia et al., 2011).  
Following our findings that TMEM16F is the Ca2+ sensor for large exocytosis and that 
in the absence of TMEM16F MEND occurs, we hypothesised that intracellular 
polyamines were able to block TMEM16F. 
Figure 3.9 shows the effect of intracellular spermine on Ca2+ activated membrane 
movements and TMEM16F channel activity in WT Jurkat T cells. At 250µM spermine, 
cells underwent an intermediate phenotype of partial endocytosis followed by 
exocytosis as shown in Figure 3.9A. At 500µM all WT cells underwent endocytosis 
(Figure 3.9B). This change in phenotype was matched by a dose-dependent decrease 
in peak membrane conductance through TMEM16F. 
These data demonstrate that intracellular spermine inhibits both TMEM16F-induced 
exocytosis and ion conduction. 
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Figure 3.8 Spermine blocks TMEM16F function in a dose-dependent manner. 
A,B,C WT Jurkat cells were patch-clamped with spermine added to cytoplasmic 
solutions at given concentrations and held for at least 200s before recordings began. 
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3.2.5 TMEM16F-regulated membrane movements are conserved across cell 
types 
TMEM16F is ubiquitously expressed across cell types (Tian et al., 2012).  We next 
wanted to establish whether TMEM16F-induced exocytosis is also ubiquitous across 
cell types. We therefore conducted whole-cell patch clamp experiments on THP-1 
macrophages and NCX1-expressing HEK293 cells. Ca2+ activates a large exocytosis 
and membrane conductance in THP-1 cells (Figure 9A). Membrane area decrease 
following exocytosis is likely to be due to microvesicle shedding (MacKenzie et al., 
2001). 
Next we tested WT HEK293 cell responses with Ca2+ transients produced by NCX1 
reverse exchange. The NCX1 sodium-calcium exchanger is physiologically important 
in removing Ca2+ from the cytoplasm by employing the normal sodium gradient. By 
loading cells with sodium in whole-cell patch-clamp experiments, and then placing 
cells in Ca2+ -containing extracellular solution, this ‘reverses’ the exchanger leading 
to a Ca2+ transient. This produces a membrane conductance and also an outward 
current, as three sodium ions are exchanged for every one Ca2+ ion.  
TMEM16F was deleted in HEK293 cells employing the same strategy outlined in 
Figure 3.5, targeting Exon 5 on TMEM16F. Figures 3.8B and 3.8C show Ca2+ activated 
membrane movements in HEK293 WT and TMEM16F-null cells. Ca2+ influx via NCX1 
induces a ~20% increase in plasma membrane area in WT cells which is converted to 
MEND of ~50% plasma membrane in TMEM16F-null cells. Membrane conductance is 
not significantly changed between WT and TMEM16F-null cells. Though responses 
closely correspond to those shown in Jurkat T cells, it is of note that quantity of 
exocytosed membrane is significantly smaller in HEK293 cells. 
These data indicate that the findings detailed so far in this chapter are broadly 
applicable across cell types, occurring irrespective of whether Ca2+ influx is transient 
(via NCX1 reverse exchange) or sustained (via ionophore).  
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Figure 3.9 TMEM16F regulated membrane movements occur across cell types 
and with Ca2+ influx initiated by NCX1 reverse exchange.  
WT THP-1 cells were treated with 5µM ionomycin either with standard cytoplasmic 
solutions (A) or cytoplasmic solutions containing 500µM spermine (B). C WT and 
TMEM16F-null TREx cells that express the cardiac Na/Ca2+ exchanger, NCX1, were 
patch clamped using solutions that maximize Ca2+ influx via outward 3Na+:1Ca2+ 
exchange current when extracellular Ca2+ is applied. TMEM16F-deficient TreX cell 
line was produced by CRISPR Cas9 targeting to Exon 5. 
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3.2.6 TMEM16F-induced phospholipid scrambling and microvesicle shedding 
are coupled to exocytosis 
In 2010 it was discovered that TMEM16F is the Ca2+ activated phospholipid 
scramblase and that it is the loss of TMEM16F that leads to the bleeding disorder 
Scott syndrome (Suzuki et al., 2010). Here we have demonstrated that TMEM16F 
regulates a large exocytosis of internal membranes. We therefore next examined the 
relationship between exocytosis and phospholipid scrambling. 
Figure 3.10A shows the phenotype of WT and TMEM16F-null cells before and after 
treatment with ionomycin. Cells were probed with the fluorochrome-labelled PS 
binding protein Annexin V, as well as with the Ca2+ sensitive dye Fluo-4 AM.  In WT 
cells, Ca2+ influx, confirmed by increased Fluo-4 fluorescence, leads to AnxV binding 
to PS on the outer leaflet of the plasma membrane (Figure 3.10A). In TMEM16F-null 
cells AnxV does not bind to cells following Ca2+ influx, indicating that membrane 
scrambling has not occurred. This data confirms that TMEM16F is necessary for Ca2+ 
activated plasma membrane phospholipid scrambling. 
Next we aimed to establish how the kinetic of phospholipid scrambling related to 
that of TMEM16F induced exocytosis. It was not possible to use AnxV for this 
experiment due to the slow binding kinetic of AnxV to PS. Prof. Hilgemann has 
developed a probe for real-time analysis of phospholipid scrambling, which consists 
of the cationic peptide Heptalysine, composed of seven Lysines conjugated to 
Rhodamine (K7-Rho). This cationic peptide binds quickly to anionic PS and so is 
suitable for real-time microscopy.  K7-Rho is also readily washed in the same way as 
FM4-64 dye, which allows for insights into the directionality of membrane 
movements.  As Figure 3.10B Image 1 shows, in resting cells that have PS only on the 
inner leaflet of their plasma membrane, no K7-Rho binds to the membrane. 
The kinetic of TMEM16F-induced exocytosis and that of plasma membrane 
phospholipid scrambling is identical (Figure 3.10B). As discussed for Figure 3.4, a 
slow shedding of plasma membrane microvesicles follows TMEM16F- induced 
exocytosis. In a similar approach to that used in Figures 3.1 and 3.6, K7-Rho was 
periodically washed from the membrane throughout the experiment. Complete 
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reversibility of K7-Rho binding throughout the decrease in capacitance corroborates 
the findings of Figure 3.4, namely that the slow loss in plasma membrane area is due 
to shedding of membrane and not endocytosis. Whole WT Jurkat T cells stimulated 
with ionomycin in Ringer containing K7-Rho showed similar responses (Video 3.2). 
Phospholipid scrambling also occurs during apoptosis. Figure 3.11 shows 
experiments on WT and TMEM16F-null Jurkat T cells, where gene expression was 
deleted by targeting either Exon 2 or Exon 5. Cells were stimulated with ionomycin 
for 15 minutes or treated overnight with Etoposide, a topoisomerase inhibitor that 
triggers apoptosis via the DNA damage pathway (Karpinich et al., 2002). Though 
Ca2+-activated scrambling is blocked in TMEM16F-null cells, apoptotic scrambling is 
unaffected. This concurs with recent data from others that implicate other 
‘scramblase’ machinery involved in apoptosis-induced scrambling (Segawa et al., 
2014; Suzuki et al., 2013). 
Finally, as demonstrated in Figures 3.4 and 3.10, microvesicle shedding follows 
TMEM16F-induced exocytosis in WT cells. The mechanism for Ca2+ induced 
microvesicle shedding, which occurs in a wide variety of cell types, remains 
unknown. Following our previous finding that microvesicle shedding follows 
TMEM16F-induced exocytosis, we hypothesised that TMEM16F was necessary for 
Ca2+ activated microvesicle shedding. We quantified shed microvesicles using a 
FACS-based assay. Cells and vesicles were pelleted at high speed (3000 rpm for 10 
mins) and subcellular events gated by FSC/SSC (Figure 3.12). Apoptotic bodies and 
microvesicles were separated using a cell-permeable DNA dye that stained DNA 
fragments present only in apoptotic bodies. Figure 3.12 shows shed microvesicles 
only in WT cells and not in TMEM16F-null cells. This indicates that TMEM16F is 
necessary for Ca2+ activated microvesicle release in Jurkat T cells. 
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Figure 3.10 TMEM16F-induced phospholipid scrambling and membrane 
exocytosis proceed with identical kinetics. A Fluo4-AM loaded WT and 
TMEM16F-null Jurkat T cells were treated with 5µM Ionomycin for 15 min and 
stained with Annexin V. B Real-time membrane scrambling and membrane area 
were measured with Polylysine-Rhodamine (K7) membrane binding with concurrent 
whole-cell patch-clamp of WT Jurkat T cells using standard solutions following 
ionomycin treatment. Images are of K7 binding to the cell at indicated time points 
with scale bar representing 10µm. 
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Figure 3.11 TMEM16F deletion abolishes Ca2+ activated but not apoptotic 
plasma membrane scrambling. WT and TMEM16F-null Jurkat T cells CRISPR-
targeted to either Exon 2 or Exon 5 were treated with 5µM ionomycin for 15 mins or 
2µM Etoposide overnight and stained with Annexin V and compared to untreated 
cells. 
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Figure 3.12 TMEM16F is necessary for Ca2+ activated microvesicle shedding. WT 
Jurkat T cells were treated for 15 min with ionomycin in Ringer and stained with 
DNA dye. Subcellular sized events were gated and apoptotic bodies distinguished 
from microvesicles by DNA dye uptake. Numbers are percentage of total events. 
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3.3 Discussion 
3.3.1 TMEM16F is a Ca2+ sensor for exocytosis 
The fusion of intracellular vesicles to the plasma membrane is a key function of 
living cells, from yeast to sea urchins to neurons. Regulation of exocytosis is 
necessary to pair specific stimuli with vesicle fusion. This is important for the timely 
secretion of molecules (e.g. cytotoxic granzyme and perforin by T lymphocyte 
effectors), expression of transmembrane proteins (e.g. aquaporin 2 in the kidney 
duct cells) and addition of new membrane to the plasma membrane (e.g. during 
membrane repair). The key controller of regulated exocytosis is intracellular Ca2+. 
The last 20 years have seen significant advances in the understanding of the only 
known mechanism of Ca2+ activated membrane fusion. Those awarded the Nobel 
Prize in 2013 pioneered the discovery of the SNARE/synaptotagmin model of 
vesicular trafficking that has been extensively studied in the context of 
neurotransmitter release into the neuronal synapse. The proteins involved also 
regulate fusion in other tissues including T lymphocyte lytic granule exocytosis 
(Matti et al., 2013). The Ca2+ sensors for this type of exocytosis are the 
synaptotagmins, proteins that sit in the vesicular membrane and possess two Ca2+ 
binding C2 domains. 
Though the protein players in the SNARE/Syn model have been identified and 
characterised, there are many mysteries yet to be solved in the field of regulated 
exocytosis. Important questions in the SNARE/synaptogamin model remain 
unanswered, not least how synaptotagmin-Ca2+ binding catalyses vesicular fusion. 
There is also growing uncertainty as to whether this model describes the only 
mechanism of Ca2+ activated exocytosis. Knockout of multiple synaptotagmin 
isoforms fails to block Ca2+ activated exocytosis in secretory (Schonn et al., 2008) and 
non-secretory cells (Wang and Hilgemann, 2008). No Ca2+ sensors have been 
identified that account for the large exocytosis seen during membrane repair.  
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We first set out to establish how plasma membrane area changes with Ca2+ influx in 
WT Jurkat T cells. Treatment with 5µM ionomycin in physiological 2mM 
extracellular Ca2+ triggers ~100% increase in plasma membrane area over ~30 
seconds (Figure 3.1). Ionomycin concentrations down to 2.5µM elicit the same 
response, but with a delay of up to several minutes (data not shown). This response 
is conserved across cell types with large exocytosis also occurring in THP-1 
macrophages and a smaller exocytosis in HEK293 cells (Figure 3.9). This exocytosis 
has a high Ca2+ threshold and so appears alike to that described in RBL and BHK cells 
by Wang et al. and Yaradanakul et al. also suggesting it is a common response across 
species (Wang and Hilgemann, 2008; Yaradanakul et al., 2008). Others have 
described exocytosis in response to large Ca2+ influx triggered by membrane injury 
(McNeil and Kirchhausen, 2005). Though different protocols were used in those 
experiments, with none of them employing real time capacitance recording, it is 
likely that the large exocytosis we see here is the same as that triggered in 
membrane repair. This will need to be investigated in further work. 
We next looked for clues as to the mechanism of this large exocytosis. Whole-cell 
patch clamp of cells allows for the detection of conductance and current as well as 
capacitance. A conductance peak always accompanies exocytosis in WT Jurkat T cells 
(Figure 3.1). Importantly, the rate of change of membrane area (dCm/dt), calculated 
from capacitance records (Cm) and filtered at 1 Hz, matches the time course of 
conductance with the peak of conductance occurring within 3 seconds of the 
maximal rate of exocytosis. Others have seen a close association between exocytosis 
and conductance, related to ‘fusion pore’ opening (Spruce et al., 1990). As Figure 1.2 
shows, in the final stage of membrane fusion a pathway opens between the vesicular 
lumen and the extracellular space termed the ‘fusion pore’. This produces a small 
conductance which is detectable during exocytosis in some experimental setups. In 
our experiments, conductance is defined as the membrane current occurring at the 
end of a square wave voltage pulse; therefore fusion pore conductances should not 
contribute to our measurements.  By setting the membrane potential to +20mV we 
were able to induce an inward current, demonstrating that the conductance 
corresponds to the flow of ions between the extracellular space and the cytoplasm 
and therefore the opening and closing of a Ca2+ activated ion channel. The 
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conductance profile is typical of a Ca2+ activated channel, with Ca2+ both activating 
and inactivating the channel. 
Due to close phenotypic similarities between the Ca2+ activated channel we were 
observing and those of TMEM16F described previously (Picollo et al., 2015), we next 
deleted TMEM16F in Jurkat T cells using the CRISPR-Cas9 method. In response to 
Ca2+ influx TMEM16F-null cells display no Ca2+ activated conductance, exocytosis is 
blocked and instead MEND occurs (Figure 3.6). TMEM16F-null HEK293 cells respond 
in the same way, with MEND replacing exocytosis (Figure 3.9C). This finding reveals 
that the Ca2+ sensor for large Ca2+ activated exocytosis is TMEM16F and uncovers an 
entirely novel mechanism of membrane fusion. 
Following our initial observation that exocytosis is accompanied by a flux of ions 
through the channel, we next asked whether this flux was necessary for exocytosis. 
Indeed, replacing all ions with sucrose completely blocks exocytosis while partial 
inhibition can be achieved by replacing only intracellular ions with sucrose, or by 
replacing all ions with NMDG and aspartate (Figure 3.3). Under conditions of partial 
inhibition by ion replacement, the amount of membrane exocytosed is significantly 
reduced while the kinetics of exocytosis remain the same. This suggests that ion 
conduction through TMEM16F is directly linked to the mechanism of exocytosis. 
TMEM16F shares no features with any of the SNARE/Synaptotagmin proteins known 
to be the machinery of exocytosis in many cell types. Neither intracellular tetanus 
toxin light chain, which cleaves synaptobrevin-2, nor the absence of ATP and GTP, 
inhibited fusion. It is likely therefore that this mechanism of exocytosis fits in a new, 
distinct paradigm. 
The close association between channel opening and exocytosis (Figure 3.2) and the 
apparent resemblance to a ‘fusion pore’ may be informative in conceiving possible 
models for the mechanism of TMEM16F-induced exocytosis. The SNARE complex 
has a three-step process for fusion (Figure 1.2). Vesicle membranes are firstly docked 
in close proximity to the plasma membrane; with an increase in intracellular Ca2+ the 
SNARE complex zippers, bending the membranes and bringing them together to 
form a stalk. This stalk separates, leading to a hemifusion intermediary. Then finally 
the fusion pore opens, completing fusion.  In this way the SNARE machinery 
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operates much like a channel, introducing a conduit between the lumen of the 
vesicle and the extracellular space.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 A model of TMEM16F-induced exocytosis 
 
An equivalent hypothetical mechanism for membrane fusion involving TMEM16F is 
presented in Figure 3.13. This is of course speculative and will need much further 
work to verify and refine. TMEM16F alone may carry out some of the functions of 
SNARE proteins. Firstly for membrane docking, it may be relevant that the yeast 
homologue of the TMEM16 family, Ist2, functions as a tethering protein between the 
ER and the PM. It is structurally similar to TMEM proteins with eight 
transmembrane domains. Ist2 is present in the ER and has a C-terminal domain that 
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binds to anionic phospholipids on the inner leaflet of the PM. Whether TMEM16F is 
able to tether membranes close to the PM docked for exocytosis in a similar way to 
Ist2 will be important to establish. Secondly, Ca2+ channel opening could be 
equivalent to fusion pore opening in breaking PM continuity and allowing vesicular 
membranes to move into the channel space. TMEM16F channel has a large lumen, 
described previously as a ‘6Å pore’ (Yang et al., 2012). Ion movement through the 
channel may be necessary to bring the membranes together and into the channel 
space. Like all ion channels, TMEM16F is a linear protein that curves around to form 
a circular channel structure. The linearization of TMEM16F, linking the internal 
membrane with the PM, may be the final step of fusion in the same way as SNARE 
complex separation.  
3.3.2 Consequences of TMEM16F-induced exocytosis 
As discussed earlier, large Ca2+ influx leads to microvesicle shedding and 
phospholipid scrambling for which the mechanisms remain unclear. We sought to 
better understand whether these are linked to TMEM16F-induced exocytosis. 
3.3.2.1 Microvesicle shedding 
We were interested in the fate of the plasma membrane following TMEM16F-
induced exocytosis. Extended capacitance recording and microscopy of ionomycin-
treated WT Jurkat T cells demonstrated a loss of plasma membrane area following 
large exocytosis that is a consequence of microvesicle shedding, not endocytosis 
(Figures 3.4 & 3.10). Microvesicle shedding immediately follows TMEM16F-induced 
exocytosis ,and furthermore in TMEM16F-null cells microvesicle shedding did not 
occur (Figure 3.12). This strongly implicates TMEM16F as essential for large Ca2+ 
activated microvesicle shedding. This serves to explain the findings from studies on 
Scott syndrome patients that demonstrate defective release of microvesicles from 
platelets as well as defective membrane scrambling (Sims et al., 1989; Toti et al., 
1996).  
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A delay has consistently been observed between Ca2+ influx and microvesicle release 
(Cocucci et al., 2007; Lee et al., 1993; MacKenzie et al., 2001; Moskovich and 
Fishelson, 2007; Stein and Luzio, 1991). It has been hypothesised that this is due to a 
need for preceding exocytosis (Cocucci et al., 2007). Our data supports this 
hypothesis and furthermore TMEM16F is also a delayed activation channel with 
channel opening delayed by minutes at lower intracellular Ca2+ concentrations 
(Grubb et al., 2013; Kim et al., 2015). Both these factors could contribute to a delay 
between Ca2+ influx and microvesicle release. 
Though we have established that TMEM16F is necessary for microvesicle shedding in 
this context of large Ca2+ influx, this explanation may not necessarily apply to other 
contexts where plasma membrane derived microvesicles are released. Microvesicle 
release in the immune synapse and following membrane injury rely on protein 
components of the ESCRT complex that is normally associated with endosomal 
membranes (Choudhuri et al., 2014; Jimenez et al., 2014). It is unclear how these 
endosomal proteins come to be associated with the plasma membrane. The finding 
in this case that exocytosis precedes microvesicle shedding could suggest that 
factors that promote budding and fission of microvesicles are recruited to the 
membrane by fusion of endosomal membrane carrying ESCRT proteins whether by a 
SNARE or TMEM16F mediated mechanism.  
3.3.2.2 Phospholipid scrambling 
A long standing question in physiology has been how phospholipids can be rapidly 
scrambled following specific stimuli such as Ca2+ influx and apoptosis. Analogous to 
membrane ‘scrambling’ experimentally is the appearance of PS on the outer leaflet 
of the plasma membrane. It has been supposed that a protein ‘scramblase’ is capable 
of translocating the hydrophilic heads of phospholipids through a protein domain, 
allowing their bidirectional movement down a concentration gradient and thus 
disrupting the normal phospholipid asymmetry. This model existed long before the 
discovery that TMEM16F is the Ca2+ activated phospholipid scramblase. Recently the 
crystal structure for a fungal TMEM protein was solved and the authors hypothesised 
that a hydrophilic cleft found in the structure of the protein was the ‘scrambling 
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domain’ (Brunner et al., 2014). Others have recently confirmed that this sequence in 
mammalian TMEM16F is indeed responsible for phospholipid scrambling (Yu et al., 
2015). This ‘scrambling domain’ would fit perfectly with the long held model.  
Here we confirm previous reports that TMEM16F is necessary for Ca2+ activated 
phospholipid scrambling and that this is not due to an inhibition of Ca2+ influx 
(Figure 3.10A). Employing real-time capacitance recording and confocal microscopy 
using the K7-Rho probe, we show that the kinetics of exocytosis and anionic lipid 
exposure are identical i.e. the rate of membrane insertion exactly matches that of 
anionic lipid appearance (K7-Rho binding) on the outer leaflet of the plasma 
membrane. This close association strongly suggests that scrambling and exocytosis 
are linked. The first possibility is that TMEM16F is indeed able to translocate 
phospholipids and that this collapse in phospholipid asymmetry may be the trigger 
for membrane fusion. The second is that TMEM16F is facilitating exocytosis by 
another mechanism and that it is the fused membrane that is not asymmetric i.e. has 
PS on its outer leaflet.  
The second possibility has been suggested previously, as described in Chapter 1. 
Mast cell degranulation leads to membrane scrambling with patches of PS emerging 
on the membrane at sites of granule exocytosis (Demo et al., 1999). Other groups 
have provided evidence that Ca2+ activated exocytosis of lysosomes may be the cause 
of membrane scrambling. Here we show that TMEM16F triggers large membrane 
exocytosis and that it may be unlikely that in doubling the quantity of plasma 
membrane, all that membrane would be perfectly asymmetric. We found no way of 
inhibiting TMEM16F induced exocytosis without blocking the function of the 
channel, so were unable to definitively establish causality between fusion and 
scrambling. The evidence however points strongly towards the model that 
membrane exocytosis is the cause of PS emergence on the outer leaflet.  
But what of the evidence implicating a "scrambling domain" in TMEM16F as 
necessary for phospholipid scrambling? Though the authors of recent papers have 
demonstrated that a domain is necessary for phospholipid scrambling, there is no 
direct evidence that phospholipids do scramble through that domain i.e. no crystal 
structure of phospholipids in complex with the domain. This domain could equally 
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be necessary for TMEM16F induced exocytosis. This alternative hypothesis could 
explain some of the more puzzling findings made by others. Yang et al found that 
heterologous overexpression of TMEM16F was not sufficient to enhance membrane 
scrambling (Yang et al., 2012). With our hypothesis, it would be the available pool of 
internal, fusible membrane that would limit scrambling, not TMEM16F expression. 
Key in definitively uncovering the mechanisms behind microvesicle shedding and 
phospholipid scrambling will be to identify the membrane that is exocytosed. It is 
remarkable that a pool equivalent to the whole plasma membrane is in readiness to 
exocytose within 30 seconds of large Ca2+ influx. Characterisation of both the 
properties of that membrane and the proteins that are associated with it may 
provide important answers. As detailed in Chapter 1 lysosomes and ‘enlargesomes’ 
are shown to fuse with the PM following large Ca2+ influx, but work is necessary to 
clarify this in the context of TMEM16F-induced exocytosis. 
For many years it was supposed that the scrambling machinery for Ca2+ induced and 
apoptosis-induced scrambling was shared (Bevers and Williamson, 2010). Ca2+ influx 
occurs during apoptosis following the loss of plasma membrane integrity and 
dysfunction of Ca2+ ATPase pumps. This Ca2+ influx may therefore lead to scrambling 
by TMEM16F and provide the mechanism for apoptotic scrambling. Figure 3.11 
demonstrates that TMEM16F is not necessary for apoptotic scrambling. This agrees 
with recent discoveries of two mechanisms for apoptotic scrambling. Firstly Segawa 
et al. found that the phospholipid flippase ATP11C is degraded by caspases during 
apoptosis via a caspase recognition site, mutation of which inhibits apoptotic 
scrambling (Segawa et al., 2014). So loss of phospholipid asymmetry follows 
deficient flippase activity rather than a lipid ‘scramblase’ in apoptosis. Secondly the 
same group (Suzuki et al., 2013) found that Xk-related protein 8 (Xkr8) also mediates 
apoptotic scrambling, activated by a caspase-3 cleavage site. The mechanism for 
phospholipid scrambling by Xkr8 is however unknown. 
3.3.3 Ca2+ activated MEND in the absence of TMEM16F activity 
This work presents two opposing responses to large Ca2+ influx that are regulated by 
TMEM16F activity. In WT cells the plasma membrane area rapidly doubles while in 
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TMEM16F-null cells, large Ca2+ influx triggers the endocytosis of ~50% membrane 
area in ~ 20 seconds (Figure 3.1 & 3.6). We were interested in the mechanism 
underlying this significant endocytic event, and how these two opposing phenomena 
may be physiologically regulated. 
Due to the scale and speed of this endocytosis we hypothesised that it was the same 
seen in BHK, HEK293 and cardiomyocytes coined as MEND (Lariccia et al., 2011). 
This endocytosis is characterised by its independence from classical endocytic and 
protein machinery. Our next experiments therefore focussed on establishing 
whether the endocytosis we saw in Jurkat T cells relied on any of these proteins 
(Figure 3.7). 
First we targeted the clathrin endocytic pathway that relies on intracellular K+ as 
well as the protein dynamin. Neither removal of K+ nor an inhibitory peptide, which 
blocks dynamin associating to CCPs, had any effect on endocytosis. Next we targeted 
the cytoskeleton, important for pathways of endocytosis including macropinocytosis 
and dorsal ruffle endocytosis. Endocytosis was not inhibited by either preventing 
actin polymerisation with Latrunculin or crosslinking actin with Phalloidin. Lastly, 
removal of ATP had no effect on endocytosis. This phenotype matches that seen in 
Lariccia et al. 2010 and strongly suggests this endocytosis is that described as MEND. 
 
The Ca2+ sensor and mechanism for MEND are unclear despite much investigation. 
Most mechanisms of endocytosis involve the assembly of a protein scaffold that 
bends the plasma membrane, bringing the curved edges together and then pinching 
off the endocytic vesicle. Previous experiments investigating the mechanism of 
MEND have ruled out many Ca2+ activated proteins including proteases in the 
mechanism of MEND. Focus has therefore turned from a protein-based mechanism 
to one where the membrane itself is compositionally changed leading to inward 
curvature. Following the observation in WT BHK and HEK293 cells that exocytosis 
always precedes MEND, Tam et al. presented evidence that the exocytosis of acid 
sphingomyelinases was the mechanism of MEND (Tam et al., 2010). ASM 
metabolises sphingomyelin to phosphatidylcholine and ceramide; ceramide domains 
on the outer leaflet of the plasma membrane curve the membrane inwards. This data 
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however has not been reproducible by others and subsequent findings put the model 
into question (Hilgemann et al., 2013; Lariccia et al., 2011). One of the main findings 
incompatible with the idea that ASM secretion is the mechanism for MEND is that 
exocytosis can be uncoupled from endocytosis by the addition of physiological 
concentrations of polyamines to the cytoplasmic solution. Polyamines, spermadine, 
spermine and putrescine are metabolites of the amino acid L-Orthinine and are 
ubiquitous in eukaryotic cells. They are cationic compounds present at several 
hundred micromolar concentrations in cells (Igarashi and Kashiwagi, 2000). They 
have many roles in cell function from gene expression (Gerner and Meyskens, 2004) 
to enzyme regulation (Coburn et al., 2002). Importantly they also regulate ion 
channels including NMDA receptors and the inward rectifying K+ channel (Kir) 
(Pearson and Nichols, 1998; Williams et al., 1991). 
The mechanism of exocytosis inhibition by polyamines was previously unclear and 
due to their diverse effects on cell function the answer was not obvious (Lariccia et 
al., 2011). Following our finding that TMEM16F is the Ca2+ sensor for this large 
exocytosis, coupled with the fact that polyamines modulate the activity of the ion 
channels, we hypothesised that polyamines were blocking TMEM16F and therefore 
exocytosis. Indeed with increasing concentrations of spermine, TMEM16F peak 
conductance is significantly reduced and accompanies a switch of phenotypes from 
exocytosis to endocytosis (Figure 3.8). At 500µM intracellular spermine conductance 
is completely blocked and endocytosis occurs. With the Kir channel, cationic 
spermine inhibits by binding to anionic pockets in the channel (Guo and Lu, 2003; 
Stanfield and Sutcliffe, 2003). Further work will be needed to establish how 
intracellular polyamines are able to block TMEM16F. Application of extracellular 
spermine did not block the channel (data not shown) though treatment with cell-
permeable EDA had the same effect as spermine in Larricia et al.  
These data present a possible mechanism by which cells can physiologically regulate 
TMEM16F activity, and therefore the plasma membrane response to large Ca2+ influx 
i.e. exocytosis, endocytosis, phospholipid scrambling and microvesicle shedding. 
Indeed a study carried out on RBC ghosts demonstrated that resealing ghosts in the 
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presence of spermine recapitulates the phenotype of Scott Syndrome cells (Bucki et 
al., 1998). 
Our data could guide the design of therapeutics that block TMEM16F. PS exposure 
on platelets is an important step in normal clotting where it provides a surface for 
activation of the coagulation cascade, lack of which lead to the bleeding disorder 
Scott Syndrome. Importantly this syndrome has no other reported major systemic 
symptoms (Sims et al., 1989; Toti et al., 1996). TMEM16F has therefore been 
suggested as a target for anticoagulation therapy (Morel et al., 2011). Compounds 
that share the characteristics of polyamines and are cell permeable would be a good 
starting point for drug screening.  
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4.1 Introduction 
The regulation of protein expression on the surface of cells is vital for effective 
intercellular communication, allowing multicellular organisms to coordinate the 
actions of billions of specialised cells. T lymphocytes, which possess the dangerous 
ability to kill other cells, must be tightly controlled. Having received signals through 
a variety of receptors, they must integrate these messages through a network of 
finely balanced stimulatory and inhibitory signalling cascades, and respond 
appropriately. The consequences of either over-zealous or inadequate T lymphocyte 
immunity can be devastating to the organism. The kinetics of receptor expression is 
therefore important in regulating lymphocyte function, for example the T cell 
receptor is rapidly downregulated following antigen presentation, while the co-
receptor PD-1 is upregulated following TCR signalling. In this way, regulating 
expression in turn regulates signalling. 
With a growing understanding of the functional roles of T lymphocyte receptors, the 
possibility of manipulating their effects for therapeutic purposes has also arisen. The 
main approach for inhibiting signalling by specific receptors is the use of blocking 
antibodies that prevent receptor-ligand binding. This approach can either work to 
enhance or suppress immune responses depending on which receptors are targeted. 
In the context of cancer, where inappropriate tolerance of tumour cells permits their 
uncontrolled proliferation, targeting of the inhibitory co-receptors PD-1 and CTLA-4 
have proved to be effective anti-cancer agents (Pardoll, 2012). 
The inhibitory influence of the PD-L1:PD-1 pathway is clear, but the details of the 
underlying mechanisms by which this is achieved are still emerging. A better 
understanding of the pathway could help in three major ways. Firstly, despite good 
therapeutic outcomes with PD-1:PD-L1 blocking antibodies, the significant 
incidence of high-grade adverse drug-related events restricts treatment to those 
with late stage disease. Insights into the factors that mediate these toxicities could 
open up treatment to a larger cohort (Sharma and Allison, 2015). Secondly, nothing 
is currently known about the mechanisms by which PD-1 is regulated at the cell 
surface. There are no endocytosis motifs on the intracellular domain and research so 
far has only served to demonstrate that the mechanism of PD-1 regulation is 
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‘atypical’ (Pentcheva-Hoang et al., 2007). High PD-1 expression on the cell surface is 
characteristic of ‘exhausted’ T lymphocytes in the context of chronic viral infection 
and cancer. Importantly, blocking PD-1 signalling can ‘rescue’ these cells, returning 
them to an effector phenotype (Barber et al., 2006; Wherry et al., 2007). An 
understanding of PD-1 regulation at the cell surface may therefore suggest new 
therapeutic approaches aimed at downregulating PD-1 expression. Thirdly, it is 
possible that PD-1 may have yet undefined mechanisms of inhibition that could be 
targeted. Research has demonstrated that PD-1 activates inhibitory phosphatases 
(Chemnitz et al., 2004) and leads to the upregulation of inhibitory Cbl-b (Karwacz et 
al., 2011) and BATF (Quigley et al., 2010), as well as causing cell motility paralysis 
(Zinselmeyer et al., 2013). Gaining a better understanding of these mechanisms as 
well as uncovering others that may occur downstream of PD-1 signalling could 
provide further targets for reversing the inhibitory effects of PD-1. 
The starting point for the work outlined in Chapters 3 to 5 was the surprising finding 
that under certain conditions, including following large Ca2+ influx, PD-1 is 
dramatically downregulated from the surface of cells. This chapter documents how T 
lymphocyte surface proteins are sorted following Ca2+ influx into cells and our 
investigation into what mediates the specificity of protein sorting. 
 
4.1.1 Research questions: 
- Are proteins sorted following large Ca2+ influx in Jurkat cells? 
- How does TMEM16F activity influence protein sorting? 
- What dictates the specificity of protein sorting? 
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4.2 Results 
4.2.1 Ca2+ activated downregulation of PD-1 in WT Jurkat T cells by 
microvesicle shedding 
In Chapter 3 we demonstrated that Ca2+ influx leads to rapid changes in plasma 
membrane area regulated by TMEM16F. We next wanted to know whether 
transmembrane proteins were sorted with this membrane on Jurkat T cells. We 
monitored a panel of transmembrane proteins that have a variety of roles in T 
lymphocyte function: the co-stimulatory receptors PD-1 and CD28, the adhesion 
molecules ICAM-1 and LFA-1, the transferrin receptor which is classically recycled 
by clathrin-medicated endocytosis, components of antigen recognition machinery 
CD3ε and CD4, and MHC Class I (HLA ABC). Protein expression was measured in 
Jurkat T cells using flow cytometry before and after ionomycin treatment. 
Figure 1 presents the percentage of protein remaining on the surface of WT Jurkat T 
cells following Ca2+ influx facilitated by ionomycin treatment. Proteins are 
differentially affected. TfR and HLA ABC are down regulated to ~75% of initial 
expression whilst PD-1 is reduced to ~10%. Clearly proteins are lost from the surface 
of cells, but these data give us no information about the destination of this protein - 
has it been shed or internalised? Our findings in Chapter 3 demonstrated that in WT 
cells, Ca2+ induces a large exocytosis followed by microvesicle shedding. We 
therefore hypothesised that the loss of proteins from the cell seen in Figure 1 was 
due to protein shedding in microvesicles. 
PD-1 is the receptor most downregulated following Ca2+ influx (Figure 1A). To track 
the destination of PD-1, we conjugated GFP to the C-terminus of PD-1 by overlap 
extension PCR and expressed this protein in Jurkat T cells with a single promoter 
lentiviral vector (pSIN-PD1GFP). Flow cytometry of PD1GFP-expressing cells allows 
us to track total PD-1 (with GFP) and surface PD-1 (using antibody-staining of intact 
live cells at 4oC).  
Figures 2A and 2B show changes in total and surface PD-1 on WT PD1GFP-
expressing Jurkat T cells after 15 minutes of ionomycin treatment. There is a ~90% 
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reduction in surface PD-1 expression, accompanied by a ~40% reduction in total PD-
1. As shown in Chapter 3, under these conditions there is a large increase in 
subcellular-sized events seen by flow cytometry corresponding to shed 
microvesicles. These microvesicles were gated by flow cytometry, as detailed for 
Figure 3.12, and surface PD-1 and total GFP was quantified for both WT control and 
WT PD1GFP expressing cells. Figure 2C demonstrates the presence of surface PD-1 
and total GFP in microvesicles shed from PD1GFP expressing cells. 
We next wanted to visualise the inclusion of PD-1 in shed microvesicles. 
Conventional confocal microscopy lacks the resolution necessary for this. We 
therefore employed super-resolution structured illumination microscopy (SR-SIM) 
and imaged Jurkat T cells expressing a PD1-mCherry fusion protein (which does not 
bleach as readily as PD1GFP). Figure 2D and Video 4.1 shows microvesicle shedding 
of PD-1 following ionomycin treatment in WT Jurkat T cells.  
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Figure 4.1 WT Jurkat T cell plasma membrane proteins are down regulated 
following Ca2+ influx. WT Jurkat T cells expressing PD-1 were treated with 5µM 
ionomycin for 15 mins in Ringer solution and stained for expression of surface 
molecules. Data are percentage of initial surface expression following ionomycin 
treatment. 
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Figure 4.2 PD-1 is shed from Jurkat T cells in microvesicles following Ca2+ 
influx. A, B PD1GFP chimera was expressed on WT Jurkat T cells. Surface PD-1 and 
total GFP with and without ionomycin treatment are shown. C WT control and WT 
PD1GFP chimera expressing Jurkat T cells were stimulated with ionomycin. 
Microvesicles were gated for as subcellular sized events with low DNA dye uptake. 
PD-1 and GFP expression on microvesicles from WT control and WT PD1GFP 
expressing Jurkat T cells is compared. D PD1-mCherry chimera was expressed in WT 
Jurkat T cells and imaged by SR-SIM microscopy before and after ionomycin 
treatment. Arrows indicate PD1-bearing microvesicles. 
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4.2.2 Ca2+ activated downregulation of PD-1 in TMEM16F-null Jurkat T cells 
by endocytosis 
In the absence of TMEM16F, Ca2+ influx activates MEND (Chapter 6, Figure 6). This 
form of endocytosis is rapid and takes in ~50% of the plasma membrane. We wanted 
to establish which proteins were sorted by MEND in T lymphocytes. In Figure 3 
TMEM16F-null Jurkat T cells were treated with ionomycin for 15 minutes and 
plasma membrane expression of proteins measured by flow cytometry. PD-1 was 
selectively down regulated with levels dropping to ~5% of untreated cell levels. 
Other proteins including CD28, ICAM-1, LFA-1 CD4, CD3 and HLA were maintained 
at ~60-80% of initial values apart from TfR which fell to ~25%. 
Our previous data from Chapter 3 would predict that this downregulation of PD-1 
was due to massive endocytosis. To confirm this, we expressed PD1GFP fusion 
protein used for Figure 2 in TMEM16F-null Jurkat T cells to track both surface and 
total PD-1. Figures 4A and 4B show that despite a ~95% reduction in surface PD-1, 
total cell PD-1 (GFP fluorescence) remains constant after Ca2+ influx. This confirms 
that PD-1 protein is internalised from the cell surface and retained in the cell. 
Again we employed SR-SIM to visualise the endocytosis of PD-1 in TMEM16F-null 
cells PD1-mCherry expressing Jurkat T cells. Figure 4C and Video 4.2 show large PD-
1 containing vesicles in cells following Ca2+ influx.  
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Figure 4.3 TMEM16F-null Jurkat T cell plasma membrane proteins are 
downregulated following Ca2+ influx. TMEM16F-null Jurkat T cells expressing PD-
1 were treated with ionomycin for 15 mins in Ringer solution and stained for 
expression of surface molecules. Data are percentage of initial surface expression 
following ionomycin treatment. 
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Figure 4.4 In the absence of TMEM16F PD-1 is endocytosed. A,B PD1GFP 
chimera was expressed on TMEM16F-null Jurkat T cells. Surface PD-1 and total GFP 
with and without ionomycin treatment are shown. C  PD1-mCherry chimera was 
expressed in TMEM16F Jurkat T cells and imaged by SR-SIM microscopy before and 
after ionomycin treatment.  
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4.2.3 PD-1 sorting is mediated via the transmembrane domain of the receptor 
We next wanted to understand what dictates the specificity of PD-1 sorting into both 
shed and endocytosed vesicles. We hypothesised that PD-1 receptors were situated 
in specific lipid domains that are susceptible to vesiculation outwards or inwards 
and that the protein transmembrane domain regulated the inclusion/exclusion of 
proteins. In all cases PD-1 was the protein most affected, with expression reduced to 
~5-10% of baseline following Ca2+ influx. HLA ABC however was maintained at the 
surface with levels dropping to ~70-80%. In order to test whether the 
transmembrane domain (TM) guides protein sorting, we constructed PD1-HLA 
chimeras where only the TM was changed. 
Figures 5A and 5B show the hydrophobicity profile of both PD-1 and HLA-A2 and 
the predicted TM domain amino acids using an algorithm designed by ExPASy 
(http://www.ch.embnet.org/software/TMPRED_form.html). Using overlap-extension 
PCR we produced two chimeras depicted in Figure 5C. Both chimeras have the 
extracellular domain of PD-1 and the intracellular domain of HLA-A2. PD1Tm has 
the PD-1 transmembrane domain and HLATm has the HLA-A2 transmembrane 
domain. These were cloned into a lentiviral vector and expressed on both WT and 
TMEM16F-null Jurkat T cells. 
Figure 5D shows the expression level of PD1Tm and HLATm chimeric proteins 
following treatment with 5µM ionomycin. In both cases there is a significant 
difference between downregulation of the two constructs. The chimera with the 
PD1Tm was downregulated significantly more (~30% vs ~60%), supporting the 
hypothesis that intramembrane interactions sort proteins into membrane domains 
that are preferentially shed and endocytosed. 
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Figure 4.5 Receptors are sorted via transmembrane domain protein-lipid 
interactions. A PD-1 and B HLA-A2 hydrophobicity score plotted with predicted 
transmembrane domain. Data sourced from ExPASy TM prediction algorithm. C 
Illustration of PD1Tm and HLATm constructs. D PD1HLA-A2 chimeras were 
produced and expressed in WT and TMEM16F-null Jurkat T cells. Percentage surface 
expression remaining after treatment with ionomycin is shown. 
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4.2.4 Ca2+ activated endocytosis of PD-1 in WT Jurkat T cells following 
excessive Ca2+ influx 
The Ca2+ threshold for microvesicle shedding in WT Jurkat T cells is high, requiring 
between 2.5 - 5µM ionomycin in physiological Ca2+ solution (2mM). By titrating up 
the amount of ionomycin, we found that when we treated WT Jurkat T cells with 
20µM ionomycin, endocytosis occurred. 
Using whole-cell patch clamp capacitance recording to monitor membrane area, 
treatment of cells with 20µM ionomycin led to a rapid exocytosis of ~30% followed 
by a loss of membrane area to ~70% of baseline expression. This was associated with 
a downregulation in T lymphocyte protein expression (Figure 6B). Again PD-1 was 
specifically downregulated. Interestingly the profile of receptors downregulated is 
not significantly different to those downregulated when WT cells are treated with 
5µM ionomycin. As before, it was unclear whether this reduction in membrane area 
is due to shedding or endocytosis of membrane. In Chapter 3 we used FM4-64 dye as 
a tracer of membrane movement directionality. The data presented in this chapter so 
far has demonstrated that we can also use PD1GFP as a tracer of shedding and 
endocytosis. When WT PD1GFP expressing Jurkat T cells are treated with 20µM 
ionomycin, PD-1 is endocytosed (Figures 6C and 6D) established by ~95% loss of 
surface PD-1, accompanied by no significant loss in total PD-1 (GFP). 
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Figure 4.6 Large Ca2+ influx triggers endocytosis without shedding in WT Jurkat 
T cells. A Real-time membrane area (capacitance) of WT Jurkat T cells measured by 
whole-cell patch-clamp treated with 20µM ionomycin. B WT Jurkat T cells 
expressing PD-1 were treated with 20µM ionomycin for 15 mins in Ringer solution 
and stained for expression of surface molecules. Data are percentage of initial 
surface expression following ionomycin treatment. C, D PD1GFP chimera was 
expressed on WT Jurkat T cells. Surface PD-1 and total GFP with and without 20µM 
ionomycin treatment are shown. 
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4.3 Discussion 
4.3.1 PD-1 is specifically sorted into microvesicles  
The study of plasma membrane derived microvesicles is an emerging field in biology. 
The known functions of microvesicles are hugely varied with roles demonstrated in 
coagulation, inflammation, the tumour microenvironment, cell membrane repair 
and at antigen presentation (Distler et al., 2005; Köppler et al., 2006; Sims et al., 
1988); (Choudhuri et al., 2014; Mochizuki and Okada, 2007; Shedden et al., 2003). 
Release of microvesicles is a secretory pathway employed by macrophages for 
secreting proteins that lack a leader sequence such as IL-1β (MacKenzie et al., 2001). 
The expression of proteins on the membranes of microvesicles is a major regulator 
of their function. Tumour derived microvesicles for example express high levels of 
Fas-L that trigger apoptosis in TILs (Albanese et al., 1998; Kim et al., 2005), whilst 
microvesicles found in the immune synapse are enriched in TCRs that can reverse-
signal through pMHC in B cells (Choudhuri et al., 2014). Microvesicle release as a 
mechanism of protein downregulation may also be important, as is suggested in the 
case of TCR release in microvesicles at the immune synapse (Choudhuri et al., 2014). 
The mechanisms that mediate protein inclusion in microvesicles are unclear. In 
lymphocytes the ESCRT protein TSG101 plays a role in TCR inclusion in 
microvesicles. Other studies have implicated membrane intrinsic factors such as 
membrane cholesterol content (Del Conde et al., 2005; Stein and Luzio, 1991). 
In Chapter 3 we demonstrated that microvesicle shedding follows Ca2+ influx in WT 
Jurkat T cells. We next wanted to know whether plasma membrane proteins were 
included in these microvesicles and thereby shed from the cell surface. In Figure 1 
we show that surface expression of a panel of T lymphocyte proteins is altered under 
the same conditions (following 5µM ionomycin treatment). Interestingly proteins 
are downregulated to a highly variable extent; TfR and HLA ABC are least affected 
whilst PD-1 expression drops to ~10% of baseline. We confirmed the downregulation 
of PD-1 was due to loss of protein in microvesicles by using a PD1GFP chimeric 
protein which allowed us to track surface and total PD-1 (Figures 2A and 2B). Both 
PD-1 and GFP levels are significantly reduced, indicating that protein has been lost 
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from the cell. The downregulation of surface PD-1 (~90%) is however greater than 
that of total PD-1 (~50%). This could suggest that either some PD-1 is endocytosed 
as well as shed, or that not all the cellular PD-1 was initially on the cell plasma 
membrane. SR-SIM microscopy reveals that significant amounts of fluorescent PD-1 
are indeed held within the cell, presumably in the Golgi and ER, which is likely to 
account for the ~50% of total PD-1 that is not lost (Figure 2D). Microscopy also 
allows us to see PD-1 inclusion in shed microvesicles, while no endocytosis is visible. 
This is in agreement with Chapter 3 Figures 4 and 10 that showed that only 
microvesicle shedding and no endocytosis follows TMEM16F-induced exocytosis in 
WT Jurkat T cells. As well as demonstrating the downregulation of PD-1 from the 
cell plasma membrane following Ca2+ influx, we confirmed the presence of PD-1 on 
the surface of shed microvesicles (defined as DNA dye-negative, subcellular sized 
events) by FACS (Figure 2C). 
These data strongly suggest that there is a mechanism for targeting proteins for 
inclusion in microvesicles. The simplest model would involve certain membrane 
regions or ‘domains’ preferentially vesiculating and the protein cargo located within 
those domains accompaning. The site of protein:membrane interaction is the 
transmembrane domain, so we hypothesised that it was this region that guides 
specificity. The protein consistently most downregulated is PD-1, and the one least 
downregulated is HLA. We therefore constructed PD-1:HLA chimeric proteins with 
only the transmembrane domain varied between the two constructs (PD1Tm and 
HLATm) (Figure 5). The construct containing the PD-1 transmembrane domain was 
downregulated to a significantly greater extent (~80%) than the one containing the 
HLA transmembrane domain (~40%). This indicates that the protein transmembrane 
domain is involved in the sorting of proteins into microvesicles. 
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4.3.2 PD-1 is specifically sorted into MEND endosomes 
We have so far demonstrated that cells can respond in two ways to large Ca2+ influx, 
either by dramatically increasing or decreasing their surface membrane area. 
TMEM16F activity regulates these phenotypes and can be modulated by intracellular 
polyamine concentration. So far we have investigated the downregulation of plasma 
membrane proteins when TMEM16F is active i.e. via protein inclusion in shed 
microvesicles. We next wanted to know how protein surface expression was altered 
following Ca2+ influx in TMEM16F-null cells i.e. under conditions known to cause 
MEND. 
First we tracked expression of a panel of proteins before and after ionomycin 
treatment in TMEM16F-null cells (Figure 4). Strikingly, PD-1 is again the receptor 
most downregulated, this time to ~5% of baseline expression, and again HLA ABC is 
least affected along with LFA-1, CD3 and CD4 with expression levels reduced to 
~80% of baseline. This again suggests a specificity of protein sorting, with PD-1 
preferentially affected. To confirm this downregulation was due to endocytosis, we 
expressed the PD1GFP fusion protein on TMEM16F-null cells and treated them with 
ionomycin. The 95% decrease in surface PD-1 expression was accompanied by a 
complete maintenance in total PD-1 (GFP) indicating that PD-1 was downregulated 
by endocytosis. We visualised PD-1 endocytosis with TMEM16F-null expressing 
PD1-mCherry chimera with SR-SIM microscopy (Figure 4C, Video 4.2). Large PD-1 
containing MEND endosomes are seen to form following Ca2+ influx. It is remarkable 
to compare the phenotypes of WT (Figure 2D) and TMEM16F-null Jurkat T cells 
(Figure 4C), to recognise that one protein can regulate such different responses and 
to find that the specificity of protein inclusion in microvesicles and MEND 
endosomes is conserved.  
Experiments focussed towards establishing the Ca2+ threshold for microvesicle 
shedding in WT Jurkat T cells revealed the surprise finding that at high ionomycin 
concentrations (i.e. very high intracellular Ca2+), MEND occurs in WT cells (Figure 6). 
When cells are treated with 20µM ionomycin, capacitance recording reveals a rapid 
exocytosis of membrane over ~5 seconds followed by a loss in membrane area over 
100 seconds to ~70% of baseline (Figure 6A). This is accompanied by a 
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downregulation of surface proteins, specifically PD-1 (Figure 6B).  PD1GFP fusion 
protein was used to track the directionality of membrane movement, and Figures 6C 
and 6D demonstrate the loss of membrane area and surface PD-1 is due to 
endocytosis (i.e. total PD1GFP not affected). Initially we hypothesised that very high 
Ca2+ was inhibiting TMEM16F function or leading to rapid channel inactivation, 
however no significant differences were seen in TMEM16F conductance (data not 
shown). Our model detailed in Figure 7.1 is that MEND is the default pathway and 
that either TMEM16F or TMEM16F-induced exocytosis inhibits MEND, hence why 
MEND only occurs in their absence. At this high Ca2+ concentration presumably 
MEND is able to overcome this inhibition so MEND occurs. If this is a membrane 
repair pathway, large membrane defects, which lead to a larger Ca2+  influx, may be 
better repaired by endocytosis, not by exocytosis and shedding. However the 
explanation of this switch is not clear – a full understanding of how the balance of 
endocytosis and exocytosis is regulated could help in deciphering the mechanisms 
that underlie these phenomena.  
These data indicate that PD-1 is specifically included in both MEND endosomes and 
shed microvesicles. Specificity of protein sorting into microvesicles is mediated via 
the protein transmembrane domain. We therefore next wanted to know where this 
was the mechanism of specificity in MEND protein sorting. Indeed, as Figure 5 
shows, the PD-1Tm construct was downregulated significantly more than the 
HLATm construct in TMEM16F-null cells. This again implicated the transmembrane 
domain as responsible for the specificity seen and suggests a role of membrane 
domains. 
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5.1 Introduction 
Two hundred billion cells are turned over in the human body each day (Nagata et al., 
2010). Apoptosis is essential for normal homeostasis and development in all 
multicellular organisms. The plasma membrane of an apoptotic cell is very 
important in safeguarding the control of demolition. Firstly, it maintains a barrier to 
contain the cellular contents, whose leakage can damage neighbouring cells and lead 
to inflammation and autoimmunity (Taylor et al., 2008a). Secondly, the plasma 
membrane undergoes changes that aid the clearance of cell ‘corpses’ by phagocytes 
(Poon et al., 2014b). 
One of the hallmarks of cells undergoing apoptosis is the loss of plasma membrane 
phospholipid asymmetry. This has recently been shown to follow Caspase-3 
activation of Xkr8 (Suzuki et al., 2013) and inactivation of ATP11C (Segawa et al., 
2014). Surface PS constitutes an ‘eat-me’ signal to phagocyte receptors BAI1 (Park et 
al., 2007), Stablin 2 (Park et al., 2008) and TIM proteins (Miyanishi et al., 2007) that 
facilitate engulfment. 
Certain cell types including T lymphocytes are broken down into smaller ‘apoptotic 
bodies’ that are more readily engulfed by phagocytes. These apoptotic bodies can 
have functional roles in immune modulation (Berda-Haddad et al., 2011; Xie et al., 
2009) and tissue repair (Zernecke et al., 2009). The mechanism by which this occurs 
is still being characterised.  Caspase-3 cleavage of ROCK1 leads to the 
phosphorylation of myosin light chain, and cell contraction. This results in a period 
of dynamic membrane blebbing in early apoptosis that is involved in the eventual 
formation of apoptotic bodies (Sebbagh et al., 2001). This contraction also leads to 
the fragmentation of the cell nucleus; a characteristic hallmark of apoptotic cells 
(Croft et al., 2005). Recent work by Poon et al. has discovered a new form of plasma 
membrane structure termed ‘apoptopodia’ that forms during apoptosis in T 
lymphocytes and monocytes (Poon et al., 2014a). These structures are string-like 
membrane protrusions with apoptotic bodies placed along them resembling ‘beads 
on a sting’ (Atkin-Smith et al., 2015). This dramatic membrane remodelling is 
enhanced by inhibition of the Pannexin 1 small molecule channel.  
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As well as plasma membrane vesiculation outwards to form apoptotic bodies and 
apoptopodia, there is also evidence of endocytic events occurring during apoptosis. 
Lee et al. describe the appearance of large internal vesicles in a variety of cell types 
during apoptosis initiated in a number of different ways (Lee et al., 2013).  These 
vesicles were seen to originate from the plasma membrane, with a surface 
biotinylation assay confirming the presence of plasma membrane derived proteins 
on the membrane of these vesicles. 
In Chapters 3 and 4 we have investigated large Ca2+ activated plasma membrane 
vesiculation outwards, producing microvesicles, and inwards, during MEND. We 
have found that proteins, specifically PD-1, are sorted with these large membrane 
movements. During apoptosis of lymphocytes, significant membrane remodelling 
occurs. We therefore next investigated whether expression of surface receptors was 
altered during apoptosis, and sought to understand the mechanisms underlying this 
trafficking. 
5.1.1 Research questions 
- Are proteins sorted from the plasma membrane during apoptosis? 
- Is sorting due to membrane shedding or endocytosis? 
- Is sorting Ca2+ dependent? 
- What dictates the specificity of protein sorting? 
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5.2 Results 
5.2.1 Massive PD-1 endocytosis during apoptosis in Jurkat T cells 
PD-1 is preferentially sorted with large membrane movements triggered by large 
Ca2+ influx. Apoptosis, the orderly death and breakdown of cells, leads to a number 
of plasma membrane changes with large intracellular vacuoles, reminiscent of 
MEND endosomes, seen to appear inside cells (Lee et al., 2013).  
We first examined how plasma membrane protein expression, of a panel of proteins 
detailed in Chapter 4, was altered during apoptosis in Jurkat T cells. We used 
Etoposide, a topoisomerase inhibitor, to initiate apoptosis. Lack of topoisomerase 
activity leads to a DNA damage response, phosphorylation of p53, the upregulation 
of Bax and the subsequent release of cytochrome c from mitochondria (Karpinich et 
al., 2002). Cells were treated overnight with 2µM Etoposide and protein expression 
was analysed by FACS. Events with the FSC-SSC profiles of live Jurkat T cells, were 
analysed.  
Figure 5.1 shows the protein surface expression profiles of Jurkat T cells treated with 
Etoposide. Proteins were differentially affected. CD3 and HLA ABC were less 
downregulated with levels maintained at ~80%, while ICAM, LFA-1 and CD4 levels 
were reduced further to ~60%. PD-1 was most affected with expression levels 
dropping by ~99%. The other receptors most downregulated were TfR (~15%) and 
CD28 (~10%). 
PD-1 was dramatically downregulated during apoptosis, with cells losing ~99% of 
their surface expression. This is reminiscent of the massive Ca2+ activated 
downregulation of PD-1 described in Chapter 4, where PD-1 is either lost in 
microvesicles or endocytosed via MEND. We therefore next investigated whether 
this downregulation was dependent on Ca2+. Under conditions of total Ca2+ chelation 
(4mM EGTA), downregulation occurred normally (Figure 5.2). Interestingly, Figure 
5.2A suggests that this large-scale endocytosis of PD-1 is a rapid event affecting the 
whole cell, as no cells are seen to lie between the two binary states of PD-1high and 
PD-1low. 
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To understand whether PD-1 had been lost from the surface by either endocytosis or 
microvesicle shedding, we employed the assay described in Chapter 4, using the 
PD1GFP fusion protein, to track surface and total PD-1. Following Etoposide 
treatment, a ~99% reduction in surface PD-1 was accompanied by no significant 
change in total PD-1 (GFP) (Figure 5.2B). This confirms that this downregulation is 
due to endocytosis of PD-1. Imagestream X images confirmed loss of anti-PD-1 
surface staining and maintenance of total PD1GFP. In untreated cells, PD1GFP was 
distributed on the plasma membrane, whilst in etoposide treated cells there is a 
diffuse distribution of PD1GFP in the cytosol. Hoechst staining confirms that 
Etoposide treated cells are undergoing apoptosis, with high Hoescht uptake, and 
enlarged, fragmented nuclei. 
These data demonstrated that apoptosis leads to the remodelling of surface 
molecules on Jurkat T cells, with PD-1 dramatically downregulated by a massive 
Ca2+-independent endocytosis. 
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Figure 5.1 WT Jurkat T cell plasma membrane proteins are downregulated 
during apoptosis. WT Jurkat T cells expressing PD-1 were treated with 2µM 
Etoposide overnight and stained for expression of surface molecules and analysed by 
FACS. Cells were gated by FSC/SSC to exclude cellular debris. Data are percentage of 
untreated cell surface expression. 
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Figure 5.2 Apoptosis leads to a Ca2+ independent massive endocytosis of PD-1. 
A PD1GFP-expressing Jurkat T cells were treated with 2µM Etoposide overnight and 
stained for PD-1 in Ringer solution with or without 4mM EGTA. B Surface PD-1 and 
total GFP with and without Etoposide treatment. C ImagestreamX micrographs of 
PD1GFP cells stained with anti-PD-1 antibodies and Hoechst untreated or treated 
with 2µM Etoposide overnight. 
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5.2.2 Sorting of PD-1 via the transmembrane domain 
Nothing is known about the regulation of PD-1 at the cell surface. Here we present 
another physiological context, apoptosis, in which PD-1 is dramatically 
downregulated. We next wanted to gain insights into the mechanism of apoptosis-
induced downregulation of PD-1.  
Endocytic processes, such as clathrin-mediated endocytosis, often involve the 
binding of protein adaptors to specific motifs on the intracellular domain of 
receptors. We therefore wanted to establish whether portions of the PD-1 
intracellular domain are important for apoptosis-induced PD-1 endocytosis. We 
constructed a series of PD-1 receptor truncations with the intracellular domain 
progressively shortened. These constructs were expressed in Jurkat T cells using 
dual-promoter lentiviral vectors. Figures 5.3A and 5.3B show the affect of 2µM 
Etoposide on PD-1 expression. Apoptosis-induced endocytosis of PD-1 is blocked 
when the receptor is truncated to the 187th amino acid. Downregulation is inhibited 
to a small but significant extent in the PD1Δ∆193 truncation with levels dropping to 
~3% rather than ~1% in PD1WT.  Figure 5.3C shows the hydrophobicity plot of PD-1, 
with the predicted transmembrane domain lying between the 168th and 191st amino 
acid. PD-1Δ∆187 therefore truncates into the transmembrane domain by 4 amino 
acids. This suggests the transmembrane domain is involved in the sorting of surface 
proteins during apoptosis. 
In the data presented in Chapter 4 we discovered that the transmembrane domain 
dictates whether proteins are sorted into microvesicles or MEND endosomes 
following large Ca2+ influx. HLA was downregulated to a significantly smaller extent 
than PD-1, and substitution of the PD-1 and HLA transmembrane domains was able 
to regulate downregulation (Figure 4.5). Similarly, here we have found that PD-1 is 
more downregulated than HLA ABC during apoptosis (downregulated by ~99% vs. 
~20%). We next triggered apoptosis in cells expressing the PD1Tm and HLATm 
constructs, described in Figure 4.5. PD-1Tm but not HLATm underwent massive 
endocytosis during apoptosis (Figure 5.4). This again suggests the role of membrane 
domains that are preferentially endocytosed along with their protein cargo. 
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Figure 5.3 Truncation into the transmembrane domain of PD-1 prevents 
apoptosis-induced downregulation of PD-1. A and B PD-1 receptors, truncated at 
different points along the intracellular domain were expressed in Jurkat T cells using 
a dual promoter lentiviral vector. Cells were treated with 2µM Etoposide overnight 
and stained for expression of PD1. Data are percentage of untreated cell surface PD-
1 expression. P values correspond to * = 0.03 and **** = <0.0001. C PD-1 amino acid 
hydrophobicity plot with predicted transmembrane domain, showing the site of the 
PD-1Δ∆193 and PD-1Δ∆187 truncation. Data sourced from ExPASy TM prediction 
algorithm. 
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Figure 5.4 Receptors are sorted for apoptosis-induced endocytosis via their 
transmembrane domains. PD-1, PD1Tm, HLATm and HLA-A2 were expressed on 
Jurkat T cells using a dual promoter lentiviral vector. Cells were treated with 2µM 
Etoposide overnight and analysed by FACS. 
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5.3 Discussion 
The work presented so far in this thesis has focussed on the effects of Ca2+ influx on 
the plasma membrane of Jurkat T cells, uncovering mechanisms that regulate 
microvesicle shedding and MEND, as well as investigating how proteins are sorted 
with these membrane movements. We next chose to explore another physiological 
context in which significant plasma membrane changes occur - apoptosis. 
The plasma membrane plays an essential role in the controlled death, breakdown 
and clearance of cells. T lymphocytes can undergo large membrane vesiculation 
outwards and inwards during apoptosis (Lee et al., 2013). The mechanisms of 
apoptotic body formation are beginning to emerge, whilst very little is known about 
large endocytic events during apoptosis. 
Apoptotic Jurkat T cells did indeed dramatically remodel their plasma membrane 
protein expression during apoptosis (Figure 5.1). PD-1, CD28 and TfR were most 
affected with PD-1 surface expression dropping to ~1% of baseline. This 
downregulation was due to endocytosis, as total PD-1 levels remain constant (Figure 
5.2B). We hypothesised that this was Ca2+ activated MEND, described in Chapters 3 
and 4, which might follow Ca2+ influx caused by the loss of plasma membrane 
integrity during apoptosis. However, endocytosis proceeds normally in the absence 
of extracellular Ca2+ (Figure 5.2B).  Endocytosis occurs quickly and is a whole cell 
effect, with few cells seen to be transitioning between the PD-1high and PD-1low state 
(Figure 5.2A). We interrogated the intracellular domain of the receptor to establish 
whether any motifs, necessary for endocytosis, were present. Endocytosis of PD-1 
still occurred when the entire PD-1 intracellular domain was truncated, but was 
completely blocked by removal of ~4 amino acids from the C-terminal end of the 
transmembrane domain. Substitution of the PD-1 TM for HLA-A1 TM (in chimeras 
described in Figure 4.5) blocked massive endocytosis of PD-1.  
Although this endocytosis is Ca2+ independent, it resembles Ca2+ activated MEND in 
the dramatic extent to which PD-1 is specifically downregulated. Like with Ca2+ 
activated MEND, the transmembrane domain is involved in PD-1 targeting for 
endocytosis, implying the presence of lipid domains susceptible to vesiculation 
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inwards in which PD-1 is located. Substitution of the transmembrane domain and 
even removal of ~4 amino acids from the c-terminal end of the TM must exclude PD-
1 from these domains and therefore prevent PD-1 internalisation. 
As with Ca2+ activated MEND, the mechanism for this new form of endocytosis is 
unclear. This may be the same process observed in Lee et al. where large plasma 
membrane derived vesicles appear in apoptotic cells. This process was found to be 
independent of actin and dynamin in the same way as MEND (Lee et al., 2013). This 
endocytosis may also be the ‘delayed’ (occurring over minutes rather than seconds) 
MEND recently described in work by Hilgemann et al. in BHK cells (Hilgemann et al., 
2013). In this form of massive endocytosis palmitoylation of surface proteins is the 
trigger. Mitochondrial PTP opening leads to the release of Coenzyme A (CoA); this is 
then synthesised into palmitoyl-CoA, which acts as the substrate for DHHC5, an 
enzyme that then palmitoylates surface proteins. PTP opening is an important step 
in apoptosis leading to the release of cytochrome c (Ichas and Mazat, 1998). PTP 
opening does however require elevated intracellular Ca2+, though factors such as 
ROS and mitochondrial membrane potential can influence the amount of Ca2+ 
required (Brustovetsky et al., 2003).  
The physiological role of this apoptosis-induced endocytosis is not clear. Work by 
Xie et al has demonstrated that IL-1β bound to apoptotic bodies derived from 
tumour cells is able to induce CTL anergy and inhibit anti-tumour immunity (Xie et 
al., 2009). The removal of PD-1 and CD28 by endocytosis apoptotic cells and 
apoptotic bodes may suggest that these immune regulatory molecules are 
intentionally removed to prevent their competition with receptors bound to live 
cells. 
Further work is needed to uncover both the mechanism of Ca2+ independent MEND 
and its physiological role in T lymphocytes and other cell types. Manipulation of 
MEND pathway to downregulate surface PD-1 expression may provide a novel 
therapeutic approach for immunomodulation.  
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EXPRESSING EFFECTOR T CELLS 
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6.1 Introduction 
Receptors transmit signals across cell membranes following ligand binding. Ligands 
can be soluble, plasma membrane-bound or associated with other membranous 
structures such as exosomes and microvesicles. This thesis is focussed on the PD-
1:PD-L1 pathway in lymphocytes, with the aim of investigating novel ways by which 
plasma membrane dynamics may regulate the pathway. Little is know about how 
PD-1 or PD-L1 is regulated at the plasma membrane and insights in this area may 
reveal novel inhibitory mechanisms as well as providing potential therapeutic 
targets for regulating the pathway. 
Recently it was discovered that the inhibitory receptor, also in the CD28 family or 
co-receptors, CTLA-4 is able to transendocytose its ligands CD80 and CD86 from the 
surface of APCs. This involves the removal and endocytosis of these ligands, 
eventually leading to their degradation. This constitutes a mechanism of cell-
extrinsic inhibition of T lymphocytes, as these ligands are shared with the 
stimulatory receptor CD28. Depleting the pool of available ligands inhibits 
lymphocytes by preventing stimulation through CD28. This inhibition may therefore 
not only effect the CTLA-4-expressing cell that carries out transendocytosis, but 
also any T lymphocyte that subsequently comes in contact with that APC. This 
fascinating mechanism of inhibition is thought to be possible owing to the high 
affinity interaction between CTLA-4 and its ligands (Cheng et al., 2013; Collins et 
al., 2002). Affinity studies have been carried out on the CD28 family, which confirm 
this high affinity interaction. These studies also reveal that the PD-1:PD-L1 
interaction is much weaker (~5000 times weaker), and is entropy-driven i.e. 
displacing water molecules. The authors of Cheng et al. conclude that PD-1 would 
not be capable of a process like transendocytosis due to the transient, weak nature of 
the PD-1:PD-L1 interaction. Also as PD-1 does not share ligands in the same way as 
CTLA-4, the function of transendocytosis by PD-1 would not be clear. 
Recently it was found that PD-L1 can be detached by a PD-1 expressing cell, in a 
process similar to transendocytosis, termed trogocytosis (Gary et al., 2012). With 
trogocytosis, membrane-bound ligands with associated membrane is removed from 
the ligand expressing cell and rather than being sorted for degradation, the protein 
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is incorporated onto the receptor-expressing cell’s plasma membrane. This occurs 
between lymphocytes and APCs where pMHC and co-receptors can be exchanged 
(Busch et al., 2008; Game et al., 2005). 
There is, therefore, an apparent contradiction in the literature concerning the PD-
1:PD-L1 interaction. Cell-free affinity studies using techniques such as surface 
plasmon resonance have suggested that the interaction is very weak and transient, 
while other in vivo studies have suggested that PD-L1 can he transferred and 
expressed on PD-1 expressing cells in vivo. No cell-based binding assays have been 
carried out to measure the stability of PD-1:PD-L1 interactions. 
6.1.1 Research question 
- Can PD-1 form stable interactions with PD-L1? 
- Can PD-1:PD-L1 interactions extend beyond cell-cell contact? 
- Does PD-1 undergo ligand-induced downregulation? 
- What is the nature of the PD-1:PD-L1 interaction in the tumour 
microenvironment?  
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6.2 Results 
6.2.1 PD-L1 forms stable complexes with PD-1 which are maintained at the 
cell surface 
To establish whether PD-L1 was able to stably bind PD-1 on T lymphocytes, we 
conducted an in vitro FACS assay using a soluble PD-L1Fc chimeric protein and PD-1 
expressing Jurkat T cells.  Cells were incubated with soluble PD-L1Fc chimera at 
37oC for 1 hour in normal media, then the cells were washed twice in PBS, surface 
stained for 30 mins at 4oC with both anti-PD-1 and anti-PD-L1 fluorescent 
antibodies and washed again twice. As Figure 6.1A shows, PD-1 expressing cells 
incubated with PD-L1Fc become PD-L1 positive i.e.PD-L1 is bound in complex with 
PD-1 at the cell surface. PD-1 levels remain unchanged suggesting no ligand-
induced downregulation. 
Next we wanted to understand whether preservation of PD-1:PD-L1 complexes at 
the cell surface was mediated by any portion of the intracellular domain of PD-1. We 
performed the PD-L1Fc binding assay on cells expressing PD-1 receptors that had 
increasing portions of their intracellular domains truncated (Figure 6.1B). PD-L1 
bound to these cells was increased by ~3 fold between PD-1Δ∆217 and Δ∆211 (Figure 
6.1C). 
This data suggests that PD-L1 can bind stably to PD-1 and be maintained at the cell 
surface in complex with PD-1. Data with PD-1 truncations also suggests that factors 
on the intracellular domain or transmembrane domain of PD-1 regulate the 
longevity of PD-1:PD-L1 complexes remaining on the cell surface. 
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Figure 6.1 Soluble PD-L1Fc binds stably to PD-1 expressing Jurkat T cells and is 
maintained at the cell surface. A PD1WT expressing Jurkat T cells were incubated 
with 0ug/ml (Grey), 1ug/ml (Red) or 2ug/ml (Blue) PD-L1Fc for 1 hour at 37oC and 
then stained with anti-PD-1 and anti-PD-L1 antibodies. B Amino acid sequence 
showing the location of each truncation point. C  PD-1 truncations were incubated 
in 1ug/ml PD-L1Fc for 1 hour at 37oC. Cells were then stained with anti-PD-L1 
antibodies. Results show PD-L1 mean fluorescence intensity as a percentage of 
PD1WT, plotted against the total amino acid length of the protein. 
  
PD-L2
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1WT_No Fc.fcs
PD1WT_PDL2Fc 2ug.fcs
PD1WT_PDL2Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1WT_No Fc.fcs
PD1WT_B7H3Fc 2ug.fcs
PD1WT_B7H3Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
Sample
PD1WT_No Fc.fcs
PD1WT_PDL1Fc 1ug.fcs
PD1WT_PDL1Fc 2ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_PDL1Fc 1ug.fcs
PD1dCLL_PDL1Fc 2ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
PD1WT
PD1∆180
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_PDL2Fc 2ug.fcs
PD1dCLL_PDL2Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_B7H3Fc 2ug.fcs
PD1dCLL_B7H3Fc 1ug.fcs
Controls
PDL1Fc Chimera PDL2Fc Chimera B7H3Fc Chimera
   
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1WT_No Fc.fcs
PD1WT_PDL2Fc 2ug.fcs
PD1WT_PDL2Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1WT_No Fc.fcs
PD1WT_B7H3Fc 2ug.fcs
PD1WT_B7H3Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
Sample
PD1WT_No Fc.fcs
PD1WT_PDL1Fc 1ug.fcs
PD1WT_PDL1Fc 2ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_PDL1Fc 1ug.fcs
PD1dCLL_PDL1Fc 2ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
PD1WT
PD1∆180
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_PDL2Fc 2ug.fcs
PD1dCLL_PDL2Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_B7H3Fc 2ug.fcs
PD1dCLL_B7H3Fc 1ug.fcs
Controls
PDL1Fc Chimera PDL2Fc Chimera B7H3Fc Chimera
   
   
0 102 103 104 105
<A C-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1WT_No Fc.fcs
PD1WT_PDL2Fc 2ug.fcs
PD1WT_PDL2Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1WT_No Fc.fcs
PD1WT_B7H3Fc 2ug.fcs
PD1WT_B7H3Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
Sample
PD1WT_No Fc.fcs
PD1WT_PDL1Fc 1ug.fcs
PD1WT_PDL1Fc 2ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_PDL1Fc 1ug.fcs
PD1dCLL_PDL1Fc 2ug.fcs
0 102 103 104 105
<A C-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
PD1WT
PD1∆180
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_PDL2Fc 2ug.fcs
PD1dCLL_PDL2Fc 1ug.fcs
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample
PD1dCLL_No Fc.fcs
PD1dCLL_B7H3Fc 2ug.fcs
PD1dCLL_B7H3Fc 1ug.fcs
Controls
PDL1Fc Chimera PDL2Fc Chimera B7H3Fc Chimera
PD-L1PD-L1
P
D
1
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
0
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
0
0 102 103 104 105
<APC-A>: PD-L1
0
102
103
104
105
<P
E
-A
>:
 P
D
-1
0
PD1WT
PD1∆180
---- WT Jurkat PDL1 Jurkat
WT Supernatant
PD1WT
PDL1 Supernatant
Cells removed by Centrifuge
PDL1 Supernatant
Cells removed by 0.45um 
Syringe Filter
Coculture
Supernatant
Gating
0 50K 100K 150K 200K 250K
FSC-A
0
102
103
104
105
S
S
C
-A
76.4
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
S
S
C
-W
90.3
FSC-A / SSC-A FSC-A / SSC-W
0 102 103 104 105
<APC-A>: PD-L1
0
20
40
60
80
100
%
 o
f M
ax
Sample %
Supernatant_PD1WT Filtered Sup.fcs 97.7
Supernatant_PD1WT Unfiltered Sup.fcs 96.1
Supernatant_PD1WT WT Sup.fcs 97.8
PD1 PDL1
0 102 103 104 105
<PE-A>: PD-1
0
20
40
60
80
100
%
 o
f M
ax
PD-L1
P
D
1
1ug/ml
2ug/ml
PD-1WT Jurkat PD-L1FcA 
B 
C 
175 200 225 250 275 300
0
100
200
300
400
500
Amino Acid Length
PD
-L
1 
Bo
un
d 
(%
 o
f P
D
1W
T)
 
∆217 
∆211 
PD1WT 
       ∆187   ∆ 93   ∆199   ∆205   ∆211   ∆217   ∆223 
         |      |      |      |      |      |      |      
--- L VWV LAVICS RAARGT IGARRT GQPLKE DPSAVP VFSVDY GEL FQ ---  NH3 COOH 
 154 
6.2.2 PD-L1 is transferred onto PD-1 expressing cells by a cell-cell or cell-
debris dependent mechanism in vitro 
Data from Figure 6.1 suggests that PD-L1 can remain in stable complex with PD-1 at 
the cell surface. Next we wanted to know whether transfer of ligands could occur 
when PD-L1 bearing cells were co-cultured with PD-1 expressing cells. These 
proteins were stably expressed on Jurkat T cells using lentiviral vectors as shown in 
Figure 6.2A.  
PD-1 cells were co-cultured with either WT or PD-L1-expressing cells as shown in 
Figure 6.2B. Cells were then stained for both PD-L1 and PD-1 and single cells gated 
by SSC-W. Two striking results came from this experiment. Firstly, PD-1 Jurkat T 
cells cultured with PD-L1 cells downregulate PD-1 and secondly, PD-L1 is 
transferred onto the PD-1 expressing cells.  
To address the mechanism of ligand–induced downregulation of PD-1, we were 
interested in whether there was a motif on the intracellular domain of the receptor 
that mediated this downregulation as, for example, in the cases of IL-2R (Takeshita 
et al., 1992) and the TCR (Dietrich et al., 2002). Downregulation and PD-L1 transfer 
were however independent of the intracellular domain as they occurred in both 
PD1WT and PD-1Δ∆181 expressing cells. There was no change in PD-1 expression in 
PD1WT cells cultured with WT cells confirming that downregulation was PD-L1 
dependent 
We were next interested in how PD-L1 is transferred onto PD-1 expressing cells. 
Several groups have found that PD-L1 can be secreted  (Chen et al., 2011; Rossille et 
al., 2014) and in Figure 6.1 we demonstrate that soluble PD-L1 can form stable 
complexes with PD-1 at the cell surface. If PD-L1 is being secreted, it would be 
present in the supernatant of PD-L1 expressing cells. The supernatant was separated 
by pelleting cells at 2000 rpm for 5 mins. PD1WT cells were cultured with 
supernatant from WT cells or PD-L1 cells for 2 hours. The complete removal of PD-
L1 cells from the supernatant was confirmed by the absence of events in the PDL1high 
PD1low quadrant. Figure 6.3A shows that there was bound PD-L1 on the surface of 
PD1WT cells when cultured in crude PD-L1 supernatant. Importantly this did not 
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lead to a downregulation in PD-1. This PD-L1 binding was, however, abolished when 
the supernatant was filtered through a 0.45µM filter. This filter allows soluble 
protein to pass through it, but not cellular debris. We therefore asked whether PD-L1 
positive events were present in the subcellular-sized event gate. Indeed they were 
present in the culture where crude PD-L1 supernatant was used and they were not 
present in the filtered supernatant. Figure 6.3 shows the back-gating of the PD-L1high 
sub-cellular events in a FSC and Log SSC plot. 
These data so far demonstrates that PD-L1 can be transferred onto PD-1 cells 
expressing T lymphocytes. This occurs via a cell-cell or cell-debris based dependent 
way, and not by secretion of PD-L1. PD-1 is downregulated in a ligand dependent 
manner but only following cell-cell contact, not treatment with soluble PD-L1 or 
PD-L1 on cell debris. 
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Figure 6.2 Transfer of PD-L1 onto PD-1 expressing cells during co-culture in 
vitro. A WT, PD-L1 and PD1WT expressing Jurkat T cells stained anti- PD-1 and PD-
L1 antibodies. B PD1WT and PD-1Δ∆181 Jurkat T cells were co-cultured with either 
WT or PD-L1 expressing Jurkat T cells for 2 hours. Cells were then stained with anti- 
PD-1 and PD-L1 antibodies. 
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Figure 6.3 Transfer of PD-L1 is not due to secretion of PD-L1 but is cell-cell or 
cell-debris dependent. A PD1WT Jurkat T cells were cultured in crude supernatant 
from WT and PD-L1 expressing cells and 0.45µM filtered supernatant from PDL1 
Jurkat T cells. Data shows events from both the live Cell gate and the non-cell gate. 
B Back-gating of PD-L1 positive non-cell events (red) and all events (blue) on FSC 
Log SSC plot. 
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6.2.3 PD-L1 is transferred onto tumour infiltrating lymphocytes in vivo 
Our in vitro data clearly show a transfer of PD-L1 onto PD-1-expressing cells. This 
experimental system using Jurkat T cells may, however, not accurately represent a 
process that occurs in vivo. We therefore next established an in vivo tumour 
experiment that tested whether PD-L1 from a tumour could transfer onto CD4+ and 
CD8+ tumour infiltrating lymphocytes. In this case, as we needed to specifically track 
PD-L1 from the tumour, we therefore produced a PDL1-mCherry fusion protein and 
expressed it on a B16 melanoma cell line. Figure 4A shows the direct proportionality 
between PD-L1 and Cherry expression in these B16.PDL1-mCherry cells. 
C57BL/6 mice were injected with 2 x 106 tumour cells on Day 0. At day 6 and Day 8 
they were injected with 1 x 106 irradiated GM-CSF-expressing B16 cells (GVAX). This 
protocol, described in Figure 4B, was performed in collaboration with the Quezada 
lab and has been optimised for the recruitment of T cells to the tumour (Quezada et 
al., 2008; van Elsas et al., 1999). At Day 13 mice were sacrificed. Tumour infiltrating 
lymphocytes were separated by centrifugation with Ficoll. Cells were also isolated 
from the lymph nodes and spleen of the mice. Figure 4C shows the gating strategy 
for selectively assaying live CD4+ and CD8+ TILs and Figure 4 show the PD-1 and PD-
L1mCherry expression on those cells. 
In mice bearing B16.WT tumours, CD4+ and CD8+ TILs express PD-1 but do not 
fluoresce in the mCherry channel. By contrast, both CD8+ and CD4+ TILs from the 
B16.PDL1mCherry tumours are positive for PD-L1 mCherry. PD-1 expression on the 
TILs from the PD-L1mCherry expressing tumour is ~10% of that on TILs from 
WT.B16 tumours suggesting downregulation of PD-1 by PD-L1 in vivo. 
This data confirms that PD-L1 is transferred onto both CD4+ and CD8+ TILs and that 
ligand-induced downregulation of PD-1 also occurs in vivo. 
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Figure 6.4 Transfer of PD-L1 onto CD4+ and CD8+ T cells in vivo with B16 
Melanoma model. A B16.WT and B16.PDL1-mCherry cells stained with anti- mouse 
PD-L1 antibodies. B Experimental protocol carried out on C57BL/6 mice. Mice were 
either injected with 2x106 B16.WT or B16.PDL1-mCherry at Day 0 and then 1x106 
GVAX on Days 6 and 8. Mice were sacrificed on Day 13. C Gating strategy employed 
for selectively reviewing live, single, TILs. D CD4+ and CD8+ TILs isolated from either 
B16.WT or B16.PDL1-Cherry tumours stained with anti-mouse PD-1 antibodies.  
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6.3 Discussion 
6.3.1 PD-L1 transfer onto PD-1 expressing T lymphocytes 
We set out to investigate the stability of PD-1:PD-L1 interactions in a cell-based 
system. Our first step was to incubate PD-1 expressing Jurkat T cells with a soluble 
PD-L1Fc chimera to see whether the interaction was long-lived enough to detect by 
FACS. PD-L1 was found to still be in complex with PD-1 on the surface of cells 
following 5 separate washes and 30 minutes of staining at 4oC (Figure 6.1A). These 
data strongly suggest that the PD-1:PD-L1 interaction is both stable and long-lived.  
The complex of PD-1 and PD-L1 is able to remain in complex at the cell surface. To 
our surprise, when the same assay was performed on PD-1 receptors that had 
sections of the intracellular domain truncated (detailed in Chapter 5) we found that 
with some truncations there is more PD-L1 found in complex with PD-1. As the 
extracellular domains are kept constant between the truncations, these differences 
are not due to differences in PD-1:PD-L1 affinity. The level of PD-1 expression was 
made constant between truncations, with expression titrated by varying 
concentrations of lentiviral vectors used to transduce cells. What these results may 
represent is differences in rates of PD-1 recycling. If it takes time for PD-1:PD-L1 
complexes to form and the rate of recycling is high, then few complexes will be 
present at the surface at any point in time; if PD-1 recycling rates are low then more 
PD-1:PD-L1 complexes would be found at the cell surface. The sharp difference 
between the Δ∆217 and Δ∆211 truncations suggests that the 6 amino acids DPSAVP 
may form part of a motif involved in receptor turnover. Further investigation is 
needed to verify this and establish what factors might act on this motif. 
Following reports that PD-L1 could be transferred and then expressed on the surface 
of PD-1 expressing cells via trogocytosis (Gary et al., 2012), we next tested whether 
we could replicate this finding with co-cultures of Jurkat T cells expressing PD-1 and 
PD-L1. Indeed a significant amount of PD-L1 was found on the surface of PD-1 
expressing cells following co-culture (Figure 6.2). This PD-L1 was present after the 
multiple washing, re-suspension and staining steps involved in FACS. Interestingly 
the transfer is entirely one-directional, with PD-L1 transferred only onto PD-1 
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expressing cells and not visa versa. As both the ligand and receptor bearing cells 
were kept constant, this is likely to be a consequence PD-L1 or PD-1 properties. 
Daubeuf et al. made steps to address the issue of what protein properties favoured or 
facilitated trogocytosis (Daubeuf et al., 2010). They analysed a panel of proteins, 
comparing for their readiness to be trogocytosed and their plasma membrane 
anchoring. Further work is needed in this direction to understand what features of 
PD-L1 allow it to be transferred. 
So are we observing trogocytosis of PD-L1, i.e. is PD-L1 now residing in the 
membrane of the PD-1 expressing cell? This may be the case, as indeed PD-L1 is 
stainable at the cell surface. There are several factors, however, that suggest this 
may not be the case. Firstly, the intracellular domain of PD-1 is not necessary for 
this PD-L1 transfer. In trogocytosis, the ligand must be internalised and 
incorporated into a host membrane that is then fused with the plasma membrane. In 
TCR trogocytosis, endocytosis is driven by actin via the Rho GTPase TC21, and NK2D 
trogocytosis is dependent on clathrin-mediated endocytosis (Martínez-Martín et al., 
2011; Nakamura et al., 2013). In both cases, the intracellular domain is necessary for 
trogocytosis. Secondly, as demonstrated in Figure 6.1, PD-L1 can be held in complex 
with PD-1 at the cell surface. In those experiments using PD-L1Fc, there is no 
potential for PD-L1Fc to be expressed on the plasma membrane as it lacks a 
hydrophobic transmembrane region.  
Next we were interested in the mechanism of PD-L1 transfer. A mechanism that 
would explain the unidirectional nature would be that PD-L1 is secreted (Chen et al., 
2011; Rossille et al., 2014). However, when PD-1 expressing cells were incubated in 
the filtered supernatant from PD-L1 expressing cells, no PD-L1 was transferred. The 
role of exosomes and small microvesicles can also be ruled out as they would pass 
through the 0.45µm filter. Surprisingly, if the supernatant was only separated by 
centrifugation and not filtered, PD-L1 was found bound to the PD-1 expressing cells. 
This led us to find that PD-L1 is expressed on the surface of subcellular-sized cell 
debris present in the PD-L1 cell supernatant. This cell debris is likely to be mostly 
composed of apoptotic bodies and is presumably what is transferred. These data 
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indicate that the transfer of PD-L1 is not due to PD-L1 secretion, but instead is 
dependent on either cell-cell or cell-debris contact.  
We were then interested in whether these findings in vitro were also applicable in 
vivo in a physiologically relevant setting. PD-L1: PD-1 is a crucial pathway in the 
immune tolerance of cancer cells, especially in immunogenic tumours such as 
melanoma where PD-1 and PD-L1 blockade has dramatic therapeutic effects. As this 
was not a closed in vitro system we constructed a mouse PDL1-mcherry fusion 
protein, in order to track tumour-derived PD-L1, and expressed it on B16 mouse 
melanoma cells (Figure 6.4A) using a lentiviral vector (pSIN-mPDL1-mCherry). In 
collaboration with Sergio Quezada’s lab, an experimental protocol was employed 
that involved the use of GVAX to recruit tumour reactive lymphocytes to the tumour 
(Figure 6.4B). At Day 13 CD4+ and CD8+ lymphocytes were isolated from both WT and 
PDL1-mCherry expressing B16 tumours as well as from the lymph nodes and spleens 
of mice. The gating strategy ensured only single lymphocytes were analysed (Figure 
6.4C). Both CD4+ and CD8+ TILs from both WT and PD-L1 tumours were found to 
express PD-1. Crucially, those TILs from the PDL1-mCherry tumour were strongly 
positive for mCherry, indicating that tumour derived PD-L1 had transferred onto the 
T lymphocytes in vivo. PDL1-mCherry was not present on lymphocytes in either the 
lymph nodes or spleen (data not shown). 
Taken together these data demonstrate that PD-L1 is transferred onto PD-1 
expressing T lymphocytes in the physiological setting of a melanoma tumour in 
mice. The physiological significance of this transfer is unclear. If this is indeed 
trogocytosis, as suggested by Gary et al., then the PD-L1, now expressed on the 
surface of lymphocytes, may serve to spread the inhibitory microenvironment to T 
lymphocytes themselves. These may then commit ‘fratricide’ by inhibiting fellow 
TILs (Gary et al., 2012). Cheng et al. however, never actually demonstrated that PD-
L1 was expressed on the membrane i.e. that trogocytosis had actually occurred. Our 
data, with PD-L1Fc, demonstrates that stable PD-1:PD-L1 complexes can form at the 
cell surface. We also show that transfer of ligand is not dependent on the 
intracellular domain of the receptor, again suggesting that we are seeing surface 
complexes, not PD-L1 trogocytosis. 
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If these are indeed surface complexes, then this may suggest other functional roles: 
Firstly, in the same way as transendocytosis, by removing the ligand from the 
APC/target cell, the pool of available PD-L1 able to inhibit subsequent cells is 
reduced. This may constitute a form of lymphocyte-number specific regulation i.e. a 
set pool of PD-L1 would be sufficient to inhibit a certain number of lymphocytes, but 
if numbers reached a critical threshold, the pool could be sufficiently diluted so as to 
release the PD-L1:PD-1 brake on T lymphocyte function. 
Secondly, the transferred PD-L1 may continue to signal through the PD-1 are 
transferred so inhibition would be sustained beyond cell:cell contact. In the context 
of a tumour or organ with heterogeneous PD-L1 expression, cells with high PD-L1 
expression could thereby protect those with low PD-L1 expression. 
Thirdly, the transferred PD-L1 may instead block subsequent signalling through PD-
1, preventing serial triggering and eventually depleted functional PD-1. This would 
therefore have to be offset with compensatory expression of new PD-1 for inhibition 
to continue. 
Further investigation is needed to establish the function of this transferred PD-L1. 
The matter of receptor:ligand affinity also remains unresolved. SPR-based assays 
show complete wash off of PD-L1 in 5 - 15 seconds and here we demonstrate stable 
receptor:ligand complexes that have remained despite repeated washing and 
resuspension steps over a period of an hour. Presumably for transfer to occur from 
one cell to the other a high affinity (as in the case of CTLA-4) is necessary. It may be 
the case that during transfer following cell-cell contact, clusters of PD-1 remove 
clusters of PD-L1 and associated membrane, so the cumulative affinity is high 
enough to perform this function. Data with the PD-L1Fc chimera however 
demonstrates that even the monovalent interaction is relatively stable. 
If the interaction of PD-L1:PD-1 is indeed higher than that demonstrated in cell-free 
assays, this may suggest a mechanism for the motility paralysis seen with by 
Zinselmeyer et al. Here cells were seen to form very stable immune synapses with 
clusters of PD-L1 found in the cSMAC (Zinselmeyer et al., 2013). This may have a 
biophysical explanation, where highly stable PD-L1:PD-1 interactions lead to cells 
adhering to each other, and thereby inhibiting motility. 
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6.3.2 Ligand-induced downregulation of PD-1 
Many receptors undergo ligand-induced downregulation. In many cases this is a 
mechanism of negative regulation, terminating signalling and reducing the number 
of receptors on the surface accessible to more ligand. Other receptors, such as RTKs 
and EGFR, are endocytosed in order to sustain signalling, remaining active in 
endosomes (Sorkina et al., 2002). 
Here we present data that PD-1 is downregulated following ligand binding. This 
downregulation has several salient features. It occurs both in vitro with human 
(Figure 6.2) and in vivo with mouse PD-L1 and PD-1 (Figure 6.4), it occurs only when 
the ligand PD-L1 is bound to an opposing cell membrane (Figure 6.2B), and not with 
soluble PD-L1Fc (Figure 6.1) or PD-L1 bound to cell debris (Figure 6.3A) and it is 
independent of the intracellular domain of the receptor, occurring both with PD1WT 
and PD1Δ∆181 (Figure 6.2). 
As PD-L1 has been transferred and is in complex with PD-1, ligand-receptor 
interactions may be blocking the epitope of the staining antibody, and this could 
lead to a decrease in PD-1 staining shown in Figure 6.2. However, soluble PD-L1Fc 
also forms stable complexes at the surface (Figure 6.1) and under these conditions 
no PD-1 decrease is seen, therefore we can be sure that the reduction in PD-1 is not 
due to epitope blocking. 
The features listed above make this downregulation unlike other forms of ligand-
induced downregulation that rely on signalling through the receptor (Sorkin and von 
Zastrow, 2009). In our experiments however, PD-1 downregulation occurs without 
the intracellular domain. This suggests that neither internalisation motifs nor PD-1 
signalling are necessary for this downregulation. Extracellular or transmembrane 
interactions may therefore mediate internalisation. The reliance on PD-L1 
associated to an opposing cell membrane for downregulation may suggest a role for 
receptor clustering as the mechanism for downregulation. Clustering of adhesion 
molecules is sufficient to trigger a clathrin and caveolin independent 
downregulation (Muro et al., 2003). Indeed PD-1 is known to form microclusters 
with TCRs when ligated by PD-L1 which are required for inhibition. Lengthening of 
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the PD-1 extracellular domain with Ig-domain spacers in those experiments 
inhibited cluster formation (Yokosuka et al., 2012). Undertaking similar experiments 
will be necessary to clarify the potential roles of the PD-1 extracellular domain and 
receptor clustering in ligand induced downregulation of PD-1. 
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7.1 Ca2+ influx and the plasma membrane  
This work aimed to clarify uncertainties surrounding the sequence of events that 
follow large Ca2+ influx in Jurkat T cells. Figure 7.1 presents our model for the 
membrane movements that follow Ca2+ influx. With active TMEM16F, Ca2+ causes a 
rapid exocytosis of internal membranes that leads to plasma membrane scrambling 
and microvesicle shedding (Figure 1.10 and 1.12). Endocytosis does not occur in the 
presence of active TMEM16F (Figure 3.1), which implies that either TMEM16F or 
exocytosis inhibits the MEND pathway. MEND occurs in the absence of TMEM16F 
activity, perhaps following regulation by intracellular polyamines (Figure 3.8) or low 
channel expression. Endocytosis is therefore the ‘default’ or ‘backup’ pathway. It 
may be preferable for some cells (of the hematopoietic lineage for example) to 
scramble their membranes (Elliott et al., 2005; Toti et al., 1996) and shed vesicles as 
signalling modules (MacKenzie et al., 2001), whereas it may be appropriate for other 
cell types to take in membrane in response to large Ca2+ influx (Idone et al., 2008). 
We found that at excessive Ca2+ concentrations (facilitated by 20µM ionomycin in 
2mM CaCl2) in WT Jurkat T cells, MEND occurs even in the presence of TMEM16F 
activity (Figure 4.6). In this case the MEND pathway may overcome the inhibition 
exerted by the TMEM16F/exocytosis pathway. 
 
 
 
 
 
 
 
Figure 7.1 Model of response pathways to large Ca2+ influx 
 
One of the functional roles of these two TMEM16F-regulated phenotypes is likely to 
be plasma membrane repair. Rapid Ca2+ activated exocytosis, endocytosis and 
microvesicle shedding are necessary for effective repair of membranes in different 
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cell types (Idone et al., 2008; Jimenez et al., 2014; McNeil and Kirchhausen, 2005). A 
rapid response to membrane wounding is necessary to ensure cell survival, with 
patching or removal of damaged membrane having to occur within seconds (McNeil 
and Kirchhausen, 2005). The speed of both the exo- and endocytic responses is a 
striking feature of the effects we observed (Figure 3.1 and 1.6). For membrane repair, 
a primitive mechanism, independent of a large protein complex, with simple 
regulatory mechanisms is likely to be preferable. For exocytic responses it may 
therefore not be surprising that the SNARE/Syn machinery, which delivers operative 
cargos in a highly regulated manner in the neuronal and immunological synapse, is 
not the same as that needed for membrane repair.  MEND also seems to have a 
primitive mechanism without any reliance on classical endocytic proteins or 
cytoskeletal scaffolds (Figure 3.7)(Lariccia et al., 2011). Following membrane 
damage, two possible lines of defence may be necessary: membrane patching then 
shedding with TMEM16F active, and MEND as a backup pathway in the absence of 
TMEM16F activity or following large membrane wounds (higher Ca2+) where 
endocytosis may be a more effective repair pathway. 
Further work should be aimed at discovering which other proteins are necessary for 
TMEM16F-induced exocytosis, and whether our simple mechanistic model described 
in Figure 3.13 is valid. The close link between exocytosis and channel opening 
suggests the channel behaves like a fusion pore. It may be informative to establish 
why ion flux through the channel is required for exocytosis, as well as to ascertain 
the role of the recently described TMEM16F ‘scrambling domain’ (Brunner et al., 
2014; Yu et al., 2015) and the constitutively active mutants (Suzuki et al., 2010) in 
the mechanism of membrane fusion. It will also be important to establish the origin 
of the membrane pool that is fused to the plasma membrane by TMEM16F. 
The mechanism for Ca2+ dependent (Chapter 3) and independent (Chapter 5) MEND 
remains unknown. There is cause to believe they may share a mechanism as both 
specifically sort PD-1 in a manner dependent on the transmembrane domain of the 
receptor, suggesting the involvement of specific lipid domains in the mechanism. 
The sensing machinery must either be different in the two cases, or be activated by 
both Ca2+ and factors involved in apoptosis. The uncoupling of exocytosis and 
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endocytosis in TMEM16F-null cells makes the role of SMase secretion (Tam et al., 
2010) unrealistic as previously demonstrated (Lariccia et al., 2011). Following some 
encouraging results with a small molecule inhibitor of PLA2 (Lariccia et al., 2011) the 
role of phospholipases in MEND should be investigated with gene knockout studies.  
This work also uncovered some unexpected links between other Ca2+ activated 
plasma membrane responses including microvesicle shedding and phospholipid 
scrambling. TMEM16F-induced exocytosis was found to precede and be necessary 
for Ca2+ activated microvesicle shedding in Jurkat T cells (Figure 1.12). Both the 
known delay in channel activation (Grubb et al., 2013) and time taken for exocytosis 
to occur may explain the consistent observation of a delay between Ca2+ influx and 
microvesicle release (Cocucci et al., 2007; Lee et al., 1993; MacKenzie et al., 2001; 
Moskovich and Fishelson, 2007; Stein and Luzio, 1991). It will be necessary to 
establish whether this microvesicle shedding is the same as that seen during 
membrane repair (Jimenez et al., 2014). TMEM16F has a high Ca2+ threshold for 
activation so it is unlikely that microvesicle release is linked to TMEM16F-induced 
exocytosis in all physiological contexts of microvesicle release. However, exocytosis 
itself may be necessary for the biogenesis of microvesicles, either by changing the 
plasma membrane lipid composition or by trafficking specific protein machinery to 
the membrane (e.g. ESCRT proteins)(Choudhuri et al., 2014). The machinery for this 
preceding exocytosis may differ depending on the context i.e. TMEM16F with high 
Ca2+ exocytosis and SNARE/Syn in more regulated settings. Indeed both focussed 
fusion events, dependent on Syn VII (Soares et al., 2013), and microvesicle release 
(Choudhuri et al., 2014) take place in the immune synapse during antigen 
presentation. This would be compatible with the involvement of ESCRT complex 
proteins and may provide a Ca2+ dependent mechanism for their translocation to the 
plasma membrane.  
TMEM16F is the Ca2+ activated phospholipid scramblase (Suzuki et al., 2010) but the 
mechanism for this function has yet to be definitively demonstrated. The long-held 
model of the scramblase as an ATP-independent phospholipid translocator has 
endured and been given fresh support following the recent discovery of a hydrophilic 
cleft in the structure of an ancestral TMEM homologue necessary for membrane 
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scrambling (Brunner et al., 2014; Yu et al., 2015). Controversy and uncertainty still 
surround this field as some reports suggest that TMEM16F is not sufficient for 
plasma membrane scrambling (Yang et al., 2012). Here we show a new function for 
TMEM16F as a Ca2+ sensor for exocytosis, facilitating the rapid doubling of plasma 
membrane area (Figure 3.1), and furthermore show the kinetic of exocytosis and 
phospholipid scrambling are identical (Figure 3.10). This strongly suggests that the 
exocytosis of phospholipid-bearing internal membranes is the cause of TMEM16F-
induced phospholipid scrambling. Indeed PS is enriched in certain internal 
membranes and phospholipid asymmetry is not maintained to the same extent in 
these as on the plasma membrane (Leventis and Grinstein, 2010; Yeung et al., 2008).  
We found no way of selectively blocking exocytosis without also blocking TMEM16F 
channel activity so were unable to establish whether exocytosis is the cause of 
membrane scrambling. Our new model is therefore likely to be controversial. It goes 
against work carried out in artificial membranes that suggests ancestral TMEM 
homologues are sufficient for scrambling (Brunner et al., 2014; Malvezzi et al., 
2013). However, these assays have incorrectly implicated other proteins as the 
scramblase in the past (Bevers and Williamson, 2010). A point in opposition to our 
model is the fact that RBCs from Scott syndrome patients, who lack TMEM16F, do 
not scramble their plasma membrane in response to Ca2+ (Bucki et al., 1998; Toti et 
al., 1996). It is a long established fact that RBCs lack internal membranes. During 
reticulocyte maturation, the ER, Golgi and other membranes are removed (Griffiths 
et al., 2012). Therefore in the case of RBCs, TMEM16F-induced plasma membrane 
scrambling would imply that that the protein has intrinsic scrambling capacity. The 
alternative is that RBCs do contain a yet undiscovered pool of internal membrane 
(however small) that participates in exocytosis. These issues will need to be 
addressing in light of this new function of TMEM16F.   
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7.2 PD-1 regulation on the plasma membrane 
The starting point for this study was a search for mechanisms that regulate PD-1 
expression on the cell surface of T lymphocytes. There have been no published 
mechanisms by which PD-1 is trafficked to and from the plasma membrane. One 
confocal study found PD-1 to be absent from classical endocytic compartments 
(Pentcheva-Hoang et al., 2007). Here we report five potential mechanisms of PD-1 
regulation on the plasma membrane of Jurkat T cells (Figure 7.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Pathways of PD-1 downregulation 
 
Pathways 1 and 2 relate to the TMEM16F-regulated plasma membrane responses to 
Ca2+ influx - microvesicle shedding and MEND (Chapter 4 Figures and Videos 4.1 and 
4.2). PD-1 is downregulated via either mechanism by 90-95%. Other receptors, 
including HLA, are only downregulated by 15-25% under the same conditions 
(Figures 4.1, 4.3, 4.6). This specificity for PD-1 was regulated via the transmembrane 
domain of the receptor (Figure 4.5). Surprisingly a massive endocytosis of PD-1 also 
occurs during apoptosis (Figure 7.2 Pathway 3, Figure 5.1 and 5.2) and this is also 
regulated via the transmembrane domain of the receptor (Figure 5.3 and 5.4). 
Apoptotic MEND shares similarities with Ca2+ activated MEND in protein specificity, 
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but importantly is Ca2+ independent. This suggests that the mechanism for MEND 
can be triggered by a variety of stimuli. The involvement of the transmembrane 
domain suggests a role for protein lipid interactions in dictating specificity. The fact 
that PD-1 is sorted both into microvesicles and MEND endosomes suggests these 
domains may be susceptible to vesiculation in either direction. The factors in the 
PD-1 transmembrane domain that dictate this specificity will need to be established. 
In the original paper that first described Ca2+ activated MEND, the authors proposed 
the model that MEND results from a coalescence of highly ordered membrane 
domains, rich in cholesterol and sphingolipids, that are then able to spontaneously 
vesiculate inwards. There is evidence that cholesterol can facilitate both coalescence 
and membrane bending (Groves, 2007; Sarasij et al., 2007). Indeed Ca2+ activated 
MEND could be blocked when membrane cholesterol was depleted with 
cyclodextrins. This hypothesis was also reinforced by the work presented in Fine et 
al 2011 that showed the ability of amphipathic agents to trigger MEND in cells. 
These may promote domain reorganisation and coalescence.  It is as yet unclear how 
increases in intracellular Ca2+ could promote domain coalescence.  
The difficulty in verifying a membrane-intrinsic mechanism for MEND or 
microvesicle shedding, such as domain coalescence leading to vesiculation, is the 
limited selection of suitable tools available for experimentally altering the 
membrane. Interventions such as cholesterol stripping using cyclodextrins, or the 
addition of amphipaths to the membrane, may not be informative as they can have 
profound effects on the biophysical properties of the membrane and thus not 
permitting specific conclusions to be drawn.  
The functional basis for this protein regulation in T lymphocytes is unclear. There is 
a growing literature revealing the many roles of shed plasma membrane 
microvesicles in health and disease (Cocucci et al., 2009). The expression of proteins 
on these vesicles is closely related to their function (Al-Nedawi et al., 2008; 
Albanese et al., 1998; Choudhuri et al., 2014; Kim et al., 2005; MacKenzie et al., 
2001; Skog et al., 2008). Our findings that demonstrate the specific inclusion and 
exclusion of proteins on the basis of their transmembrane domains may therefore be 
of interest in a broad range of contexts from immunity to cancer. It will be important 
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to next determine whether this mechanism holds true in other cell types as well as in 
primary human T cells.  
We show for the first time that a large endocytic event occurs during apoptosis, 
which remodels the expression of surface proteins (Pathway 3). Whether this 
downregulation is physiologically important, in removing functional receptors from 
the surface of apoptotic cells and bodies, or is incidental to a yet uncharacterised 
internalisation of the plasma membrane during apoptosis, should be investigated. 
As a result of our work investigating the transfer of PD-L1 from tumour cells onto 
PD-1 expressing lymphocytes, we uncovered two other mechanisms for PD-1 
regulation (Chapter 6). Pathway 4 (Figure 7.2) describes ligand-induced 
downregulation of PD-1 (Figure 6.2, 6.3, 6.4). Crucially this only occurred when 
ligand was bound to an opposing cell membrane and not when PD-1 expressing cells 
were incubated with soluble PD-L1Fc or PD-L1 bound to cellular debris. 
Interestingly the intracellular domain of the receptor was not required for ligand-
induced downregulation (Figure 6.2). The necessity for an opposing cell membrane 
may suggest a role for receptor clustering for internalisation (Muro et al., 2003). The 
mechanism for this ligand-induced downregulation will need further investigation.  
A surprising finding was that the number of PD-1:PD-L1Fc complexes maintained at 
the cell surface is regulated by a motif between the 211th and 217th amino acid (-
DPSAVP-) of the PD-1 intracellular domain (Figure 6.1)(Pathway 5). This truncation 
cannot have an effect on ligand-receptor affinity, as it affects only intracellular 
amino acids. A higher number of receptor/ligand complexes could also not be 
explained by higher expression as this was kept constant between truncations. We 
therefore hypothesise that this relates to the constitutive receptor-recycling rate, 
with a longer duration of receptor exposure at the cell surface leading to a higher 
probability of receptor-ligand complex formation.  There are straightforward 
receptor recycling assays that could be carried out to test this hypothesis as well as 
further mutagenesis to establish which individual amino acids are responsible for 
this effect. 
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7.3 PD-L1 transfer onto T lymphocytes 
The PD-1/PD-L1 interaction is a major therapeutic target for the treatment of a 
broad range of tumour types (Pardoll, 2012). The kinetics of the interaction that 
leads to the inhibitory influence of this pathway is, however, poorly characterised. 
Despite very low receptor-ligand affinities being reported in cell-free assays (Cheng 
et al., 2013), PD-L1 has been found to transfer onto PD-1 expressing T lymphocytes 
by trogocytosis (Gary et al., 2012). Here we found that PD-L1 and PD-1 can form a 
stable complex that is maintained at the cell surface (Figure 6.1). This occurs when 
either soluble PD-L1Fc, PD-L1 bearing cells or debris are incubated with PD-1 
expressing cells (Figure 6.1, 6.2). Transfer happened both in vitro with Jurkat T cells 
and in vivo in a mouse melanoma model on both CD4+ and CD8+ TILs (Figure 6.4). 
The strength of the interaction was not quantified but complexes were present after 
multiple centrifugation, washing and re-suspension steps, suggesting that they may 
be stable in vivo. Interestingly, despite the PD-1:PD-L1 interaction being 
monovalent, there was no transfer of PD-1 onto PD-L1 expressing cells. This implies 
a feature of either PD-1, in being securely anchored to the plasma membrane, or PD-
L1, in being susceptible to release from the plasma membrane, that allows for this 
unidirectional transfer. Once the mechanism of transfer is uncovered and can be 
blocked, it will be important to establish whether this feature of the PD-1:PD-L1 
interaction contributes to the inhibitory effects of the pathway. Indeed it is unclear 
whether this PD-L1:PD-1 complex will continue to signal through PD-1 or block 
further signalling. In the same way as transendocytosis of ligands carried out by 
another family member CTLA-4, this transfer of ligands may confer an extrinsic 
influence on signalling events after the termination of cell-cell contact. It will also 
be important to establish whether the strength of the interaction is involved in the 
brake on migration that PD-1:PD-L1 confers. These points should be addressed as 
they may prove to be an important addition to the understanding of PD-1: PD-L1 
biology. 
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7.4 Possible therapeutic implications  
7.4.1 Targeting TMEM16F for anticoagulation 
Scott syndrome is a rare inherited bleeding disorder that is caused by the deficient 
expression of TMEM16F (Suzuki et al., 2010). This symptom is caused by absent PS 
exposure on the surface of activated platelets, a necessary step in catalysing the 
clotting cascade (Toti et al., 1996). No other systemic effects have been reported in 
Scott patients. The Scott syndrome pathway has therefore been suggested as a drug 
target for anti-coagulation therapy (Morel et al., 2011). 
Here we present evidence that intracellular polyamines are able to block TMEM16F 
activity. This insight could be a good starting point for designing a drug candidate 
screen.  The polyamines we tested were all cell-impermeable so could only be used 
in whole-cell patch clamp experiments. The candidates should therefore be designed 
to include cell-permeable polyamine–like compounds. The screening assay would 
involve a straightforward 96 well FACS-based assay with Jurkat T cells incubated 
with candidate compounds, triggered with ionomycin in Ringer solution and stained 
with annexin V. Successful candidates should then proceed to validation in vivo with 
thrombosis assays. 
7.4.2 Microvesicle-related therapies 
Following the extensive exposition of the physiological roles of microvesicles, their 
application for therapeutics is now being explored. Microvesicles and exosomes can 
carry a variety of protein, mRNA and non-coding RNA cargoes (Cocucci et al., 2009). 
Microvesicles can therefore act as liposomes, transfecting their cargoes into cells of 
interest. Synthetic RNA delivery approaches such as lipid nanoparticles have met 
with technical difficulties due to their rapid sequestration by serum proteins 
(Dobrovolskaia et al., 2008), a problem which microvesicles, as physiological 
messengers for intercellular communication, do not encounter. One example of such 
a study was recently carried out by Mizrak et al. and demonstrated the anti-cancer 
potential of a microvesicle-based therapy (Mizrak et al., 2013). Microvesicles 
originating from cells that had been genetically engineered to express the enzyme 
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CD-UTRP, that converts the prodrug 5-fluorocysteine into 5-flurouracil, were 
injected into schwannoma tumours. This was followed by a significantly improved 
tumour remission after treatment with the prodrug.  
Here we show that the biogenesis of microvesicles following Ca2+ influx is linked to 
the function of TMEM16F. This may inform the design of cell-based protocols for the 
synthesis of therapeutic microvesicles. Conversely, tumour derived microvesicles are 
important in regulating the tumour microenvironment (Al-Nedawi et al., 2008; Skog 
et al., 2008). It will therefore be important to establish whether the biogenesis of 
tumour-derived microvesicles is linked to TMEM16F and whether interventions that 
block this pathway could prove therapeutically significant in disrupting this 
microenvironment. 
7.4.3 PD-1 downregulation from the plasma membrane 
Regulation of the PD-1 pathway by anti-PD-1 and anti-PD-L1 antibodies has proved 
a promising therapeutic approach for the treatment of cancer (Pardoll, 2012). 
Another strategy to modulate the pathway could be to downregulate PD-1 
expression at the plasma membrane of lymphocytes. We have uncovered a number 
of pathways which PD-1 can dramatically downregulate. A better understanding of 
the mechanism of both MEND and ligand induced PD-1 downregulation may 
uncover therapeutic targets that can regulate surface expression. 
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APPENDIX I – VIDEO LEGENDS 
Video 3.1. Ca2+ induced exocytosis and shedding probed with FM4-64 in WT Jurkat T 
cells. WT Jurkat cells were plated in a chambered coverslip in Ringer with 5µM FM 4-
64. 5µM ionomycin was added at 30 seconds. The scale bar represents 10µm.  
Video 3.2. Ca2+ induced PS exposure probed with K7-Rhodamine in WT Jurkat T 
cells. WT Jurkat cells were plated in a chambered coverslip in Ringer with 3µM K7-
Rhodamine. 5µM ionomycin was added at 50 seconds. The scale bar represents 
10µm.  
Video 4.1. In WT Jurkat T cells PD-1 is shed following ionomycin treatment. PD1-
mCherry expressing WT Jurkat T cells were imaged by SR-SIM Microscopy. 
Ionomycin was added to the opposite side of the chambered cover slip 10 seconds 
before the video starts. Scale bar represents 10µm.  
Video 4.2. In TMEM16F-null Jurkat T cells PD-1 is endocytosed following 
ionomycin treatment. PD1-mCherry expressing TMEM16F-null Jurkat T cells were 
imaged by SR-SIM Microscopy. Ionomycin was added to the opposite side of the 
chambered cover slip 10 seconds before the video starts. Scale bar represents 10µm.  
 
